学术周报 · IF≥10 或专科旗舰刊
骨科领域文献阅读汇编
2026年第45周 (2026-11-06) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选: IF≥10 或专科旗舰刊 · 完整摘要不截断
数据来源: PubMed E-utilities · 影响因子筛选: IF≥10 或专科旗舰刊 · 完整摘要不截断
★本周 Top 10 高影响力文献
Ŧ期刊分布统计
| 期刊 | 篇数 | IF |
|---|---|---|
| The Journal of bone and joint surgery. American volume | 10 | IF 4.5 |
| Clinical orthopaedics and related research | 10 | IF 4.3 |
| Bioactive materials | 9 | IF 23.6 |
| The American journal of sports medicine | 8 | IF 5.4 |
| Biomaterials | 6 | IF 13.6 |
| Annals of the rheumatic diseases | 3 | IF 24.0 |
| Journal of advanced research | 3 | IF 17.1 |
| Journal of the American Chemical Society | 2 | IF 16.6 |
| Advanced healthcare materials | 2 | IF 11.0 |
| Kidney international | 2 | IF 21.8 |
1骨质疏松/骨代谢 (14篇)
临床研究 (1篇)
Although exocrine pancreatic insufficiency (EPI) is thought to be common in type 1 diabetes, little is known about the relationship of EPI with type 1 diabetes parameters or food intake and abdominal complaints. Characterising individuals with EPI could help prevent EPI-related complications such as malabsorption and osteoporosis. In a cross-sectional cohort of 443 individuals with type 1 diabetes (62% female, median age 42 years [IQR 29-54], mean BMI 25±4 kg/m2, median diabetes duration 16 years [IQR 6-29]), we associated faecal elastase (FE) levels, as a marker of EPI, with type 1 diabetes parameters and clinical features, using linear and Poisson regression models. The mean FE level (±SD) was 349.5±146.8 µg/g faeces. A number of variables were independently associated with lower FE levels: older age (-10.97 µg/g faeces per 10 years; 95% CI -21.02, -0.92), longer diabetes duration (-13.09 µg/g per 10 years; 95% CI -23.54, -2.64), higher HbA1c (-1.44 mmol/mol per 1 SD increase in FE levels, 95% CI -2.59, -0.30), male sex (-54.07 µg/g; 95% CI -81.41, -26.73) and smoking (-85.06 µg/g; 95% CI -128.52, -41.60). In a linear analysis, we found no evidence of associations between FE levels and markers of residual beta cell function, liver disease, macronutrient intakes or gastrointestinal complaints. Using a cut-off of 200 µg/g faeces, 76 individuals (17%) were found to have EPI, which was associated with a 4.31 mmol/mol (0.39%) higher HbA1c (95% CI 1.35, 7.26), an 8% higher mean glucose (95% CI 2, 14), a 9% lower fibre intake (95% CI 1, 17) and an 8% lower energy intake (95% CI 1, 15). The lack of evidence for associations with clinical parameters in this relatively healthy population of individuals with type 1 diabetes does not support the use of FE for routine screening for EPI. However, the high prevalence of low FE levels and their association with lower food intake and higher glucose levels justify a need for clinical awareness for EPI and its complications, especially in individuals with long diabetes duration.
中文摘要:胰腺外分泌功能不全(EPI)被认为在1型糖尿病中常见,但其与1型糖尿病参数、食物摄入及腹部不适的关系所知甚少。识别EPI个体有助于预防吸收不良和骨质疏松等EPI相关并发症。在443例1型糖尿病患者的横断面队列中(女性62%,中位年龄42岁[IQR 29-54],平均BMI 25±4 kg/m2,中位糖尿病病程16年[IQR 6-29]),采用线性回归和泊松回归模型,将作为EPI标志物的粪便弹性蛋白酶(FE)水平与1型糖尿病参数及临床特征进行关联分析。FE平均水平(±SD)为349.5±146.8 µg/g粪便。多个变量与较低FE水平独立相关:年龄较大(每10岁-10.97 µg/g粪便;95% CI -21.02, -0.92)、糖尿病病程较长(每10年-13.09 µg/g;95% CI -23.54, -2.64)、HbA1c较高(FE水平每升高1个标准差对应-1.44 mmol/mol;95% CI -2.59, -0.30)、男性(-54.07 µg/g;95% CI -81.41, -26.73)和吸烟(-85.06 µg/g;95% CI -128.52, -41.60)。线性分析未发现FE水平与残存β细胞功能、肝病、宏量营养素摄入或胃肠道症状标志物相关的证据。以粪便200 µg/g为界值,76例(17%)存在EPI,其与HbA1c高4.31 mmol/mol(0.39%)(95% CI 1.35, 7.26)、平均血糖高8%(95% CI 2, 14)、纤维摄入低9%(95% CI 1, 17)及能量摄入低8%(95% CI 1, 15)相关。在这一相对健康的1型糖尿病人群中,未发现与临床参数相关的证据,不支持将FE用于EPI常规筛查。低FE水平的高发生率及其与较低食物摄入和较高血糖水平的关联,说明需要临床关注EPI及其并发症,尤其是在糖尿病病程较长的个体中。
基础研究 (13篇)
Osteoclastogenesis requires precise coordination between mitochondrial bioenergetics and anabolic programs, yet the underlying mechanisms remain unclear. Here, we identify the mitochondrial citrate carrier (CIC, encoded by SLC25A1) as a crucial link that couples mitochondrial bioenergetics to glutathione (GSH)-dependent redox regulation during osteoclastogenesis. CIC expression was elevated in the osteoclast-lineage cells from postmenopausal osteoporosis (PMOP) patients and ovariectomized (OVX) mice, and was positively correlated with classical osteoclast markers. During osteoclastogenesis, CIC was progressively upregulated. Pharmacologic inhibition of CIC with CTPI-2 not only suppressed osteoclastogenesis but also disrupted core metabolic processes, including tricarboxylic acid cycle engagement, amino acid biosynthesis, and mitochondrial respiration. Integrative transcriptomic and metabolomic profiling further revealed a compensatory shift toward enhanced GSH synthesis. Mechanistically, CIC associated with the glutamate-cysteine ligase modifier subunit (GCLM), linking mitochondrial metabolic regulation to the GSH synthetic machinery. CIC inhibition increased GCL activity, intracellular GSH content, and the GSH/GSSG ratio, accompanied by reduced reactive oxygen species accumulation. The functional importance of the GSH axis was evident, as GCL inhibition by buthionine sulfoximine partially reversed the anti-osteoclastogenic effects of CIC inhibition. Consistently, osteoclast-targeted silencing of CIC in OVX mice mitigated bone loss. Collectively, these findings support a role for CIC as a metabolic integrator of energy and redox metabolism in osteoclasts, and highlight its potential as a candidate target for limiting excessive bone resorption in PMOP.
中文摘要:破骨细胞形成需要线粒体生物能量代谢与合成代谢程序之间的精确协调,其机制尚不清楚。研究确认线粒体柠檬酸载体(CIC,由SLC25A1编码)是破骨细胞形成过程中将线粒体生物能量代谢与谷胱甘肽(GSH)依赖性氧化还原调控耦联起来的关键环节。在绝经后骨质疏松(PMOP)患者和去卵巢(OVX)小鼠的破骨细胞谱系细胞中,CIC表达升高,并与经典破骨细胞标志物呈正相关。破骨细胞形成过程中CIC逐步上调。用CTPI-2药理学抑制CIC不仅抑制破骨细胞形成,还破坏核心代谢过程,包括三羧酸循环参与、氨基酸生物合成和线粒体呼吸。转录组与代谢组整合分析显示向增强GSH合成的代偿性转变。机制上,CIC与谷氨酸-半胱氨酸连接酶修饰亚基(GCLM)结合,将线粒体代谢调控与GSH合成机制连接起来。抑制CIC可提高GCL活性、细胞内GSH含量和GSH/GSSG比值,并伴随活性氧累积减少。GSH轴的功能重要性得到体现:用丁硫氨酸亚砜亚胺抑制GCL可部分逆转CIC抑制的抗破骨细胞生成作用。在OVX小鼠中靶向破骨细胞沉默CIC可减轻骨丢失。这些发现支持CIC作为破骨细胞能量与氧化还原代谢的代谢整合因子,并提示其作为限制PMOP过度骨吸收的候选靶点。
Secondary hyperparathyroidism is a major contributor to skeletal fragility in chronic kidney disease, yet fracture risk remains high despite parathyroid hormone-lowering therapy. In a rat model of chronic kidney disease, Allen et al. showed that combining the prebiotic fiber inulin with a calcimimetic further suppresses elevated bone turnover while improving cortical bone architecture and mechanical properties. These findings highlight the potential of gut-targeted interventions to complement established parathyroid hormone-lowering strategies for improving skeletal health.
中文摘要:继发性甲状旁腺功能亢进是慢性肾脏病中骨骼脆性的主要驱动因素,但即使接受降低甲状旁腺激素的治疗,骨折风险仍居高不下。Allen等人在慢性肾脏病大鼠模型中发现,将益生元纤维菊粉与拟钙剂联合使用,可进一步抑制升高的骨转换,同时改善皮质骨结构和力学性能。这些结果提示,靶向肠道的干预有望补充现有的降低甲状旁腺激素策略,以改善骨骼健康。
Type 2 diabetic osteoporosis (T2DOP) features impaired bone quality and high fracture risk, with unclear pathogenesis and limited targeted therapies. This study explored the therapeutic effect and molecular mechanism of kaempferol against T2DOP via m⁶A modification and ferritinophagy-dependent ferroptosis using bioinformatic, cellular and animal approaches. We analyzed the single-cell RNA-seq dataset GSE212726, and predicted core targets of kaempferol through network pharmacology and molecular docking. A high-glucose-high-fat (HGHF)-induced T2DOP cellular model and streptozotocin plus high-fat diet-induced mouse T2DOP model were established for functional verification with multiple molecular assays and DC-Y13-27 (a selective YTHDF2 antagonist) rescue experiments. We found ferritinophagy and ferroptosis were highly activated in T2DOP-derived BMSCs. HGHF triggered ferroptosis, disrupted BMSC functions and osteogenic-adipogenic balance, which was rescued by kaempferol. Mechanistically, kaempferol elevates METTL3 expression to promote m⁶A modification of PTEN mRNA. Subsequent recognition of methylated PTEN by YTHDF2 accelerates PTEN degradation, which further activates PI3K/AKT signaling and ultimately suppresses ferritinophagy-triggered ferroptosis. In vivo, kaempferol alleviated bone microstructure deterioration in T2DOP mice, while DC-Y13-27 reversed these protective effects. In summary, kaempferol alleviates T2DOP by suppressing ferritinophagy-dependent ferroptosis via the METTL3/YTHDF2/PTEN/PI3K/AKT axis, offering a promising therapeutic candidate for T2DOP.
中文摘要:2型糖尿病性骨质疏松(T2DOP)表现为骨质量受损和骨折风险升高,发病机制尚不明确,靶向治疗有限。本研究通过生物信息学、细胞和动物方法,探讨山奈酚经m⁶A修饰及铁蛋白自噬依赖性铁死亡对抗T2DOP的治疗作用与分子机制。我们分析单细胞RNA测序数据集GSE212726,并通过网络药理学和分子对接预测山奈酚的核心靶点。建立高糖高脂(HGHF)诱导的T2DOP细胞模型和链脲佐菌素联合高脂饮食诱导的小鼠T2DOP模型,用多种分子实验和DC-Y13-27(选择性YTHDF2拮抗剂)挽救实验进行功能验证。我们发现T2DOP来源BMSCs中铁蛋白自噬和铁死亡高度激活。HGHF触发铁死亡,破坏BMSC功能及成骨-成脂平衡,山奈酚可逆转上述改变。机制上,山奈酚升高METTL3表达,促进PTEN mRNA的m⁶A修饰。随后YTHDF2识别甲基化PTEN并加速其降解,进一步激活PI3K/AKT信号,最终抑制铁蛋白自噬触发的铁死亡。体内实验中,山奈酚改善T2DOP小鼠骨微结构退化,DC-Y13-27逆转这些保护作用。山奈酚通过METTL3/YTHDF2/PTEN/PI3K/AKT轴抑制铁蛋白自噬依赖性铁死亡,从而缓解T2DOP,提示其可作为T2DOP有前景的治疗候选。
With accelerating population aging, age-related bone loss, osteoporosis, and delayed bone defect repair have become major challenges in regenerative medicine. Bone aging is not caused by the decline of a single cell type, but is a multilevel pathological process driven by the continuous coupling and mutual reinforcement of intracellular damage accumulation, senescence signal propagation, and microenvironmental deterioration. Based on established aging theories, this review integrates regenerative impairment in aged bone into three interconnected pathological cycles from the perspectives of dynamic feedback and regenerative intervention. Intracellular damage and homeostatic imbalance promote cellular senescence; senescent cells spread senescence signals through SASP and immune dysregulation, inducing abnormalities in metabolism, extracellular matrix (ECM) structure, and intercellular communication; the deteriorated microenvironment then further aggravates intracellular damage and homeostatic disruption, forming a self-reinforcing pathological loop. Within this framework, we summarize biomaterial strategies targeting intracellular damage, senescent cells and SASP-mediated propagation, and the aged microenvironment, and discuss multifunctional and responsive materials for staged or multi-level intervention. This framework organizes dispersed aging mechanisms into a dynamic network of feedback relationships and actionable nodes, providing guidance for mechanism-oriented biomaterial design and strategy selection in aged bone regeneration.
中文摘要:随着人口老龄化加速,年龄相关骨丢失、骨质疏松和骨缺损修复延迟已成为再生医学的重要难题。骨衰老并非单一细胞类型衰退所致,而是细胞内损伤累积、衰老信号传播与微环境恶化持续耦合、相互强化所驱动的多层次病理过程。基于既有衰老理论,从动态反馈与再生干预角度,可将老年骨再生受损整合为三个相互关联的病理循环。细胞内损伤与稳态失衡促进细胞衰老;衰老细胞通过SASP和免疫失调传播衰老信号,诱导代谢、细胞外基质结构及细胞间通讯异常;恶化后的微环境又进一步加重细胞内损伤与稳态破坏,形成自我强化的病理环路。在此框架下,总结针对细胞内损伤、衰老细胞及SASP介导传播、衰老微环境的生物材料策略,并讨论用于分期或多层次干预的多功能与响应性材料。该框架将分散的衰老机制组织为具有反馈关系和可干预节点的动态网络,为老年骨再生中面向机制的生物材料设计与策略选择提供指导。
Chronic kidney disease (CKD) has devastating effects on the skeletal system, resulting in an increased fracture risk. CKD results in the buildup of metabolites in the blood (often referred to as uremic toxins), and several uremic toxins have been linked to adverse skeletal outcomes. We have shown that dietary fiber inulin reduced uremic toxins and had a positive effect on bone. Here, we determine whether combining inulin with parathyroid hormone (PTH)-lowering therapies could improve skeletal properties beyond either therapy alone. An animal model of CKD-mineral bone disorder (CKD-MBD) (Cy/+ rats) was treated with or without inulin in the presence or absence of the PTH-suppressing agents (KP-2326, an analogue of the calcimimetic etelcalcetide, or 2% calcium). Key outcome measures included bone architecture, bone remodeling, mechanical properties and serum biomarkers. Dietary inulin groups had lower circulating levels of the uremic toxin p-cresol sulfate and higher circulating butyrate levels, indicating diet-induced differences in gut-derived metabolites. Combining inulin with KP-2326 resulted in lower cortical bone porosity than that in untreated animals and lower trabecular bone turnover (relative to untreated animals) than did either treatment alone. Combining inulin with KP-2326 led to improved mechanical properties. Combining inulin with calcium treatment suppressed bone turnover below healthy control levels. The improvement in bone remodeling and mechanical properties speaks favorably for combining dietary fiber intervention with calcimimetics for reducing the skeletal deterioration in CKD with hyperparathyroidism.
中文摘要:慢性肾脏病(CKD)对骨骼系统有严重破坏作用,导致骨折风险增加。CKD导致代谢物在血液中蓄积(常称为尿毒症毒素),多种尿毒症毒素与不良骨骼结局相关。我们已显示膳食纤维菊粉可降低尿毒症毒素并对骨产生积极作用。此处,我们确定将菊粉与降低甲状旁腺激素(PTH)的治疗联合是否可较任一单药治疗进一步改善骨骼特性。采用CKD-矿物质骨异常(CKD-MBD)动物模型(Cy/+大鼠),在有或无菊粉条件下,联合或不联合PTH抑制药物(KP-2326,拟钙剂etelcalcetide的类似物,或2%钙)进行处理。关键结局指标包括骨结构、骨重建、力学性能和血清生物标志物。膳食菊粉组循环尿毒症毒素对甲酚硫酸盐水平较低,循环丁酸水平较高,表明饮食诱导的肠源性代谢物差异。菊粉联合KP-2326使皮质骨孔隙率低于未治疗动物,并使骨小梁骨转换低于未治疗动物,且低于任一单药治疗。菊粉联合KP-2326改善力学性能。菊粉联合钙治疗将骨转换抑制至低于健康对照水平。骨重建和力学性能的改善支持将膳食纤维干预与拟钙剂联合用于减轻伴甲状旁腺功能亢进的CKD中的骨骼恶化。
The treatment of bone defects in osteoporotic (OP) patients remain a significant clinical challenge. The most important and challenging task is to promote sufficient bone formation in the early stage and effectively inhibit bone resorption all period of bone healing. Unfortunately, the efficacy of current strategies falls short of meeting this requirement. In this study, we developed a dual-delivery system that allows spatiotemporal release of bone marrow stem cell-derived exosomes (BMSC-Exo) and alendronate (Aln) by core-shell nanofiber to match the spatiotemporal dynamics of bone healing and effectively treat OP bone defects. Core-shell polycaprolactone/polyvinyl alcohol (P/PVA) nanofibers were fabricated through coaxial electrospinning, incorporating Aln within the core layer and BMSC-Exo functionalized onto the surface of nanofiber via chemical modification with polyethyleneimine (PEI). Physicochemical characterization confirmed the successful fabrication of PEI@P/PVA-Aln nanofibers, which exhibited excellent mechanical strength (22.77 MPa), hydrophilicity (9.66°), and enabled the spatiotemporal release of BMSC-Exo and Aln. In vitro experiments showed that Exo-PEI@P/PVA-Aln scaffold effectively promoted osteogenic differentiation by miR-486 in the BMSC-Exo through regulation of the PTEN/AKT signaling axis and significantly reduced osteoclastic differentiation. Under a rat OP cranial defect model, the Exo-PEI@P/PVA-Aln scaffold demonstrated substantially enhanced bone repair efficiency after 4 and 10 weeks. To conclude, our results showed that the dual delivery of BMSC-Exo and Aln with spatiotemporal release orchestrates osteoblastic and osteoclastic activity, providing a potential strategy to facilitate the regeneration of OP bone defects.
中文摘要:骨质疏松(OP)患者骨缺损的治疗仍是临床难题。关键且具挑战性的任务是早期促进足够骨形成,并在整个骨愈合期有效抑制骨吸收。现有策略的疗效难以满足这一要求。本研究构建了核壳纳米纤维双递送系统,可时空释放骨髓干细胞来源外泌体(BMSC-Exo)和阿仑膦酸钠(Aln),以匹配骨愈合的时空动态并有效治疗OP骨缺损。采用同轴静电纺丝制备核壳聚己内酯/聚乙烯醇(P/PVA)纳米纤维,将Aln载入核心层,并通过聚乙烯亚胺(PEI)化学修饰将BMSC-Exo功能化于纳米纤维表面。理化表征证实PEI@P/PVA-Aln纳米纤维制备成功,其具有优良的机械强度(22.77 MPa)和亲水性(9.66°),并能时空释放BMSC-Exo和Aln。体外实验显示,Exo-PEI@P/PVA-Aln支架通过BMSC-Exo中的miR-486调控PTEN/AKT信号轴,有效促进成骨分化,并显著降低破骨细胞分化。在大鼠OP颅骨缺损模型中,Exo-PEI@P/PVA-Aln支架在4周和10周后均显著提高骨修复效率。结果表明,BMSC-Exo与Aln的时空双递送可协调成骨细胞和破骨细胞活动,为促进OP骨缺损再生提供了潜在策略。
Bisphosphonates (BPs) are the most widely used anti-resorptive agents and first-line drugs for managing bone-related diseases, such as osteoporosis, Paget disease of bone, and bone metastatic cancer. BPs are known to inhibit osteoclasts' functions, and recent studies have highlighted the importance of macroautophagy/autophagy in osteoclasts. However, the involvement of autophagy in BP-mediated inhibition of osteoclast functions remains unclear. In this study, we showed that BPs inhibit the bone resorptive functions of osteoclasts by blocking autophagy. At the non-apoptotic doses, zoledronic acid (ZOL) inhibited autophagy by blocking autophagic flux and delaying the degradation of autophagy-related proteins. ZOL also prevented the cleavage and secretion of secretory proteins such as CTSK, ACP5/TRAP, and MMP9 essential for bone resorption. Mechanistically, ZOL inhibits the prenylation of the RAB7 small GTPase, a key protein that is required for autolysosome formation. In vivo studies showed that osteoclast-specific rab7 conditional knockout mice exhibited osteopetrotic phenotypes. These findings provide insights into how BPs disrupt osteoclast function by blocking autophagy and suggest that targeting autophagy in osteoclasts could be a potential therapeutic approach for bone-related diseases.Abbreviations: ACP5/TRAP: acid phosphatase 5, tartrate resistant, ATG: autophagy related, 54 BafA1: bafilomycin A1, BECN1: beclin 1, BMM: bone marrow-derived macrophage, CQ: 55 chloroquine, CSF1/M-CSF: colony stimulating factor 1, CTSK: cathepsin K, CTX-I: C-terminal 56 telopeptide of type I collagen, FPPS: farnesyl pyrophosphate synthase, GFP: green fluorescent 57 protein, GGTI: geranylgeranyltransferase I inhibitor, LAMP1: lysosome associated membrane 58 protein 1, MAP1LC3/LC3: microtubule associated protein 1 light chain 3, MMP9: matrix 59 metallopeptidase 9, N-BPs: nitrogen-containing bisphosphonates, P1NP: procollagen type I N- 60 terminal propeptide, PGGT1B: protein geranylgeranyl transferase type I subunit beta, RABGGTB: 61 Rab geranylgeranyltransferase subunit beta, RFP: red fluorescent protein, SQSTM1/p62: 62 sequestosome 1, TNFSF11/RANKL: TNF superfamily member 11, ZOL: zoledronic acid.
中文摘要:双膦酸盐(BPs)是使用最广泛的抗骨吸收药物,也是骨质疏松症、Paget骨病和骨转移癌等骨相关疾病的一线治疗药物。已知BPs可抑制破骨细胞功能,近期研究强调了大自噬/自噬在破骨细胞中的重要性,但自噬是否参与BP介导的破骨细胞功能抑制仍不清楚。研究显示,BPs通过阻断自噬抑制破骨细胞的骨吸收功能。在非凋亡剂量下,唑来膦酸(ZOL)通过阻断自噬流和延迟自噬相关蛋白降解来抑制自噬。ZOL还阻止骨吸收所必需的分泌蛋白如CTSK、ACP5/TRAP和MMP9的剪切和分泌。机制上,ZOL抑制RAB7小GTP酶异戊二烯化,而RAB7是自噬溶酶体形成所需的关键蛋白。体内研究显示,破骨细胞特异性rab7条件性敲除小鼠表现出骨硬化表型。这些发现揭示了BPs如何通过阻断自噬破坏破骨细胞功能,并提示靶向破骨细胞自噬可能成为骨相关疾病的潜在治疗策略。缩略语:ACP5/TRAP:抗酒石酸酸性磷酸酶5;ATG:自噬相关;BafA1:巴弗洛霉素A1;BECN1:Beclin 1;BMM:骨髓来源巨噬细胞;CQ:氯喹;CSF1/M-CSF:集落刺激因子1;CTSK:组织蛋白酶K;CTX-I:I型胶原C端端肽;FPPS:法尼基焦磷酸合酶;GFP:绿色荧光蛋白;GGTI:香叶基香叶基转移酶I抑制剂;LAMP1:溶酶体相关膜蛋白1;MAP1LC3/LC3:微管相关蛋白1轻链3;MMP9:基质金属蛋白酶9;N-BPs:含氮双膦酸盐;P1NP:I型前胶原N端前肽;PGGT1B:蛋白香叶基香叶基转移酶I型亚基β;RABGGTB:Rab香叶基香叶基转移酶亚基β;RFP:红色荧光蛋白;SQSTM1/p62:螯合体1;TNFSF11/RANKL:TNF超家族成员11;ZOL:唑来膦酸。
Functional bone regeneration relies on cross talk between nerves and bone, yet the regulatory mechanisms linking Schwann cells (SCs) to osteoporotic bone marrow mesenchymal stem cells (OP-BMSCs) remain unclear. This study demonstrated that SC-Exosomes (Exos) promoted the osteogenic differentiation of OP-BMSCs, and miRNA-mRNA sequencing revealed that SC-Exos, which contained the key mediator miR-212-3p, facilitated osteogenesis by suppressing the ferroptosis pathway in OP-BMSCs. miR-212-3p overexpression combined with transferrin (TF) knockdown or overexpression confirmed that miR-212-3p suppresses TF expression and validated the role of the miR-212-3p/TF axis, which maintained iron homeostasis in BMSCs, alleviated iron overload and oxidative stress, and promoted osteogenic differentiation. Furthermore, an injectable SC-Exos-loaded gelatin methacrylate hydrogel (SC-Exos/GelMA) targeting BMSCs was constructed. In vitro, SC-Exos/GelMA enabled sustained release of Exos and promoted BMSCs osteogenesis. In vivo, SC-Exos/GelMA downregulated TF expression via the miR-212-3p/TF axis, mitigated ferroptosis, restored iron homeostasis, accelerated angiogenesis/neurogenesis, and promoted bone regeneration. This study not only elucidated the role of the miR-212-3p/TF axis in the modulation of BMSCs iron homeostasis, but also constructed an injectable SC-Exos/GelMA hydrogel for bone regeneration, offering mechanistic insights and a translational therapeutic strategy for bone regeneration in clinic.
中文摘要:功能性骨再生依赖神经与骨之间的交互,但施万细胞(SCs)与骨质疏松骨髓间充质干细胞(OP-BMSCs)之间的调控机制仍不清楚。该研究显示,施万细胞来源外泌体(SC-Exos)促进OP-BMSCs成骨分化,miRNA-mRNA测序发现含关键介质miR-212-3p的SC-Exos通过抑制OP-BMSCs铁死亡通路促进成骨。miR-212-3p过表达联合转铁蛋白(TF)敲低或过表达证实miR-212-3p抑制TF表达,并验证miR-212-3p/TF轴维持BMSCs铁稳态、减轻铁过载与氧化应激、促进成骨分化的作用。研究进一步构建了靶向BMSCs的可注射SC-Exos负载甲基丙烯酰化明胶水凝胶(SC-Exos/GelMA)。体外,SC-Exos/GelMA可持续释放Exos并促进BMSCs成骨。体内,SC-Exos/GelMA经miR-212-3p/TF轴下调TF表达,减轻铁死亡,恢复铁稳态,促进血管生成/神经发生并促进骨再生。该研究阐明了miR-212-3p/TF轴在BMSCs铁稳态调控中的作用,也构建了用于骨再生的可注射SC-Exos/GelMA水凝胶,为临床骨再生提供机制认识和转化治疗策略。
The loss of endogenous bioelectrical rhythms in bone is a critical driver of osteoporosis initiation and progression. Reconstructing bioelectrical rhythms synchronized with mechanical stimulation is critical for restoring bone homeostasis. Here, we propose a motion-activated skeletal "bioelectrical pacemaker" strategy that microfluidically encapsulates alendronate-modified BaTiO3 piezoelectric nanoparticles (BTO@ALN) within chitosan/alginate core-shell hydrogel microspheres, enabling gastric protection, pH-responsive intestinal release, and noninvasive oral delivery with systemic skeletal enrichment. Upon skeletal enrichment, the piezoelectric units compensate for impaired electrophysiological responsiveness in osteoporotic bone and are activated by physiological mechanical stimuli during daily motion to generate movement-synchronized dynamic bioelectrical signals. This process reconstructs endogenous bone bioelectrical rhythms systemically, thereby restoring bone homeostasis. Experimentally, BTO@ALN exhibited 6.8-fold higher skeletal accumulation than controls; oral administration led to a 52% increase in bone piezoelectric performance within 24 h, accompanied by concurrent suppression of osteoclast activity and promotion of osteogenesis. When combined with low-intensity exercise, motion-triggered piezoelectric output further amplified therapeutic efficacy, resulting in a 2.4-fold increase in osteogenesis and a 1.5-fold stronger suppression of bone resorption. Collectively, this closed-loop strategy integrating oral delivery, bone-targeted enrichment, and motion-synchronized electrical activation systematically re-establishes endogenous bone bioelectrical rhythms, introducing a strategy for osteoporosis based on electrophysiological regulation of bone.
中文摘要:骨内源性生物电节律的丧失是骨质疏松发生和进展的关键驱动因素。重建与机械刺激同步的生物电节律对于恢复骨稳态至关重要。我们提出一种运动激活的骨骼「生物电起搏器」策略,通过微流控将阿仑膦酸修饰的BaTiO3压电纳米颗粒(BTO@ALN)封装于壳聚糖/海藻酸核壳水凝胶微球中,实现胃内保护、pH响应性肠道释放、无创口服递送以及全身骨骼富集。骨骼富集后,压电单元补偿骨质疏松骨中受损的电生理响应,并在日常运动中的生理机械刺激下被激活,产生与运动同步的动态生物电信号。该过程在全身层面重建内源性骨生物电节律,从而恢复骨稳态。实验显示,BTO@ALN的骨骼蓄积量较对照高6.8倍;口服给药后24小时内骨压电性能提高52%,同时抑制破骨细胞活性并促进成骨。与低强度运动联合时,运动触发的压电输出进一步增强疗效,使成骨提高2.4倍,对骨吸收的抑制增强1.5倍。该闭环策略整合口服递送、骨靶向富集和运动同步电激活,系统性地重建内源性骨生物电节律,为基于骨电生理调控的骨质疏松治疗提供了新思路。
Long-term bisphosphonates (BPs) are widely used to treat osteoporosis, however, they are paradoxically associated with the development of atypical femoral fractures (AFFs), which often characterized by impaired healing. In this study, we induced an AFF model using zoledronate (ZOL) administration in ovariectomized (OVX) osteoporotic rats, following a unilateral femoral fracture. Here we identified that a local pro-senescent microenvironment causes persistent inflammation and impairs effective regeneration in rat AFFs. Molecular hydrogen has demonstrated anti-senescence and anti-inflammatory properties, yet its effects on AFF healing remain unexplored. Therefore, we treated the AFF rats with hydrogen rich water (HRW). The outcomes were assessed by radiographs, histology, micro-CT, and biomechanical tests. The fracture microenvironment was analyzed based on the indicators of senescence, fibrosis, macrophage polarization, cytokine expression, and angiogenesis. We found that HRW significantly promoted callus bridging and resolved the non-union gap in ZOL-induced AFFs, whereas the ZOL group exhibited persistent fibrous tissue. Micro-CT and biomechanical tests confirmed that HRW did not compromise the mechanical strength of the bone mass elevated by BPs. Instead, HRW specifically attenuated the local senescent microenvironment, with a reduction in both SA-β-gal activity and the expression of p16, p21 within the fracture gap. This was accompanied by clearance of pathological fibroblasts, a shift from pro-inflammatory M1 to anti-inflammatory M2 macrophages, a rebalanced cytokine profile, and restored formation of osteogenesis-coupled type-H vessels. Our findings confirm that molecular hydrogen facilitates AFFs healing by locally reversing the senescent microenvironment, rather than boosting systemic bone formation. This creates a favorable niche for callus bridging, representing a novel therapeutic strategy for fracture delayed union or non-union.
中文摘要:长期使用双膦酸盐(BPs)广泛用于骨质疏松治疗,却与不典型股骨骨折(AFFs)的发生相关,这类骨折常表现为愈合受损。研究在去卵巢(OVX)骨质疏松大鼠中给予唑来膦酸(ZOL)并造成单侧股骨骨折,建立AFF模型。结果发现,局部促衰老微环境导致持续性炎症并损害大鼠AFF的有效再生。分子氢具有抗衰老和抗炎特性,但其对AFF愈合的作用尚未被探讨。因此,研究用富氢水(HRW)治疗AFF大鼠,并通过X线、组织学、micro-CT和生物力学测试评估结局。围绕衰老、纤维化、巨噬细胞极化、细胞因子表达和血管生成指标分析骨折微环境。结果显示,HRW显著促进骨痂桥接并消除ZOL诱导AFF中的骨不连间隙,而ZOL组持续存在纤维组织。Micro-CT和生物力学测试证实,HRW未削弱BPs提高的骨量所具有的机械强度。HRW反而特异性减轻局部衰老微环境,使骨折间隙内SA-β-gal活性和p16、p21表达均下降。伴随病理性成纤维细胞清除、促炎M1向抗炎M2巨噬细胞转变、细胞因子谱重新平衡,以及成骨耦联的H型血管形成恢复。研究结果证实,分子氢通过局部逆转衰老微环境促进AFF愈合,而非增强全身骨形成。这为骨痂桥接创造了有利微环境,为骨折延迟愈合或骨不连提供了新的治疗策略。
Achieving optimal peak bone mass (PBM) during adolescence through adequate intake of trace element such as selenium is crucial for reducing osteoporosis risk in later life. We previously developed novel functionalized selenium nanoparticles (Cs4-SeNPs) utilizing polysaccharide-protein complex isolated from Cordyceps sinensis for prevention of osteoporosis. The gut microbiota, functioning as the "second gene pool", plays a crucial role in maintaining bone homeostasis. However, how Cs4-SeNPs regulate bone metabolism via the gut microbiota-bone axis remains unclear. To elucidate how the gut microbiota and microbial metabolites mediate the bone-promoting effect of Cs4-SeNPs. Growing mice model was used to assess the effect of Cs4-SeNPs on bone development. Metagenomics, metabolomics, and proteomics analyses were conducted to uncover the mechanism of action of Cs4-SeNPs. In vitro osteoblast and osteoclast models were employed to validate the effects of key gut microbial metabolites regulated by Cs4-SeNPs on osteogenesis and osteoclastogenesis. Pseudo-germ-free mice model treated with antibiotics was employed to determine the role of gut microbiota in bone-promoting effects of Cs4-SeNPs. We found that Cs4-SeNPs significantly enhanced bone mass in growing mice, as evidenced by improved bone microarchitecture and increased expression of bone extracellular matrix-related markers. Notably, antibiotic treatment-induced microbial depletion abolished the effects of Cs4-SeNPs on bone development in growing mice. Increased abundance of beneficial gut bacterial genera, notably Adlercreutzia and Parvibacter, were observed following Cs4-SeNPs administration. Proteomics analysis and subsequent verification experiments demonstrated that Cs4-SeNPs inhibited the TNF-R1/TAB2/NF-κB inflammatory pathway and upregulated the expression of antioxidant proteins including SERPINA3K, GPX1, and SOD in the bone tissue. Metabolomic analysis revealed that Cs4-SeNPs treatment significantly elevated fecal and serum levels of two key metabolites: kynurenic acid and trehalose. Further in vitro studies confirmed that kynurenic acid and trehalose could reproduce the effects of Cs4-SeNPs on osteoblastic and osteoclastic differentiation. Our findings suggest that Cs4-SeNPs optimize PBM and promote bone development in growing mice by improving the osteoblast/osteoclast balance via the modulation of the inflammatory TNF-R1/TAB2/NF-κB axis and the enhancement of antioxidant activity through the elevated levels of gut microbial metabolites kynurenic acid and trehalose in a gut microbiota-dependent manner.
中文摘要:青春期通过充足摄入硒等微量元素达到最佳峰值骨量(PBM),对降低成年后骨质疏松风险至关重要。我们此前利用从冬虫夏草中分离的多糖-蛋白复合物开发了新型功能化硒纳米颗粒(Cs4-SeNPs),用于预防骨质疏松。肠道菌群作为「第二基因库」,在维持骨稳态中起关键作用。但Cs4-SeNPs如何通过肠道菌群-骨轴调节骨代谢仍不清楚。为阐明肠道菌群及微生物代谢物如何介导Cs4-SeNPs的促骨效应,采用生长期小鼠模型评估Cs4-SeNPs对骨发育的影响。通过宏基因组学、代谢组学和蛋白质组学分析揭示Cs4-SeNPs的作用机制。采用体外成骨细胞和破骨细胞模型验证Cs4-SeNPs调控的关键肠道微生物代谢物对成骨和破骨形成的影响。采用抗生素处理的伪无菌小鼠模型确定肠道菌群在Cs4-SeNPs促骨效应中的作用。发现Cs4-SeNPs显著提高生长期小鼠骨量,表现为骨微结构改善和骨细胞外基质相关标志物表达增加。抗生素处理导致的微生物耗竭消除了Cs4-SeNPs对生长期小鼠骨发育的影响。Cs4-SeNPs给药后观察到有益肠道菌属丰度增加,尤其是Adlercreutzia和Parvibacter。蛋白质组学分析及后续验证实验表明,Cs4-SeNPs抑制TNF-R1/TAB2/NF-κB炎症通路,并上调骨组织中SERPINA3K、GPX1和SOD等抗氧化蛋白的表达。代谢组学分析显示,Cs4-SeNPs处理显著升高粪便和血清中两种关键代谢物犬尿喹啉酸和海藻糖的水平。进一步体外研究证实,犬尿喹啉酸和海藻糖可重现Cs4-SeNPs对成骨细胞和破骨细胞分化的影响。研究结果提示,Cs4-SeNPs以肠道菌群依赖的方式,通过调节炎症性TNF-R1/TAB2/NF-κB轴改善成骨/破骨平衡,并通过升高肠道微生物代谢物犬尿喹啉酸和海藻糖水平增强抗氧化活性,从而优化PBM并促进生长期小鼠骨发育。
Osteo-immune diseases require immunoregulatory strategies that suppress pathological inflammation and restore the balance between immunity and bone remodeling. Here, we demonstrate that a subcutaneously implanted bone-mimetic scaffold generates an ectopic osteo-immune niche that confers systemic protection against osteoporosis. Following implantation, the scaffold elicited a structured foreign body response that organized recruited host cells into a compartmentalized immune microenvironment. And this osteo-immune niche is associated with regulatory immune features, including a FOXP3+ regulatory T cell (Treg)-enriched profile. In an osteoporosis model, this approach was linked to attenuation of systemic bone loss together with immunological changes consistent with an increased Treg population, suggesting that local niche engineering can influence whole-body skeletal health. Collectively, these findings support bone mimetic, immune instructive biomaterial scaffold as a potential therapeutic platform for osteo-immune disorders without the need for complex cell processing.
中文摘要:骨免疫疾病需要既能抑制病理性炎症、又能恢复免疫与骨重建平衡的免疫调节策略。研究显示,皮下植入的仿骨支架可形成异位骨免疫微环境,对骨质疏松产生全身性保护作用。植入后,支架引发结构化的异物反应,使募集来的宿主细胞组织成区室化的免疫微环境。该骨免疫微环境具有调节性免疫特征,包括富含FOXP3+调节性T细胞(Treg)的表型。在骨质疏松模型中,这一方法伴随全身性骨丢失减轻,并出现与Treg群体增加一致的免疫学变化,提示局部微环境工程可影响全身骨骼健康。总体而言,这些结果支持将仿骨、具有免疫指导作用的生物材料支架作为骨免疫疾病的潜在治疗平台,且无需复杂的细胞处理。
Postmenopausal osteoporosis (PMOP), driven primarily by estrogen deficiency, represents a major public health challenge. Although estrogen's anti-resorptive effects are well established, the direct osteogenic actions by which it regulates the osteogenic differentiation of mesenchymal stem cells (MSCs) remain poorly understood. This study aimed to elucidate a novel mechanism by which estrogen regulates osteogenic differentiation in MSCs and to identify key downstream molecular events. We employed single-cell RNA sequencing to profile the transcriptional landscape of osteoporotic MSCs. The pro-osteogenic effects of estradiol (E2) were validated in ovariectomized mice and primary mouse bone marrow-derived MSCs through in vitro differentiation assays and mitochondrial functional analyses. Downstream targets of estrogen receptor were identified by integrating CUT&Tag-seq with transcriptomic data and validated using conditional knockout mice. Protein interactions and phosphorylation sites were mapped via co-immunoprecipitation, mass spectrometry, site-directed mutagenesis, and mitochondrial morphology assays. Osteoporotic MSCs displayed concurrent impairments in osteogenic differentiation and mitochondrial function. E2 stimulated mitochondrial fission, enhanced maximal respiration, and induced DRP1 translocation to mitochondria. The combined evidence from our CUT&Tag-seq, RNA-seq, and the additional CUT&Tag-qPCR and ERα knockdown data supports the conclusion that Pdk4 is a direct transcriptional target of ERα. This finding is further corroborated by the compromised osteogenesis observed in conditional Pdk4 knockout mice. Mechanistically, PDK4 catalyzed MYH9 phosphorylation at serine 1943, thereby facilitating DRP1 recruitment to mitochondria and subsequent fission. Both pharmacological inhibition of PDK4 and introduction of the phosphorylation-deficient MYH9 S1943A mutant abolished the E2-induced effects. Notably, Pdk4 overexpression in ovariectomized mice reversed bone loss in the absence of exogenous estrogen. This study identifies an unrecognized ERα-PDK4-MYH9 signaling axis through which estrogen drives mitochondrial fission to promote osteogenic differentiation of MSCs. These findings expand the current understanding of estrogen's skeletal actions by revealing a pro-osteogenic effect on MSCs, and suggest PDK4 as a potential candidate for therapeutic exploration in PMOP.
中文摘要:绝经后骨质疏松(PMOP)主要由雌激素缺乏驱动,是重要公共卫生挑战。雌激素的抗骨吸收作用已较明确,但其调控间充质干细胞(MSCs)成骨分化的直接成骨作用仍了解不足。为阐明雌激素调控MSCs成骨分化的新机制并识别关键下游分子事件,采用单细胞RNA测序描绘骨质疏松MSCs的转录图谱。通过体外分化实验和线粒体功能分析,在去卵巢小鼠及原代小鼠骨髓来源MSCs中验证雌二醇(E2)的促成骨作用。整合CUT&Tag-seq与转录组数据识别雌激素受体下游靶点,并用条件性敲除小鼠验证。通过免疫共沉淀、质谱、定点突变和线粒体形态实验解析蛋白互作及磷酸化位点。骨质疏松MSCs同时存在成骨分化和线粒体功能受损。E2刺激线粒体分裂,增强最大呼吸,并诱导DRP1转位至线粒体。CUT&Tag-seq、RNA-seq以及补充的CUT&Tag-qPCR和ERα敲低数据共同支持Pdk4是ERα直接转录靶点的结论。条件性Pdk4敲除小鼠成骨受损进一步佐证该发现。机制上,PDK4催化MYH9在丝氨酸1943位点磷酸化,促进DRP1募集至线粒体并引发分裂。药理学抑制PDK4和引入磷酸化缺陷MYH9 S1943A突变体均消除E2诱导的效应。Pdk4过表达可在无外源雌激素情况下逆转去卵巢小鼠骨丢失。该工作识别出此前未被认识的ERα-PDK4-MYH9信号轴,雌激素经该轴驱动线粒体分裂以促进MSCs成骨分化。这些发现通过揭示雌激素对MSCs的促成骨作用拓展了对雌激素骨骼作用的认识,并提示PDK4可作为PMOP治疗探索的潜在候选。
2骨关节炎/软骨 (10篇)
临床研究 (4篇)
This randomized controlled trial evaluated the 12-month outcomes of a single intra-articular injection of autologous adipose-derived stromal vascular fraction (SVF), prepared and administered during the same clinical encounter, for the treatment of moderate-to-severe knee osteoarthritis (OA). To evaluate the efficacy of a single intra-articular injection of 25 million autologous adipose-derived SVF cells for moderate-to-severe knee OA, compared with placebo, at 12 months. The authors hypothesized that SVF-treated patients would demonstrate a significantly greater responder rate based on prespecified clinically meaningful improvements in pain and function derived from composite outcomes of the index and contralateral knees. Randomized controlled trial; Level of evidence, 1. Adults aged 35 to 85 years with symptomatic unilateral or bilateral knee OA were eligible if the index knee demonstrated a Western Ontario and McMaster Universities Osteoarthritis Index pain score of ≥8, an Outerbridge grade of 2 to 4 on magnetic resonance imaging (MRI), and a Kellgren-Lawrence grade of 2 to 4 on radiographs. Autologous adipose-derived SVF was prepared using a point-of-care isolation system during the same clinical encounter, assessed against predefined release criteria, and administered as a single intra-articular injection into the index knee. MRI of the index knee was obtained at baseline and at 12 months. A total of 618 participants were assessed for eligibility, of whom 114 were randomized (SVF, n = 83; placebo, n = 31). At 12 months, a single intra-articular injection of 25 million SVF cells demonstrated statistical superiority over placebo for the primary composite clinical endpoint. The responder rate was 51.8% (43/83) in the SVF group compared with 29% (9/31) in the placebo group (difference, 22.8% [95% CI, 3.5%-42%]; 1-sided P = .0149). No serious investigational device-related adverse events were reported. A single intra-articular injection of 25 million autologous adipose-derived SVF cells resulted in statistically superior and clinically meaningful improvements in pain and function at 12 months compared with placebo, with no serious investigational device-related adverse events reported. IDE 16734; ClinicalTrials.gov NCT04440189.
中文摘要:该随机对照试验评估单次关节腔内注射自体脂肪来源基质血管组分(SVF),在同一个临床就诊过程中制备并给药,治疗中重度膝骨关节炎(OA)的12个月结局。目的是在12个月时评价单次关节腔内注射2500万个自体脂肪来源SVF细胞相较安慰剂治疗中重度膝OA的疗效。作者假设,基于指数膝和对侧膝复合结局中预设的疼痛与功能临床意义改善,SVF治疗患者将显示显著更高的应答率。研究为随机对照试验;证据等级1。35至85岁有症状的单侧或双侧膝OA成人,若指数膝西安大略和麦克马斯特大学骨关节炎指数疼痛评分≥8、磁共振成像(MRI)Outerbridge分级2至4级、X线Kellgren-Lawrence分级2至4级,则符合入选条件。自体脂肪来源SVF在同一个临床就诊过程中使用床旁分离系统制备,按预设放行标准评估,并作为单次关节腔内注射给予指数膝。基线和12个月时获取指数膝MRI。共评估618名参与者的合格性,其中114名被随机分组(SVF组n=83;安慰剂组n=31)。12个月时,单次关节腔内注射2500万个SVF细胞在主要复合临床终点上显示相对安慰剂的统计学优效性。SVF组应答率为51.8%(43/83),安慰剂组为29%(9/31)(差值22.8%[95%CI,3.5%-42%];单侧P=.0149)。未报告与试验器械相关的严重不良事件。与安慰剂相比,单次关节腔内注射2500万个自体脂肪来源SVF细胞在12个月时带来统计学优效且有临床意义的疼痛和功能改善,未报告与试验器械相关的严重不良事件。IDE 16734;ClinicalTrials.gov NCT04440189。
This study aims to determine the association of recognised HFE genotypes with arthropathy fulfilling European Alliance of Associations for Rheumatology (EULAR) haemochromatosis arthropathy (HA) classification criteria (CC), and the contributory role of iron loading. We analysed 373 participants from the EULAR HA inception cohorts: group 1, C282Y homozygous with significant iron overload (n = 154); group 2A, C282Y homozygous without significant iron overload (n = 27); group 2B, other HFE genotypes irrespective of iron status (n = 72); group 3 (osteoarthritis/calcium pyrophosphate arthropathy controls without iron overload (n = 120). Group 2 were selected from rheumatology patients with persistent unexplained joint pain, potential HA, and/or pre-existing genotyping. Between-group comparisons and genotype-stratified analyses were performed. In group 2, associations among ferritin, transferrin saturation, and HA-CC fulfilment were assessed using regression analyses. HA-CC were fulfilled in 71.4% of group 1, 22.2% group 2A, 43.1% group 2B, and 6.7% group 3 (P < .001 all comparisons). Compared with group 3, group 2 demonstrated significantly higher prevalence of HA-CC fulfilment and 5 HA-CC features (P < .003 all items), including participants with H63D variants. Ferritin levels and transferrin saturation were not associated with HA-CC fulfilment odds ratio (OR) 1.000 per 1 µg/L increase, 95% CI: 1.000-1.001, P = .28; OR 0.98 per 1% increase, 95% CI: 0.96-1.01, P = .14, respectively). A substantial proportion of individuals without haemochromatosis but carrying HFE genotypes fulfil EULAR HA-CC, without an association with ferritin levels or transferrin saturation. This supports a potential iron-independent contribution of HFE variants to arthropathy. Although 'haemochromatosis arthropathy' is found in people with genetic haemochromatosis, 'HFE associated arthropathy without genetic haemochromatosis' describes metacarpophalangeal and/or ankle joint disease with any HFE genotype.
中文摘要:本研究旨在确定已识别的HFE基因型与符合欧洲抗风湿病联盟(EULAR)血色病性关节病(HA)分类标准(CC)的关节病之间的关联,以及铁负荷的作用。我们分析了EULAR HA起始队列中的373名参与者:第1组为C282Y纯合且伴显著铁过载者(n=154);第2A组为C282Y纯合但不伴显著铁过载者(n=27);第2B组为其他HFE基因型且不论铁状态者(n=72);第3组为无铁过载的骨关节炎/焦磷酸钙关节病对照(n=120)。第2组选自因持续不明原因关节痛、可能HA和/或已有基因分型的风湿科患者。进行了组间比较和按基因型分层分析。在第2组中,采用回归分析评估铁蛋白、转铁蛋白饱和度与HA-CC符合情况之间的关联。HA-CC符合率在第1组为71.4%,第2A组为22.2%,第2B组为43.1%,第3组为6.7%(所有比较P<.001)。与第3组相比,第2组HA-CC符合率及5项HA-CC特征显著更高(所有项目P<.003),包括携带H63D变异者。铁蛋白水平和转铁蛋白饱和度与HA-CC符合情况无关联(铁蛋白每增加1 µg/L,OR 1.000,95% CI:1.000-1.001,P=.28;转铁蛋白饱和度每增加1%,OR 0.98,95% CI:0.96-1.01,P=.14)。相当比例的无血色病但携带HFE基因型个体符合EULAR HA-CC,且与铁蛋白水平或转铁蛋白饱和度无关联。这支持HFE变异可能以不依赖铁的方式参与关节病。尽管「血色病性关节病」见于遗传性血色病患者,「无遗传性血色病的HFE相关关节病」描述的是任何HFE基因型伴掌指关节和/或踝关节病变。
Clinical outcomes after platelet-rich plasma (PRP) treatment for knee osteoarthritis are inconsistent, and some well-designed trials show no benefit. Whether a standardized multicomponent pathway improves outcomes relative to conventional PRP care is uncertain. To compare the efficacy, safety, satisfaction, and costs of a standardized PRP pathway versus physician-directed conventional PRP care in Kellgren-Lawrence grade I and II knee osteoarthritis. Randomized controlled trial; Level of evidence, 1. At 3 hospitals, 240 patients were randomized 1:1 to a standardized PRP clinical pathway (PRP-CP; n = 120) or physician-directed conventional PRP care (PRP-C; n = 120). PRP-CP combined standardized selection, quality-controlled leukocyte-poor PRP, ultrasound-guided injections, staged rehabilitation, and systematic follow-up. Primary 12-month outcomes were visual analog scale (VAS) pain, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) total, and International Knee Documentation Committee (IKDC) scores; secondary outcomes included achievement of the minimal clinically important difference, satisfaction, adverse events, and costs. At 12 months, PRP-CP produced greater changes than PRP-C in VAS (mean difference [MD], -2.98 [95% CI, -3.64 to -2.32]), WOMAC total (MD, -8.63 [95% CI, -11.35 to -5.90]), and IKDC (MD, 10.25 [95% CI, 8.37 to 12.13]) scores (all P < .001). Achievement of the minimal clinically important difference favored PRP-CP at 3, 6, and 12 months for the VAS and at 6 and 12 months for the IKDC and WOMAC (P < .05). Satisfaction was greater with PRP-CP (odds ratio, 1.79 [95% CI, 1.11-2.89]; P = .017). An adverse event occurred in 17 of 115 patients in the PRP-CP group (14.8%) versus 36 of 113 patients in the PRP-C group (31.9%) (Fisher exact test: P = .003). Mean costs were CN¥15,199.9 versus CN¥14,754.4, respectively; the incremental cost-effectiveness ratio was CN¥66.0 per WOMAC point. Effects were generally consistent across centers, and blinding was maintained. The standardized multicomponent pathway produced greater 12-month improvements in pain and function than conventional PRP care, with fewer adverse events. Because components were bundled and no placebo group was included, the trial does not establish PRP efficacy or component-specific effects.
中文摘要:富血小板血浆(PRP)治疗膝骨关节炎的临床结局并不一致,一些设计良好的试验未显示获益。标准化多组分路径相较常规PRP治疗能否改善结局仍不确定。本研究在Kellgren-Lawrence I级和II级膝骨关节炎患者中比较标准化PRP路径与医生主导的常规PRP治疗在疗效、安全性、满意度和费用方面的差异。随机对照试验;证据等级1。3家医院共240例患者按1:1随机分配至标准化PRP临床路径组(PRP-CP;n=120)或医生主导的常规PRP治疗组(PRP-C;n=120)。PRP-CP整合标准化筛选、质量控制的贫白细胞PRP、超声引导注射、分期康复和系统随访。12个月主要结局为视觉模拟量表(VAS)疼痛、西安大略和麦克马斯特大学骨关节炎指数(WOMAC)总分及国际膝关节文献委员会(IKDC)评分;次要结局包括达到最小临床重要差异、满意度、不良事件和费用。12个月时,PRP-CP较PRP-C在VAS(平均差[MD],-2.98[95% CI,-3.64至-2.32])、WOMAC总分(MD,-8.63[95% CI,-11.35至-5.90])和IKDC(MD,10.25[95% CI,8.37至12.13])评分上产生更大变化(均P < .001)。达到最小临床重要差异在VAS的3、6和12个月以及IKDC和WOMAC的6和12个月支持PRP-CP(P < .05)。PRP-CP满意度更高(比值比,1.79[95% CI,1.11-2.89];P = .017)。PRP-CP组115例中17例发生不良事件(14.8%),PRP-C组113例中36例(31.9%)(Fisher精确检验:P = .003)。平均费用分别为CN¥15,199.9和CN¥14,754.4;增量成本效果比为每WOMAC分CN¥66.0。各中心效应总体一致,盲法得以维持。标准化多组分路径在12个月时对疼痛和功能的改善大于常规PRP治疗,不良事件更少。由于各组分被打包且未设安慰剂组,该试验不能确定PRP的疗效或各组分的特异性效应。
A systematic literature review (SLR) of publications from 2000 to 2022 identified terminology for calcium pyrophosphate crystal deposition (CPPD) and revealed substantial heterogeneity and poor adherence to recommendations. This study aimed to standardise CPPD terminology by developing an international consensus on labels and definitions. Members of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) were invited by email to participate in a 3-round Delphi exercise. A steering committee identified key components of CPPD aetiology, pathophysiology, and clinical presentation among elements appearing in >10% of SLR papers, adding or removing items when scientifically justified. Participants selected preferred labels for each element. Respondents to the first round were invited to subsequent rounds. This paper reports the resulting G-CAN CPPD nomenclature. Consensus was reached for 'calcium pyrophosphate (CPP) crystal' and 'calcium pyrophosphate crystal deposition (CPPD)' to describe the deposition process. The unified term 'calcium pyrophosphate crystal deposition on imaging' was adopted across imaging modalities, whereas 'chondrocalcinosis' was redefined as conventional radiographic cartilage calcification consistent with CPPD. Four clinical manifestations were identified: 'acute CPP crystal arthritis' (with 'flare' for acute episodes), 'chronic CPP crystal arthritis', 'crowned dens syndrome', and 'osteoarthritis with CPPD'; the term 'pseudogout' received no support. The condition is now classified as 'asymptomatic CPPD' or 'CPPD disease' for symptomatic presentations. This G-CAN nomenclature is the first systematic effort to align CPPD terminology with contemporary biological and imaging evidence. By resolving longstanding ambiguities-particularly regarding 'chondrocalcinosis'-it provides a framework for consistent research definitions, clinical trial homogeneity, and improved patient care.
中文摘要:2000至2022年发表文献的系统文献综述(SLR)识别了焦磷酸钙晶体沉积(CPPD)相关术语,并显示术语存在明显异质性且对推荐意见依从性差。该研究旨在通过制定关于名称与定义的国际共识来标准化CPPD术语。痛风、高尿酸血症与晶体相关疾病网络(G-CAN)成员经电子邮件受邀参加三轮德尔菲法。指导委员会在超过10%的SLR文献中出现的要素里确定CPPD病因学、病理生理学和临床表现的关键组成部分,并在有科学依据时增删条目。参与者为每个要素选择偏好的名称。第一轮应答者被邀请参加后续轮次。该文报告由此形成的G-CAN CPPD命名。就用于描述沉积过程的「焦磷酸钙(CPP)晶体」和「焦磷酸钙晶体沉积(CPPD)」达成共识。所有影像学模态采用统一术语「影像学上的焦磷酸钙晶体沉积」,而「软骨钙化」被重新定义为传统X线摄影上符合CPPD的软骨钙化。识别出四种临床表现:「急性CPP晶体关节炎」(急性发作时称「发作」)、「慢性CPP晶体关节炎」、「齿状突加冠综合征」和「伴CPPD的骨关节炎」;「假性痛风」一词未获支持。该病现在分类为「无症状CPPD」,有症状表现则称为「CPPD疾病」。G-CAN命名是首次系统性地使CPPD术语与当代生物学和影像学证据保持一致。通过解决长期存在的歧义,尤其是关于「软骨钙化」的歧义,它为一致的研究定义、临床试验同质性和改善患者照护提供了框架。
基础研究 (6篇)
Degenerative osteoarthritis (OA) of the hip often arises from structural abnormalities that alter load distribution, which leads to progressive chondrolabral damage. Although substantial advances have been made, the existing terminology in the field of hip preservation remains heterogeneous and inconsistently applied, limiting scientific communication and treatment standardization. The aim of this article is to link evidence from existing literature to develop a framework in the form of a structured lexicon, one that defines the morphological features and pathomechanical mechanisms that are relevant to the symptomatic, pre-arthritic hip. This descriptive framework was developed through the synthesis of current biomechanical, radiographic, and clinical evidence, combined with expert consensus from an international, multidisciplinary panel. Foundational concepts were derived from basic science research, including tribology, mechanobiology, and contact mechanics, to establish a unified terminology. Three principal wear modes-instability, impingement, and mixed mechanisms-are proposed, corresponding to distinct pathological loading environments. Wear mechanisms include dysplasia with rim overload and stress-related cartilage failure, impingement with cam-induced shear or pincer rim conflict, and secondary inflammatory degeneration. Wear damage is classified by tissue involvement, encompassing labral degeneration, chondrolabral detachment, staged cartilage delamination, and subchondral bone changes (sclerosis, cystic change). By linking lesion topography to underlying mechanics, this framework has diagnostic and therapeutic relevance as well as encompasses radiographic measurements and clinical features of wear that are pertinent to hip instability and femoroacetabular impingement. This lexicon provides a coherent framework for pre-arthritic hip disease, establishing a shared terminology to guide basic-science research integration and the interpretation of current clinical practice in hip preservation.
中文摘要:髋关节退行性骨关节炎(OA)常由改变负荷分布的结构异常引起,并导致软骨-盂唇进行性损伤。尽管已取得显著进展,保髋领域的现有术语仍不统一且应用不一致,限制了科学交流与治疗标准化。该文旨在把现有文献证据联系起来,以结构化术语表的形式建立框架,界定有症状的关节炎前期髋关节相关形态学特征与病理力学机制。该描述性框架通过整合当前生物力学、影像学与临床证据,并结合国际多学科专家组的共识而形成。基础概念来自基础科学研究,包括摩擦学、力学生物学与接触力学,以建立统一术语。提出三种主要磨损模式——不稳定、撞击与混合机制——分别对应不同的病理负荷环境。磨损机制包括发育不良伴边缘过载及应力相关软骨失效、撞击伴凸轮所致剪切或钳型边缘冲突,以及继发性炎症退变。磨损损伤按组织受累情况分类,涵盖盂唇退变、软骨-盂唇分离、分期软骨分层及软骨下骨改变(硬化、囊性变)。该框架将病变分布与底层力学相联系,具有诊断和治疗意义,并涵盖与髋关节不稳定及股骨髋臼撞击相关的磨损影像学测量和临床特征。该术语表为关节炎前期髋关节疾病提供了连贯框架,建立共享术语,以指导基础科学研究整合并解释保髋的当前临床实践。
Osteoarthritis (OA) is associated with excessive reactive oxygen species (ROS) production, which contributes substantially to chondrocyte dysfunction, oxidative stress, and cartilage degradation. Although stimuli-responsive hydrogels have emerged as promising platforms for OA therapy, conventional hydrogel-based systems exhibit limited sensitivity and require external detection equipment, highlighting the need for a simple, sensitive, and directly observable monitoring system. To address these challenges, we developed a ROS-triggered, in situ-forming gel-sol transition of a polydopamine (PDA)-loaded, diselenide-crosslinked polymer dot (PD) injectable hydrogel (HGC-PDA@PD or OA gel) as a monitorable theranostic for OA therapy at physiological temperature (37°C). The monitorable OA microenvironment-responsive hydrogel relied on interactions between the high ROS levels in OA cartilage and the OA gel, which triggered diselenide bond cleavage and the release of PDA from PD, causing a unique gel-sol transition of the OA gel. Owing to PDA release after diselenide breakage, the fluorescence and electroconductivity of the OA gel changed, which could serve as additional signals during OA detection. In vitro studies demonstrated the sensitive gel-sol transition of OA gel towards OA-induced immature articular chondrocytes (IL-1β/siSOD1/siCatalase-transfected iMACs). Furthermore, the OA gel showed a distinct gel-sol transition in cartilage of an in vivo OA mouse model compared with that in control mice. The lower transcription levels of cartilage matrix-degrading enzymes (ADAMTS4, ADAMTS5, MMP-3, and MMP-13) observed after OA gel injection confirmed that the OA gel could scavenge ROS and attenuate cartilage damage, revealing its potential application for dual-function OA diagnosis and rehabilitation.
中文摘要:骨关节炎(OA)伴随活性氧(ROS)过度产生,后者在很大程度上造成软骨细胞功能障碍、氧化应激与软骨降解。刺激响应性水凝胶已成为OA治疗中颇具前景的平台,但常规水凝胶体系灵敏度有限,且依赖外部检测设备,因此需要一种简便、灵敏、可直接观察的监测体系。为此,我们构建了负载聚多巴胺(PDA)、以二硒键交联的聚合物点(PD)可注射水凝胶(HGC-PDA@PD,简称OA凝胶),其在生理温度(37°C)下由ROS触发原位成胶并发生凝胶向溶胶的转变,可作为OA治疗中可监测的诊疗一体化体系。该可监测的OA微环境响应水凝胶依靠OA软骨内高水平ROS与OA凝胶之间的相互作用,触发二硒键断裂及PDA自PD释放,使OA凝胶出现独特的凝胶-溶胶转变。二硒键断裂后PDA释放,使OA凝胶的荧光与电导率发生改变,可作为OA检测过程中的附加信号。体外研究显示,OA凝胶对OA诱导的未成熟关节软骨细胞(经IL-1β/siSOD1/siCatalase转染的iMACs)表现出灵敏的凝胶-溶胶转变。在体内OA小鼠模型中,OA凝胶在软骨内的凝胶-溶胶转变与对照小鼠明显不同。注射OA凝胶后,软骨基质降解酶(ADAMTS4、ADAMTS5、MMP-3和MMP-13)的转录水平降低,证实该凝胶可清除ROS并减轻软骨损伤,显示出在OA诊断与康复中的双功能应用潜力。
Abnormal remodeling of subchondral bone (SB), driven by osteoclast sealing zone formation and insufficient adaptation to joint mechanical stress, accelerates the progression of osteoarthritis (OA) and remains a major therapeutic challenge. Here, we developed a mechanically self-reinforcing injectable hydrogel in which amino-hydroxyapatite (amHap)-encapsulating spindle-shaped tellurium (Te) nanoparticles (Te@amHap, Team) were embedded within an oxidized alginate-gelatin matrix (Te@amHap/OG Gel, Team Gel). Team Gel contains dynamic Schiff base bonds, enabling controlled release of Team under joint mechanical forces. Within the acidic microenvironment of the osteoclast sealing zone, Team degrades and releases Te to be oxidized into TeO3 2- by osteoclast-derived H2O2. These ions can react with the thiol-containing residues of F-actin to form Te─S bonds, leading to F-actin degradation to disrupt the sealing zone and suppress bone resorption. Notably, Ca2+ from amHap interacts with alginate to form an egg-box secondary crosslinking structure, enhancing the crosslinking density beyond the original Schiff base network, thereby enhancing the mechanical strength of Team Gel and extending its retention time. Acting together, PO4 3 --mediated inhibition of osteoclast differentiation and Te-driven disruption of the mature osteoclast sealing zone suppress osteoclastogenesis and bone resorption. This sealing zone disruption strategy preserves bone quality and joint integrity, suggesting a promising osteoclast-targeted therapy for OA.
中文摘要:由破骨细胞封闭带形成及对关节机械应力适应不足所驱动的软骨下骨异常重塑会加速骨关节炎进展,仍是重大治疗挑战。本研究开发了一种机械自增强可注射水凝胶,将包封氨基羟基磷灰石的纺锤形碲纳米颗粒(Te@amHap,Team)嵌入氧化海藻酸盐-明胶基质中(Te@amHap/OG Gel,Team Gel)。Team Gel含有动态席夫碱键,可在关节机械力作用下控制Team释放。在破骨细胞封闭带的酸性微环境中,Team降解并释放Te,Te被破骨细胞来源的H2O2氧化为TeO3 2-。这些离子可与F-actin的含硫醇残基反应形成Te─S键,导致F-actin降解,从而破坏封闭带并抑制骨吸收。amHap中的Ca2+与海藻酸盐相互作用形成egg-box二级交联结构,使交联密度超过原始席夫碱网络,从而增强Team Gel的机械强度并延长其滞留时间。PO4 3-介导的破骨细胞分化抑制与Te驱动的成熟破骨细胞封闭带破坏共同作用,抑制破骨细胞生成和骨吸收。这种封闭带破坏策略可保持骨质量和关节完整性,提示其作为骨关节炎破骨细胞靶向治疗具有前景。
Articular cartilage repair in osteoarthritis (OA) remains a major clinical challenge. Although approaches using mesenchymal stem cells (MSCs) have demonstrated partial efficacy in OA, the regenerated tissue is often unable to form stable hyaline-like cartilage phenotype. Here, we introduce immunity-and-matrix-regulatory cells (IMRCs), derived from human embryonic stem cells (ESCs), as an alternative cell source for OA therapy. Using a multiple-level platform including 2D chondrocytes, 3D OA cartilage organoids (OCOs), rabbit cartilage explants, and a rat OA model, we demonstrate that IMRCs significantly enhance hyaline-like matrix formation while suppressing inflammation, angiogenesis, and fibrotic remodeling. Mechanistically, IMRC-mediated cartilage repair is partially associated with MMP1-dependent matrix remodeling. This study establishes a translational evaluation strategy for IMRCs and points to their potential as an alternative cell source for inducing cartilage repair in OA. Notably, the OCOs established in this study provide a pathologically relevant in vitro platform for evaluating cartilage regeneration in OA.
中文摘要:骨关节炎(OA)中的关节软骨修复仍是临床难题。间充质干细胞(MSCs)治疗OA已显示部分疗效,但再生组织往往难以形成稳定的透明样软骨表型。研究引入来源于人胚胎干细胞(ESCs)的免疫与基质调节细胞(IMRCs),作为OA治疗的替代细胞来源。借助二维软骨细胞、三维OA软骨类器官(OCOs)、兔软骨外植体和大鼠OA模型构成的多层次平台,研究显示IMRCs可明显促进透明样基质形成,抑制炎症与血管生成,并减轻纤维化重塑。机制上,IMRC介导的软骨修复部分与MMP1依赖的基质重塑相关。该工作建立了IMRCs的转化评估策略,并提示其作为诱导OA软骨修复的替代细胞来源的潜力。研究所建立的OCOs为评估OA软骨再生提供了与病理相关的体外平台。
The spatiotemporal histopathological features of articular cartilage in osteoarthritis (OA) remain inadequately characterized, which impedes the advancement of strategies to halt irreversible joint deterioration. Herein a murine OA model, the initial phase (<10 days post-surgery) is characterized by pronounced mitochondrial dysfunction in chondrocytes and concurrent activation of subchondral osteoclasts. Beyond this period, irreversible cartilage degeneration ensues, marked by chondrocyte apoptosis and subchondral bone sclerosis. We further identified magnesium (Mg) as a key regulator of cellular metabolic balance, capable of reinstating homeostasis in inflamed chondrocytes while modulating osteoclast overactivity. Based on this, we developed dual-concentration Mg-releasing biphasic microspheres that effectively halted early OA progression in vivo. In contrast, delayed administration conferred benefits predominantly limited to the subchondral bone, without achieving cartilage preservation. These results underscore the existence of a critical therapeutic window for metabolic intervention in OA, wherein Mg-based biomaterials exert protective effects exclusively during the early disease stage. Thus, this study offers a new strategic perspective for the clinical management of OA.
中文摘要:骨关节炎(OA)关节软骨的时空组织病理学特征仍缺乏充分描述,这阻碍了阻止不可逆关节退变策略的进展。在小鼠OA模型中,术后早期(<10天)以软骨细胞线粒体功能障碍明显并伴软骨下骨破骨细胞激活为特征。超过该时期后,出现不可逆的软骨退变,表现为软骨细胞凋亡和软骨下骨硬化。我们进一步确定镁(Mg)是细胞代谢平衡的关键调节因子,能够恢复炎症软骨细胞的稳态,同时调节破骨细胞过度活跃。基于此,我们开发了双浓度释镁双相微球,在体内有效阻止早期OA进展。相反,延迟给药带来的获益主要局限于软骨下骨,未能实现软骨保护。这些结果强调OA代谢干预存在关键治疗窗口,其中镁基生物材料仅在疾病早期阶段发挥保护作用。因此,该结果为OA临床管理提供了新的策略视角。
Genetic manipulation technologies (GMTs) serve as potent instruments for elucidating the molecular and cellular mechanisms that underly both physiological and pathological processes. However, the increasing recognition of the cellular heterogeneity in terms of their spatial distribution, cellular subtypes, and functional states in complex tissues, has posed new challenges to the applicability and precision of these technologies. While current GMTs facilitate precise genetic interventions at the molecular level, their capacity for achieving cell-specific genetic regulation remains constrained. In this context, we utilize research on fibroblast growth factors (FGFs)/FGF receptors (FGFRs) signaling in osteoarthritis (OA) as a case to demonstrate the technical limitations faced by existing GMTs. To address these constraints, we propose a conceptual framework termed Materialogenetics, which integrates advances in biomaterials science with genetic manipulation approaches. Advanced biomaterials with active-targeting and stimuli-responsive properties have been widely explored in disease diagnosis and therapy. When combined with GMTs, these materials can theoretically greatly improve cell-specific and spatiotemporally controlled genetic manipulation at both molecular and cellular levels. Moreover, biomaterial-assisted genetic manipulation offers several practical advantages, including cost-effectiveness, operational simplicity, and a high degree of tunability, rendering the platform highly adaptable to a wide range of research contexts. Collectively, Materialogenetics establishes a conceptual framework that bridges the fields of materials science and genetics, representing a versatile and promising platform for achieving precise genetic manipulation in complex biological systems.
中文摘要:基因操作技术(GMTs)是阐明生理和病理过程背后分子与细胞机制的有力工具。复杂组织中细胞在空间分布、细胞亚型和功能状态上的异质性日益被认识,对这些技术的适用性和精确性提出了新挑战。现有GMTs虽能在分子水平实现精确的基因干预,但实现细胞特异性基因调控的能力仍有限。我们以骨关节炎(OA)中成纤维细胞生长因子(FGFs)/FGF受体(FGFRs)信号研究为例,说明现有GMTs面临的技术局限。为应对这些限制,我们提出一个称为材料遗传学(Materialogenetics)的概念框架,将生物材料科学的进展与基因操作策略整合。具有主动靶向和刺激响应特性的先进生物材料已在疾病诊断和治疗中广泛探索。这些材料与GMTs结合,理论上可在分子和细胞水平大幅提升细胞特异性和时空可控的基因操作。生物材料辅助的基因操作还具备若干实际优势,包括成本效益、操作简便和高度可调性,使该平台能适应广泛的研究情境。总体来看,材料遗传学建立了一个连接材料科学与遗传学的概念框架,为在复杂生物系统中实现精确基因操作提供了通用且有前景的平台。
3关节外科/置换 (7篇)
临床研究 (2篇)
Sodium-glucose cotransporter-2 inhibitors (SGLT-2is) have evolved from glucose-lowering agents to foundational therapies for the management of type 2 diabetes mellitus, heart failure, and chronic kidney disease, with substantial benefits for cardiovascular, kidney, and survival outcomes. As their indications continue to expand, a comprehensive understanding of their safety and tolerability has become increasingly important for optimizing patient care. Building on our recent state-of-the-art review of glucagon-like peptide-1 receptor agonists, this review provides a contemporary synthesis of the evidence on the safety and tolerability of SGLT-2is. We critically appraise data from randomized controlled trials, cardiovascular and kidney outcome trials, pharmacovigilance databases, large observational studies, and systematic reviews and meta-analyses. The available evidence demonstrates that SGLT-2is have a favorable overall safety profile, with genital mycotic infections representing the most consistently observed adverse event. Volume depletion and euglycemic diabetic ketoacidosis remain clinically important but are uncommon and are largely preventable through appropriate patient selection, patient education, and temporary treatment interruption during high-risk clinical situations. Fournier's gangrene should be regarded as a very rare but serious complication requiring prompt recognition and treatment. In contrast, randomized trials and meta-analyses generally indicate a reduced risk of acute kidney injury, while evidence concerning fracture, lower-limb amputation, hepatotoxicity, pancreatitis, and cancer is less definitive. Although consistent class-wide increases in these latter outcomes have not been established, uncommon or agent-specific risks cannot be excluded, particularly where event numbers are small or follow-up is limited. Overall, treatment discontinuation because of adverse events is low across major cardiovascular, heart failure, and kidney outcome trials, supporting the excellent tolerability of this therapeutic class. Comparative evidence suggests only modest differences among individual SGLT-2is, although definitive conclusions remain limited by the absence of direct, large, randomized head-to-head trials. We also summarize practical strategies for adverse-event mitigation, monitoring, temporary treatment interruption, and individualized patient selection. As the clinical applications of SGLT-2is continue to broaden, ongoing pharmacovigilance, inclusive clinical trials, and comparative safety studies will be essential to further refine their benefit-risk profile and optimize their safe use across diverse patient populations.
中文摘要:钠-葡萄糖共转运蛋白2抑制剂(SGLT-2is)已从降糖药物发展为治疗2型糖尿病、心力衰竭和慢性肾脏病的基础疗法,对心血管、肾脏和生存结局具有显著获益。随着适应证不断扩展,全面理解其安全性与耐受性对优化患者管理愈发重要。在近期关于胰高血糖素样肽-1受体激动剂的最新综述基础上,本综述对SGLT-2is安全性与耐受性的证据进行了当代整合。我们批判性评估了随机对照试验、心血管和肾脏结局试验、药物警戒数据库、大型观察性研究以及系统综述和荟萃分析的数据。现有证据显示,SGLT-2is总体安全性良好,生殖器真菌感染是最一致观察到的不良事件。容量不足和正常血糖性糖尿病酮症酸中毒仍具有临床重要性,但并不常见,且通过合适的患者选择、患者教育以及在高风险临床情境中暂时中断治疗,大多可以预防。福尼尔坏疽应视为非常罕见但严重的并发症,需要及时识别和处理。相比之下,随机试验和荟萃分析通常提示急性肾损伤风险降低,而关于骨折、下肢截肢、肝毒性、胰腺炎和癌症的证据尚不明确。尽管尚未确立这些 latter 结局在全类别中一致性增加,但不能排除少见或药物特异性风险,尤其是在事件数较少或随访有限时。总体而言,在主要心血管、心力衰竭和肾脏结局试验中,因不良事件停药的比例较低,支持该治疗类别具有良好耐受性。比较证据提示各SGLT-2is之间差异不大,但由于缺乏直接、大型、随机头对头试验,确定性结论仍受限。我们还总结了不良事件缓解、监测、暂时中断治疗和个体化患者选择的实用策略。随着SGLT-2is临床应用持续扩大,持续的药物警戒、具有包容性的临床试验和比较安全性研究对于进一步细化其获益-风险特征并在不同患者群体中优化安全使用至关重要。
Given that patients undergoing orthopaedic surgery frequently share risk factors that are associated with metabolic syndrome, the patients orthopaedic surgeons treat may be especially likely to have undiagnosed dysglycemia. Although its broader impact is documented in other specialties, its specific prevalence and association with postoperative outcomes after orthopaedic procedures remains incompletely defined. Quantifying this hidden burden is important to developing individual risk profiles, refining perioperative decision-making, and establishing targeted preoperative medical management strategies for patients considering orthopaedic surgery. In a large-database study, we asked: (1) In adults who underwent orthopaedic surgery, what proportion of patients had previously undiagnosed dysglycemia? (2) Was undiagnosed dysglycemia associated with increased odds of 30-day readmission and reoperation compared with patients with normoglycemia? (3) What was the relationship between preoperative HbA1c levels and the 30-day risk of complications in patients who underwent orthopaedic surgery? Among the 2,990,063 procedures recorded in the American College of Surgeons National Surgical Quality Improvement Program database (2021-2023), 25% (735,259 of 2,990,063) were orthopaedic. After excluding 75% (2,254,804 of 2,990,063) of nonorthopaedic procedures and 16% (493,272 of 2,990,063) of orthopaedic procedures without documented preoperative HbA1c, 8% (241,987 of 2,990,063) of all procedures were analyzed. Patients were assigned to one of eight glycemic groups (normoglycemic, undiagnosed prediabetes, undiagnosed diabetes, or diagnosed diabetes with near-normal, very good, good, poor, and very poor glycemic control) based on diabetes diagnosis and HbA1c level. The study cohort included patients undergoing a range of procedures, primarily consisting of total joint arthroplasty, fracture fixation, and spine surgery. The mean ± SD patient age was 66 ± 12 years and 56% [134,741 of 241,987] of patients were female. To address the first research question, the percentage of patients with previously undiagnosed dysglycemia in each cohort was measured, supplemented by a best-case sensitivity analysis to provide a conservative estimate for the entire surgical population. The second and third research questions investigated the association of undiagnosed dysglycemia on 30-day odds of readmission and reoperation and the relationship between preoperative HbA1c and 30-day odds of complications, using multivariable logistic regression adjusted for demographic, comorbidity, and procedural factors. To illustrate variation across operations, the 30-day complication rate of patients across HbA1c strata was evaluated for the 10 most frequent primary Current Procedural Terminology-coded procedures. We found that 22% (52,609 of 241,987) of patients with a recorded preoperative HbA1c had undiagnosed prediabetes and 4% (10,690 of 241,987) of patients met the criteria for undiagnosed diabetes. In a best-case sensitivity analysis in which we assumed that all patients without an HbA1c measurement did not have diabetes and had normoglycemia, the smallest percentage of patients with previously undiagnosed dysglycemia would have been 9% (63,299) across all 735,259 patients who underwent orthopaedic surgery. After adjusting for potentially confounding variables, neither prediabetes nor diabetes was independently associated with increased odds of 30-day readmission (adjusted OR 0.95 [95% CI 0.88 to 1.0]; p = 0.12 and adjusted OR 0.99 [95% CI 0.84 to 1.2]; p = 0.94) or reoperation (adjusted OR 0.94 [95% CI 0.85 to 1.0]; p = 0.25 and adjusted OR 0.99 [95% CI 0.84 to 1.2]; p = 0.94) compared with patients with normoglycemia. The adjusted ORs for any 30-day complication were higher in patients with undiagnosed diabetes (adjusted OR 1.1 [95% CI 1.0 to 1.2]; p = 0.03) and increased across HbA1c strata in those with diagnosed diabetes (adjusted OR 1.2, 1.1, 1.2, 1.4, and 2.0; all p ≤ 0.009) compared with patients with normoglycemia. Procedure-level analyses showed consistent patterns with variable magnitude: 30-day rates of any complication in THA rose from 5% (1425 of 27,812) to 17% (49 of 294) across HbA1c strata, whereas 30-day complication rates peaked at 30% (203 of 675) in hinged TKA and at 22% (11 of 49) in revision TKA. On the other hand, 30-day complication rates in shoulder procedures and knee arthroscopy remained uniformly low (< 6%) with minimal variation by HbA1c. Unrecognized dysglycemia is common among patients undergoing orthopaedic surgery and is associated with postoperative morbidity. Selective preoperative HbA1c assessment and procedure-specific targets may improve perioperative risk stratification. Examining these effects in clinical studies with procedure-specific preoperative HbA1c screening to identify and appropriately treat patients at risk could help to further validate these findings. Level III, therapeutic study.
中文摘要:接受骨科手术的患者常同时具有与代谢综合征相关的危险因素,骨科医生治疗的患者可能尤其容易出现未被诊断的血糖异常。其他专科已记录其更广泛影响,但其在骨科手术后的具体患病率及与术后结局的关联仍未完全明确。量化这一隐匿负担,对于建立个体化风险画像、改进围手术期决策,以及为考虑骨科手术的患者制定有针对性的术前内科管理策略具有意义。这项大型数据库研究提出:(1)在接受骨科手术的成人中,既往未被诊断的血糖异常占多大比例?(2)与血糖正常患者相比,未被诊断的血糖异常是否与30天再入院和再手术的几率升高相关?(3)在接受骨科手术的患者中,术前HbA1c水平与30天并发症风险之间是什么关系?在美国外科医师学会国家外科质量改进计划数据库(2021—2023年)记录的2,990,063例手术中,25%(735,259/2,990,063)为骨科手术。排除75%(2,254,804/2,990,063)的非骨科手术和16%(493,272/2,990,063)未记录术前HbA1c的骨科手术后,分析了全部手术中的8%(241,987/2,990,063)。根据糖尿病诊断和HbA1c水平,患者被分为8个血糖组:血糖正常、未诊断的糖尿病前期、未诊断的糖尿病,以及已诊断糖尿病且血糖控制接近正常、很好、良好、较差和很差。研究队列涵盖多种手术,主要包括全关节置换、骨折固定和脊柱手术。患者平均年龄为66±12岁,56%(134,741/241,987)为女性。针对第一个研究问题,测量各队列中既往未被诊断的血糖异常患者百分比,并以最佳情况敏感性分析补充,为整个手术人群提供保守估计。第二和第三个研究问题采用多因素logistic回归,校正人口学、合并症和手术因素,分析未被诊断的血糖异常与30天再入院和再手术几率的关系,以及术前HbA1c与30天并发症几率的关系。为展示不同手术间的差异,按HbA1c分层评估了10种最常见的主要Current Procedural Terminology编码手术的30天并发症率。结果发现,在记录术前HbA1c的患者中,22%(52,609/241,987)存在未诊断的糖尿病前期,4%(10,690/241,987)符合未诊断糖尿病标准。在最佳情况敏感性分析中,假设所有未测HbA1c的患者均无糖尿病且血糖正常,全部735,259例接受骨科手术的患者中,既往未被诊断的血糖异常比例最低为9%(63,299)。校正潜在混杂变量后,与血糖正常患者相比,糖尿病前期和糖尿病均未独立增加30天再入院几率(校正OR 0.95[95% CI 0.88至1.0],p=0.12;校正OR 0.99[95% CI 0.84至1.2],p=0.94)或再手术几率(校正OR 0.94[95% CI 0.85至1.0],p=0.25;校正OR 0.99[95% CI 0.84至1.2],p=0.94)。与血糖正常患者相比,未诊断糖尿病患者任何30天并发症的校正OR更高(校正OR 1.1[95% CI 1.0至1.2],p=0.03);在已诊断糖尿病患者中,校正OR随HbA1c分层升高(分别为1.2、1.1、1.2、1.4和2.0;所有p≤0.009)。手术层面的分析显示一致模式,但幅度不同:全髋关节置换术的任何30天并发症率随HbA1c分层从5%(1,425/27,812)升至17%(49/294),铰链式全膝关节置换术的30天并发症率最高达30%(203/675),翻修全膝关节置换术为22%(11/49)。肩部手术和膝关节镜的30天并发症率均较低(<6%),随HbA1c变化很小。未被识别的血糖异常在骨科手术患者中常见,并与术后并发症相关。选择性术前HbA1c评估和手术特异性目标可能改善围手术期风险分层。在临床研究中以手术特异性术前HbA1c筛查来识别并适当治疗风险患者,并检验这些效应,有助于进一步验证上述发现。治疗性研究,证据等级III。
基础研究 (5篇)
Electrocatalytic conversion of CO2 into chemicals and fuels offers a promising route toward a circular carbon economy. High-temperature CO2 electroreduction in solid oxide electrolysis cells (SOECs) delivers high selectivity and energy efficiency, but balancing mechanical robustness and electrochemical performance remains challenging. Here, we address this challenge by introducing a hybrid ionic-conductor architecture that spatially decouples electrocatalysis, ionic transport, and mechanical support into function-specific layers. The resulting cell combines high mechanical robustness (fracture load > 7 N) with 1.5-3.0-fold higher CO2-to-CO activity than state-of-the-art SOECs over 600-800 °C. Stable operation is maintained for over 1000 h at 1.0 A cm-2. Furthermore, we demonstrate scalability with a single-cell area of 100 cm2, achieving total currents up to 120 A and powers up to 200 W. This work establishes an effective strategy for developing mechanically resilient, efficient, and scalable energy conversion devices.
中文摘要:电催化将CO2转化为化学品和燃料,为循环碳经济提供了一条有前景的路径。固体氧化物电解池(SOECs)中的高温CO2电还原具有高选择性和能量效率,但兼顾机械强度与电化学性能仍具挑战。我们通过引入混合离子导体架构来应对这一挑战,该架构将电催化、离子传输与机械支撑在空间上解耦为功能特定的层。所得电池兼具高机械强度(断裂载荷大于7 N)和在600至800摄氏度范围内比当前最先进SOECs高1.5至3.0倍的CO2到CO活性。在1.0 A cm-2下稳定运行超过1000小时。我们展示了单电池面积100平方厘米的可扩展性,总电流最高达120 A,功率最高达200 W。这项工作为开发机械韧性、高效且可扩展的能量转换装置建立了有效策略。
Anode-free high-energy-density potassium metal batteries (AFPMBs) are critically constrained by the irreversible accumulation of dead potassium (K) and severe dendrite growth. These issues stem from sluggish interfacial kinetics and the continuous fracture of the solid electrolyte interphase (SEI). A multifunctional electrolyte engineering strategy is proposed by incorporating bismuth iodide (BiI3) into a carbonate-based system to simultaneously regulate the bulk K+ solvation sheath, reconstruct the interfacial solvation structure, and reactivate dead K. Experimental and theoretical analyses reveal that the iodide/triiodide (I-/I3-) species weaken the coordination of K+ with solvents and FSI- in the bulk electrolyte, generating a weakly coordinated solvation structure, which facilitates K+ desolvation. At the electrode interface, Bi-derived sites preferentially recruit and selectively adsorb free FSI- over carbonate solvents and promote their enrichment toward the inner Helmholtz layer, thereby reconstructing an anion-rich interfacial solvation structure that directs the formation of a robust inorganic-rich SEI. In parallel, the reversible I-/I3- redox couple can reactivate dead K. Benefiting from the synergistic suppression of dendrite growth, reduction of irreversible K loss, and enhancement of interfacial kinetics, the symmetric cells demonstrate stable cycling for over 1300 h at 0.5 mA cm-2 and 0.5 mAh cm-2. AFPMBs also demonstrate markedly improved cycling stability and capacity retention in the carbonate-based electrolyte. This work provides a foundation for designing advanced electrolyte additives to enhance electrochemical stability in AFPMBs.
中文摘要:无负极高能量密度钾金属电池(AFPMBs)受失活钾不可逆积累和严重枝晶生长的关键制约。这些问题源于缓慢的界面动力学和固体电解质界面(SEI)的持续破裂。提出一种多功能电解质工程策略,将碘化铋(BiI3)引入碳酸酯基体系,以同时调控体相K+溶剂化鞘、重构界面溶剂化结构并再激活失活钾。实验与理论分析表明,碘化物/三碘化物(I-/I3-)物种削弱K+与体相电解质中溶剂及FSI-的配位,形成弱配位溶剂化结构,促进K+去溶剂化。在电极界面,Bi衍生位点优先富集并选择性吸附游离FSI-而非碳酸酯溶剂,并促使其向内亥姆霍兹层富集,从而重构富阴离子界面溶剂化结构,引导形成坚固的富无机物SEI。同时,可逆的I-/I3-氧化还原对可再激活失活钾。得益于对枝晶生长的协同抑制、不可逆钾损失的减少以及界面动力学的增强,对称电池在0.5 mA cm-2和0.5 mAh cm-2下实现超过1300小时的稳定循环。AFPMBs在碳酸酯基电解质中也表现出显著改善的循环稳定性和容量保持率。该工作为设计先进电解质添加剂以提升AFPMBs电化学稳定性提供了基础。
Chronic diseases can continue to progress after the initiating insult has subsided, indicating that injured tissues may retain a persistent imprint of failed repair. Here, senescent repair memory refers to a tissue state in which transient repair-associated senescence fails to resolve and is maintained by persistent senescent cells, altered secretory and metabolic programmes, defective immune clearance, epigenetic stabilization and spatial niche interactions. Once established beyond the adaptive repair window, this state can perpetuate inflammation, fibrosis and functional decline even after the original injury has diminished. This Review examines how failed resolution may contribute to chronic kidney disease, cardiovascular disease, pulmonary fibrosis, metabolic liver disease, neurodegeneration and osteoarthritis. Evidence is strongest in kidney disease, pulmonary fibrosis and metabolic liver disease. Cardiovascular disease and osteoarthritis are supported mainly by experimental or associative studies, whereas the application of this model to neurodegeneration remains largely indirect. Senescent repair memory is therefore presented not as a new molecular pathway or a universal explanation for chronic disease, but as a testable framework linking the persistence, maintenance, spatial organization and functional consequences of unresolved senescence. By distinguishing adaptive repair from disease-sustaining senescence, this perspective may inform the development of stage- and tissue-specific biomarkers and interventions.
中文摘要:慢性疾病在初始损伤消退后仍可继续进展,提示受损组织可能保留失败修复的持续印记。这里,衰老修复记忆指一种组织状态:短暂与修复相关的衰老未能消退,并由持续存在的衰老细胞、改变的分泌与代谢程序、缺陷的免疫清除、表观遗传稳定化及空间微环境相互作用所维持。一旦在适应性修复窗口之后确立,该状态可在原始损伤减轻后仍持续推动炎症、纤维化和功能衰退。本综述考察失败消退如何参与慢性肾脏病、心血管疾病、肺纤维化、代谢性肝病、神经退行性疾病和骨关节炎。证据在肾病、肺纤维化和代谢性肝病中最强。心血管疾病和骨关节炎主要得到实验性或关联性研究支持,而该模型在神经退行性疾病中的应用仍多为间接。因此,衰老修复记忆并非作为新的分子通路或慢性疾病的普适解释提出,而是作为一个可检验的框架,连接未消退衰老的持续性、维持、空间组织和功能后果。通过区分适应性修复与疾病维持性衰老,这一视角可能为分期和组织特异性生物标志物及干预措施的开发提供信息。
Coalbed methane flowback and produced water (CBM FPW) is characterized by complex composition, high salinity, and precious metals with notable recovery value, while the accompanying heavy metals posing potential environmental hazard. To date, most studies have focused on the analysis of individual components in CBM FPW rather than comprehensive characterization of its water quality, resulting in a limited holistic understanding of CBM FPW composition. An analytical framework encompassing "water quality characterization-resource evaluation-control mechanisms" was established, and the spatiotemporal evolution characteristics of inorganic constituents in FPW from the Ordos Basin were systematically analyzed. The water quality analysis results indicated that the FPW exhibited an overall weak acidity (pH 6.30) and an ionic composition dominated by Ca2+, primarily caused by the combined effects of organic matter-driven organic acid generation and fracture-controlled water-rock interactions, which is significantly distinct from typical Na+-type CBM wastewater. Furthermore, the results of trace elements evolution revealed that the majority of elements exhibited a "high-concentration plateau stage" during the flowback process. Na+, K+, Mg2+, Sr2+, and certain precious metal elements (e.g., Ga, Pd, Rh, Sc, Au) were found to possess considerable recovery value, with economic feasibility exceeding 0.1 dollars/m3. In addition, heavy metals such as Ba, Fe, and Mn exhibited relatively high concentrations (>10 mg/L), posing potential environmental risks if inadequately managed. By employing this integrated analytical framework, a complete characterization of CBM FPW water quality was achieved, providing systematic and valuable references for the subsequent resource recovery of precious metals and heavy metal pollution control.
中文摘要:煤层气返排液与产出水(CBM FPW)组成复杂、盐度高,含具有明显回收价值的贵金属,同时伴生重金属可能带来环境风险。迄今多数研究仅分析CBM FPW中的单一组分,缺少对其水质的综合表征,对CBM FPW组成的整体认识有限。研究建立了涵盖「水质表征—资源评价—控制机制」的分析框架,系统分析鄂尔多斯盆地FPW中无机成分的时空演化特征。水质分析结果显示,FPW整体呈弱酸性(pH 6.30),离子组成以Ca2+为主,这主要是有机质驱动有机酸生成与裂隙控制的水岩作用共同造成,明显不同于典型Na+型煤层气废水。微量元素演化结果表明,多数元素在返排过程中出现「高浓度平台阶段」。Na+、K+、Mg2+、Sr2+及部分贵金属元素(如Ga、Pd、Rh、Sc、Au)具有可观回收价值,经济可行性超过0.1美元/m3。Ba、Fe、Mn等重金属浓度较高(>10 mg/L),若管理不当会带来潜在环境风险。采用该集成分析框架,实现了CBM FPW水质的完整表征,为后续贵金属资源回收和重金属污染控制提供系统而有价值的参考。
Mesenchymal stem/stromal cells (MSCs) continue to drive innovation in regenerative medicine, yet the field is undergoing a critical evolution from the early concept of cellular engraftment to complex paracrine-mediated tissue repair. This review systematically evaluates the core scientific questions defining this transition, highlighting the latest advancements in MSC biology and the rapidly expanding therapeutic frontier of MSC-derived extracellular vesicles (MSC-EVs). We critically appraise recent progress in decoding MSC therapeutic mechanisms, specifically their profound capacity for immune modulation and microenvironmental remodeling. By synthesizing current findings across diverse and challenging clinical applications-encompassing oral tissue regeneration, osteoarthritis, and complex immune disorders-we provide expert insights into the discrepancies between promising preclinical data and variable clinical outcomes. Crucially, we address persistent translational bottlenecks, including inherent donor heterogeneity, manufacturing scalability, and the lack of standardized potency assays. It is our perspective that overcoming these limitations demands a strategic pivot towards precise cell-free MSC-EV therapies and advanced bioengineering strategies. Ultimately, this review highlights key directions for future research. By connecting basic mechanistic insights with clinical demands, we aim to accelerate the translation of effective MSC-based therapies.
中文摘要:间充质干细胞/基质细胞(MSCs)持续推动再生医学创新,该领域正经历从早期细胞植入概念到复杂旁分泌介导组织修复的关键演变。这篇综述系统评估界定这一转变的核心科学问题,重点介绍MSC生物学的最新进展以及MSC来源细胞外囊泡(MSC-EVs)快速扩展的治疗前沿。我们审慎评价解码MSC治疗机制的最新进展,尤其是其免疫调节和微环境重塑的强大能力。通过综合口腔组织再生、骨关节炎和复杂免疫疾病等多样且具挑战性的临床应用中的现有发现,我们提供专家视角,剖析有前景的临床前数据与多变临床结局之间的差异。我们讨论持续存在的转化瓶颈,包括固有的供者异质性、生产可扩展性以及缺乏标准化效力检测。我们的观点是,克服这些局限需要战略转向精准的无细胞MSC-EV疗法和先进生物工程策略。这篇综述强调未来研究的关键方向。通过连接基础机制认识与临床需求,我们旨在加速有效MSC疗法的转化。
4生物材料/植入物 (6篇)
基础研究 (6篇)
Synthetic polymer networks typically lack the ability to autonomously remodel and strengthen under mechanical stress, a capability commonly observed in natural materials. Here we introduce adapt-ring networks (ARNs) that establish a general design principle for adaptive polymer materials. ARNs couple a covalent polyethylene glycol network with reconfigurable α-cyclodextrin crystalline domains whose strain-directed fragmentation, translocation and alignment form kinetically trapped architectures encoding local mechanical history. Mechanical training enhances Young's modulus, tensile strength, fracture energy and fatigue threshold by up to an order of magnitude, with full reversibility through solvent-induced crystalline-domain reformation. Spatially resolved adaptation and 3D printability enable gradient materials and customized architectures. Incorporating polyethylene glycol side chains to form dangling-chain ARNs enables strain-controlled out-of-equilibrium growth through threading and crystallization of external α-cyclodextrins. These hydrogels autonomously generate spatially self-organized, strain-dependent reinforcement, including non-local, environment-fed stiffening conceptually analogous to biological reinforcement. These features establish a general approach to bio-inspired, non-equilibrium soft materials that adapt, remember, regrow and readapt.
中文摘要:合成聚合物网络通常缺乏在机械应力下自主重塑和增强的能力,而这种能力在天然材料中常见。自适应环网络(ARNs)为自适应聚合物材料建立了一种通用设计原则。ARNs 将共价聚乙二醇网络与可重构的α-环糊精晶畴耦合,这些晶畴在应变引导下发生碎裂、迁移和取向,形成动力学捕获结构,从而编码局部力学历史。力学训练可使杨氏模量、拉伸强度、断裂能和疲劳阈值提高至多一个数量级,并可通过溶剂诱导的晶畴重组实现完全可逆。空间分辨自适应与3D打印能力可实现梯度材料和定制结构。引入聚乙二醇侧链形成悬垂链ARNs,可通过外部α-环糊精的穿入和结晶实现应变控制的非平衡生长。这些水凝胶可自主产生空间自组织、应变依赖的增强,包括非局域、由环境供给的硬化,在概念上类似于生物增强。这些特征为适应、记忆、再生长和再适应的仿生非平衡软材料建立了一种通用途径。
Medical devices have revolutionized patient care; however, their abiotic surfaces remain highly susceptible to bacterial biofilm formation, enabling immune evasion and antibiotic resistance. Although antibacterial coatings can mitigate bacterial colonization, many rely on antimicrobial agents that may drive resistance and often lack the capacity to actively modulate host immunity or promote osteogenesis. Here, we introduce innovative Commensal Hybrid Materials (CHMs), multifunctional implant interfaces generated by coating titanium with commensal microflora via a heat-anchoring inactivation process to create a safe, stable surface layer. Surface analyses (SEM/EDS, FTIR, Raman, XPS) confirmed a thick, near-hydrophobic coating with a polar biomolecular overlayer bearing protein (amide), lipid (C-H), and phosphate/phosphoryl signatures. CHMs were non-haemolytic, biocompatible with human cells, enhanced macrophage antimicrobial activity by increasing reactive oxygen species production while maintaining balanced phagocytosis, and reduced biofilm formation by the periodontal pathogen Porphyromonas gingivalis. CHMs induced balanced macrophage polarization and osteoimmunomodulation, increasing expressions of IL-1β, TNF-α (M1), IL-10 (M2), and the osteoinductive mediator oncostatin M (OSM), while significantly upregulating RUNX2 in co-cultured periodontal ligament stem cells with an early, self-limiting cytokine profile. In a clinically relevant human immunocompetent three-dimensional implant-tissue-oral-bacterial-biofilm (INTERbACT) model integrating fibroblasts, epithelial cells, macrophages, and multispecies biofilms, CHMs preserved epithelial integrity under dysbiotic challenge and significantly reduced biofilm volume while tuning macrophages toward both antimicrobial (M1) and reparative (M2) states. CHMs also reduced pro-inflammatory cytokine expression under both sterile and biofilm-exposed conditions. Collectively, CHMs uniquely combine biofilm resistance, immune-mediated clearance, and osteogenic stimulation, supporting translation to dental and orthopaedic implants.
中文摘要:医疗器械极大改变了患者诊疗,但其非生物表面仍极易形成细菌生物膜,从而帮助免疫逃逸并促进抗生素耐药。抗菌涂层可减轻细菌定植,但许多依赖可能诱导耐药的抗菌剂,且常缺乏主动调节宿主免疫或促进成骨的能力。这里介绍创新的共生杂化材料(CHMs),通过热锚定灭活工艺将共生菌群包覆于钛表面,形成安全稳定的多功能植入物界面。表面分析(SEM/EDS、FTIR、拉曼、XPS)证实形成较厚、近疏水的涂层,其极性生物分子外层具有蛋白(酰胺)、脂质(C-H)和磷酸/磷酰基特征。CHMs无溶血性,与人细胞生物相容,通过增加活性氧产生增强巨噬细胞抗菌活性,同时维持吞噬作用平衡,并减少牙周致病菌牙龈卟啉单胞菌的生物膜形成。CHMs诱导平衡的巨噬细胞极化和骨免疫调节,上调IL-1β、TNF-α(M1)、IL-10(M2)及成骨诱导介质制瘤素M(OSM)表达,并在共培养的牙周膜干细胞中显著上调RUNX2,呈现早期、自限性细胞因子谱。在临床相关的人免疫健全三维植入物-组织-口腔细菌生物膜(INTERbACT)模型中,整合成纤维细胞、上皮细胞、巨噬细胞和多物种生物膜,CHMs在菌群失调挑战下保持上皮完整性,显著减少生物膜体积,并将巨噬细胞调节至兼具抗菌(M1)和修复(M2)状态。CHMs还降低无菌和暴露于生物膜条件下的促炎细胞因子表达。CHMs将抗生物膜、免疫介导清除和成骨刺激结合在一起,支持其向牙科和骨科植入物转化。
Conventional alloys achieve mechanical reliability and corrosion resistance at the expense of bioactivity, necessitating exogenous surface treatments that introduce long-term interfacial instability. In this study, we demonstrate that atomic-scale ordering, specifically the coexistence of chemical short-range order (CSRO) and ordered oxygen complexes (OOCs), can intrinsically integrate these otherwise contradictory requirements within a single metallic system. This strategy exploits the principle that atomic arrangements governing bulk mechanical behavior concurrently regulate surface physicochemical properties, thereby eliminating the need for extrinsic modification. A Ti-30Zr-14Nb-3O medium-entropy alloy (MEA) designed with CSRO-OOCs synergy exhibits bone-matched elastic modulus (∼42 GPa) and high yield strength (∼1040 MPa), overcoming the conventional strength-modulus trade-off. Importantly, this atomic configuration intrinsically generates nanoscale surface roughness (Ra ∼50.80 nm) and optimized surface energy distribution-features typically achieved only through artificial surface engineering. These ordering-regulated surface characteristics promote accelerated osteogenic differentiation in vitro without additional surface treatment. Molecular dynamics simulations reveal enhanced Ca2+ and PO4 3- adsorption on OOC-enabled surfaces, facilitating early calcium phosphate nucleation. In a rat cranial defect model, this intrinsic bioactivity translates into rapid, continuous bone formation along the implant surface, achieving a bone surface (BS) value of 70.63 ± 21.35 mm2 at 4 weeks, which was 3.5 times greater than that of the control group and significantly exceeds that of TC4. This work establishes atomic-scale ordering as a promising design framework for integrating mechanical compatibility with enhanced spontaneous osteoconductivity in metallic biomaterials.
中文摘要:传统合金以牺牲生物活性为代价获得力学可靠性与耐腐蚀性,往往需要外源性表面处理,而这会带来长期界面不稳定。该研究证明,原子尺度有序,即化学短程有序(CSRO)与有序氧复合体(OOCs)共存,可在单一金属体系内将原本相互矛盾的需求整合起来。该策略利用控制块体力学行为的原子排布同时调控表面物理化学性质,从而无需外在改性。按CSRO-OOCs协同设计的Ti-30Zr-14Nb-3O中熵合金(MEA)具有与骨匹配的弹性模量(约42 GPa)和高屈服强度(约1040 MPa),突破了传统的强度-模量权衡。这种原子构型本身即可产生纳米级表面粗糙度(Ra约50.80 nm)和优化的表面能分布,而这些特征通常只能通过人工表面工程获得。这些由有序结构调控的表面特征在未额外进行表面处理时促进体外成骨分化加速。分子动力学模拟显示,具有OOC的表面增强了对Ca2+和PO4^3−的吸附,促进早期磷酸钙成核。在大鼠颅骨缺损模型中,这种内在生物活性转化为沿植入物表面的快速、连续骨形成,4周时骨表面(BS)值达70.63 ± 21.35 mm²,为对照组的3.5倍,并显著高于TC4。该工作将原子尺度有序确立为一种有前景的设计框架,用于在金属生物材料中整合力学相容性与增强的自发骨传导性。
Tendon injuries are prevalent in both athletic and general populations, leading to significant pain, lost productivity, and disabilities. However, surgical reconstruction of ruptured tendons remains a clinical challenge and requires tough, regenerative artificial tendons to promote functional restoration. Here, inspired by the structure of native tendons, we introduce a facile approach that synergistically combines directional-freezing and hot-stretching strategies to produce tough and hierarchically-structured silk hydrogels, named DFHS hydrogels, for artificial tendons. At a high water content of about 70 wt%, DFHS hydrogels exhibit an ultimate tensile strength of 13.9 MPa, comparable to human anterior cruciate ligament, and a fracture toughness of 45.5 kJ m-2, 5 times as high as natural rubber. Additionally, the high crystallinity and aligned multi-level structures prolong the degradation and thus improve long-term integrity and mechanical stability both in vitro and in vivo. DFHS hydrogels exhibit multi-level anisotropy, featuring micrometer-scale honeycomb-like pore walls that harbor nanoscale-oriented β-sheets. These bioinspired topological niches induce significant cell alignment, guide the ingrowth of neo-tendon, upregulate pathways related to the extracellular matrix, promote mature tendon formation, and thereby facilitate tendon healing. This strategy, transferable to other semicrystalline polymers, presents a water-based fabrication approach for the development of tough hydrogels toward clinical translations.
中文摘要:肌腱损伤在运动员和普通人群中均较常见,会造成明显疼痛、生产力损失和功能障碍。断裂肌腱的手术重建仍是临床难题,需要坚韧且具再生能力的人工肌腱来促进功能恢复。受天然肌腱结构启发,作者提出一种简便方法,将定向冷冻与热拉伸策略协同结合,制备用于人工肌腱的坚韧多级结构丝素水凝胶,称为DFHS水凝胶。在约70 wt%的高含水量下,DFHS水凝胶的极限拉伸强度为13.9 MPa,与人前交叉韧带相当,断裂韧性为45.5 kJ m-2,是天然橡胶的5倍。高结晶度和取向的多级结构延长了降解时间,从而在体外和体内均提高了长期完整性和力学稳定性。DFHS水凝胶具有多级各向异性,其特征是微米级蜂窝状孔壁内含纳米级取向β-折叠片层。这些仿生拓扑微环境诱导显著的细胞取向,引导新肌腱长入,上调细胞外基质相关通路,促进成熟肌腱形成,从而促进肌腱愈合。该策略可推广至其他半结晶聚合物,为坚韧水凝胶的临床转化提供了一种水基制备方法。
Titanium (Ti)-based implants often exhibit poor osseointegration in osteoporotic bone defects, primarily due to osteoporosis frequently accompanied by excessive reactive oxygen species (ROS), which induce mitochondrial oxidative stress within osteoblasts, leading to dysfunctional mitochondria. To address this challenge, a piezo-metastructured array composed of BaTiO3 nanorods decorated with hydroxyapatite (HA) nanoparticles (termed as BTH array) was constructed on Ti, which can significantly enhance piezoelectric potential (PP) under low-intensity pulsed ultrasound (LIPUS) treatment. Based on the simulation results, the enhanced PP of BTH array under LIPUS arises from the effects of nanorod pattern induced acoustic impedance matching and the overlapping built-in electric field at BaTiO3/HA interface. The elevated PP activates voltage-gated calcium channels in osteoblasts under osteoporosis mimicking conditions, allowing Ca2+ released from degraded HA to flux into cells and appropriately elevate mitochondrial calcium levels, thereby promoting ATP synthesis. The enhanced ATP synthesis supports cytoskeletal remodeling of cells, thereby triggering migrasome formation to eliminate damaged mitochondria and promote the fission of healthy ones. This process restores mitochondrial quality control, leading to the mitigation of mitochondrial oxidative stress and ultimately enhancing osseointegration of Ti-based implants in osteoporosis bone. Thus, piezo-metastructured array coating mediated ATP synthesis in osteoblasts under LIPUS represents a promising strategy to improve implant osseointegration under osteoporosis conditions.
中文摘要:钛基植入体在骨质疏松性骨缺损中常表现出较差的骨整合,主要因为骨质疏松常伴随过量活性氧(ROS),诱导成骨细胞内线粒体氧化应激,造成线粒体功能障碍。为应对这一问题,在钛表面构建了由钛酸钡纳米棒并以羟基磷灰石(HA)纳米颗粒修饰的压电超结构阵列(称为BTH阵列),该阵列在低强度脉冲超声(LIPUS)处理下可显著增强压电电位(PP)。模拟结果显示,BTH阵列在LIPUS下增强的PP源于纳米棒图案诱导的声阻抗匹配以及BaTiO3/HA界面处重叠的内建电场。在模拟骨质疏松条件下,升高的PP激活成骨细胞中的电压门控钙通道,使降解HA释放的Ca2+流入细胞并适度提高线粒体钙水平,从而促进ATP合成。增强的ATP合成支持细胞骨架重塑,进而触发迁移体形成以清除受损线粒体并促进健康线粒体分裂。该过程恢复线粒体质量控制,减轻线粒体氧化应激,最终增强钛基植入体在骨质疏松骨中的骨整合。因此,LIPUS下压电超结构阵列涂层介导的成骨细胞ATP合成是改善骨质疏松条件下植入体骨整合的有前景策略。
Magnesium-titanium (Mg-Ti) composites have the potential in applications to bone repair and orthopedic implants due to their mechanical properties derived from Ti and biological functions derived from Mg. However, the degradation rate of Mg in the composite is accelerated due to the effect of galvanic corrosion, which has affected its clinical application. In order to regulate the degradation behavior of Mg-Ti composites,3D printing technology was employed to prepare Ti scaffolds with porous structures of different pore areas and pore shapes (square, hexagonal, and triangular), then Mg was infiltrated into the porous Ti scaffold to obtain the Mg-Ti composites. The results showed that the groups with smaller pore areas had a faster initial degradation rate and could reach a stable stage earlier. The degradation of the square structure composite was more controllable compared to the other two composites, so it was selected for the subsequent study on osteogenic properties. The addition of Mg in the composite enhanced the apatite-forming ability, upregulated the expression of osteogenic-related genes such as RUNX2, ALP, and OPN, and promoted the generation of bone tissue and collage. The results indicated that the Mg-Ti composite could regulate the content and the degradation rate of Mg through structure, thereby improving the osteogenic properties by regulating the release of Mg2+ in the surrounding microenvironment. This study explored the degradation mechanism and systematically established a relationship between structure, degradation, and osteogenesis of Mg-Ti composites, thereby providing ideas for the structural optimization of Mg-Ti composites and offering references for applications in medical bone repair.
中文摘要:镁钛复合材料兼具钛提供的力学性能和镁提供的生物学功能,在骨修复和骨科植入物应用中具有潜力。但电偶腐蚀会加快复合材料中镁的降解速率,影响其临床应用。为调控镁钛复合材料的降解行为,采用3D打印制备不同孔隙面积和孔隙形状(方形、六边形、三角形)的多孔钛支架,再将镁浸渗到多孔钛支架中得到镁钛复合材料。结果显示,孔隙面积较小的组初始降解速率更快,并能更早达到稳定阶段。方形结构复合材料的降解较另外两种复合材料更可控,因此被选用于后续成骨性能研究。复合材料中镁的加入增强了磷灰石形成能力,上调了RUNX2、ALP和OPN等成骨相关基因的表达,促进了骨组织和胶原的生成。结果表明,镁钛复合材料可通过结构调控镁的含量和降解速率,并通过调节周围微环境中Mg2+的释放改善成骨性能。该研究探讨了镁钛复合材料的降解机制,系统建立了结构、降解与成骨之间的关系,为镁钛复合材料的结构优化提供了思路,也为医学骨修复应用提供了参考。
5关节置换 (6篇)
临床研究 (5篇)
Unicompartmental knee arthroplasty (UKA) is an alternative to total knee arthroplasty for isolated compartment osteoarthritis; however, concerns persist regarding its long-term durability. The purpose of this study was to evaluate revision-free survivorship, risk factors for revision, and clinical outcomes in a large consecutive series of contemporary UKAs. We retrospectively reviewed consecutive primary UKAs performed from 2000 to 2021 at a single tertiary academic center. Revision-free survivorship was estimated using a Kaplan-Meier analysis, and risk factors for revision were assessed using Cox proportional hazards modeling. Clinical outcomes were assessed using the Knee Society Score (KSS). A total of 2,234 UKAs were included. Fixed-bearing implants were used in 78% of UKAs. Technology assistance was used in 59% of UKAs (fluoroscopy, 43%; robotic assistance, 15%; computer navigation, 1%). The mean patient age was 65 years, the mean body mass index was 31 kg/m2, and 49% of UKAs were performed in female patients. Patient race was White in 97% of UKAs, and patient ethnicity was not Hispanic or Latino in 94%. Revision-free survivorship was 92% at 10 years and 85% at 15 years. Overall, 118 UKAs were revised, most commonly through conversion to total knee arthroplasty (97%). The most frequent indications for revision were progression of osteoarthritis in an adjacent compartment (41%), aseptic loosening (23%), unexplained pain (9%), and hardware failure (9%). Factors associated with a lower risk of revision in the univariable analysis included technology assistance (hazard ratio [HR], 0.4; p < 0.01) and high surgeon volume (HR, 0.5; p < 0.01). Mobile-bearing design (HR, 1.9; p < 0.01) was associated with an increased risk of revision in the univariable analysis. The mean KSS improved from 47 preoperatively to 75 at 5 years postoperatively (p < 0.001). In this large consecutive series, UKA demonstrated excellent long-term survivorship, with an approximately 1% annual risk of revision through 15 years. Technology assistance, a fixed-bearing implant design, and high surgeon volume were each associated with a lower risk of revision, underscoring the importance of operative technique and implant selection in achieving durable outcomes. Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.
中文摘要:单髁膝关节置换术(UKA)是孤立间室骨关节炎患者全膝关节置换术之外的替代选择,但其长期耐久性仍受关注。本研究旨在评估一大组连续现代UKA的无翻修生存率、翻修危险因素及临床结局。回顾性分析2000年至2021年在单一三级学术中心连续实施的原发性UKA。采用Kaplan-Meier分析估计无翻修生存率,采用Cox比例风险模型评估翻修危险因素。临床结局采用膝关节学会评分(KSS)评估。共纳入2,234例UKA。78%使用固定平台假体。59%使用技术辅助(透视43%;机器人辅助15%;计算机导航1%)。患者平均年龄65岁,平均体重指数31 kg/m2,49%为女性。97%患者种族为白人,94%患者族裔为非西班牙裔或拉丁裔。10年无翻修生存率为92%,15年为85%。共118例UKA接受翻修,最常见为转为全膝关节置换术(97%)。翻修最常见指征为邻近间室骨关节炎进展(41%)、无菌性松动(23%)、不明原因疼痛(9%)和假体部件失效(9%)。单变量分析中与较低翻修风险相关的因素包括技术辅助(风险比[HR]0.4;p<0.01)和高手术量术者(HR 0.5;p<0.01)。活动平台设计(HR 1.9;p<0.01)在单变量分析中与翻修风险增加相关。平均KSS从术前47改善至术后5年75(p<0.001)。在这一大组连续病例中,UKA显示出良好的长期生存率,15年内年翻修风险约1%。技术辅助、固定平台假体设计和高手术量术者均与较低翻修风险相关,说明手术技术和假体选择对获得持久结局很重要。治疗证据等级III。证据等级的完整说明见作者须知。
The purpose of this study was to compare the outcomes of patients who underwent a total hip arthroplasty (THA) and sustained a postoperative periprosthetic femoral fracture either within the early postoperative period, within 30 days, or at later time points. A large, all-payer national database was queried to identify patients who underwent a primary THA between 2010 and 2022. Patients who underwent a primary THA and sustained a periprosthetic femoral fracture within 30 days postoperatively were propensity-score matched on the basis of age, sex, and comorbidity burden to 3 separate cohorts based on timing: fracture between 31 and 90 days postoperatively (n = 1,725), fracture between 91 days and 1 year (n = 1,887), and no fracture within 1 year (n = 4,465). The 30-day fracture group had a mean age of 66.63 ± 10.15 years, and 75% of patients in this group were female. Regression analyses were utilized to evaluate outcomes at 90 days and 2 years. Survivorship analyses utilizing death as a competing end-point were conducted for rates of infection, refracture, and reoperation at up to 2 years. Patients who sustained a periprosthetic femoral fracture within 30 days after primary THA demonstrated significantly greater rates of complications within 90 days relative to each comparison cohort. The 2-year survivorships free of refracture and reoperation were significantly lower (p < 0.05) for the early fracture cohort relative to matched patients who sustained a fracture at other time points. Additionally, 2-year survivorships were poorer in the ≤30-day cohort than in the comparison cohort who had not sustained a fracture within 1 year postoperatively: survivorships free of infection (87.8% [95% confidence interval (CI), 86.8% to 88.8%] compared with 97.7% [95% CI, 97.3% to 98.1%]), refracture (57.4% [95% CI, 56.0% to 58.9%] compared with 99.5% [95% CI, 99.3% to 99.7%]), and reoperation (48.5% [95% CI, 47.1% to 50.0%] compared with 97.6% [95% CI, 97.2% to 98.1%]) were all significantly lower (p < 0.05). Patients who sustained an early periprosthetic femoral fracture within 30 days following primary THA were at significantly greater risk for complications than patients who sustained a periprosthetic femoral fracture at later time points. The exceedingly high rates of complications compared with patients without a periprosthetic femoral fracture stresses the importance of not only prevention but potential interventions both perioperatively and postoperatively in an attempt to mitigate the risk of complications for these at-risk patients. Therapeutic Level III . See Instructions for Authors for a complete description of levels of evidence.
中文摘要:本研究比较接受全髋关节置换术(THA)后发生假体周围股骨骨折的患者在术后早期(30天内)与较晚时间点发生骨折的结局。检索一个大型、全支付方全国数据库,识别2010年至2022年间接受初次THA的患者。将初次THA后30天内发生假体周围股骨骨折的患者按年龄、性别和合并症负担进行倾向评分匹配,分别与3个队列比较:术后31至90天发生骨折(n=1725)、91天至1年发生骨折(n=1887)以及1年内未发生骨折(n=4465)。30天骨折组平均年龄66.63±10.15岁,75%为女性。采用回归分析评估90天和2年结局。以死亡为竞争终点的生存分析用于评估至2年的感染、再骨折和再手术率。初次THA后30天内发生假体周围股骨骨折的患者,其90天内并发症发生率显著高于各比较队列。早期骨折队列的无再骨折生存率和无再手术生存率在2年时显著低于在其他时间点发生骨折的匹配患者(p<0.05)。此外,≤30天队列的2年生存率也低于术后1年内未发生骨折的比较队列:无感染生存率(87.8%[95%置信区间(CI),86.8%至88.8%]对比97.7%[95%CI,97.3%至98.1%])、无再骨折生存率(57.4%[95%CI,56.0%至58.9%]对比99.5%[95%CI,99.3%至99.7%])和无再手术生存率(48.5%[95%CI,47.1%至50.0%]对比97.6%[95%CI,97.2%至98.1%])均显著更低(p<0.05)。初次THA后30天内发生早期假体周围股骨骨折的患者,其并发症风险显著高于较晚时间点发生假体周围股骨骨折的患者。与未发生假体周围股骨骨折的患者相比,并发症发生率极高,这强调不仅要重视预防,还可能需要围手术期和术后干预,以降低这些高危患者的并发症风险。治疗性证据等级III级。完整证据等级说明见作者须知。
Periprosthetic femoral fractures (PFFs) are an increasingly common indication for revision total hip arthroplasty (THA). While patient-related risk factors are well documented, the influence of femoral stem design on PFF risk remains poorly characterized. In this study using nationwide data, we assessed the association between stem design and PFF risk. We analyzed 182,118 primary THAs (performed from 2015 to 2023) from the Swiss National Joint Registry (SIRIS). Cementless stems were categorized according to the Kheir classification, and cemented stems were categorized as double-tapered polished, triple-tapered polished, composite-beam, or custom. A multivariable Cox regression model, including variables such as age, sex, American Society of Anesthesiologists (ASA) class, body mass index (BMI), surgical indication, prior ipsilateral hip surgery, stem design, collar, dual-mobility cup, bearing, and head size, was analyzed. Hazard ratios (HRs) with 95% confidence intervals (CIs) are reported. Among 182,118 THAs (mean patient age, 68.9 ± 11.5 years; female sex in 53.1% of cases), 1,226 (0.7%) were complicated by PFF. The cumulative incidence of PFF reached 0.7% at 5 years and 1.3% at 10 years. Higher PFF risk was associated with an age of 75 to 84 years (HR = 1.68 [95% CI = 1.44 to 1.96]) and ≥85 years (HR = 1.86 [95% CI = 1.47 to 2.35]), ASA class of 3 to 5 (females, HR = 1.70; males, HR = 1.73), BMI of <18.5 kg/m 2 (HR = 1.61) or ≥40 kg/m 2 (HR = 1.64), prior ipsilateral hip surgery (HR = 1.32), and use of a dual-mobility cup (HR = 1.56). Elective procedures (HR = 0.36) and collared stems (HR = 0.26) were associated with a lower risk. Compared with cementless type-3 stems, cementless type-7 (anatomic) stems showed a higher risk of PFF (HR = 1.88), whereas cementless type-1B (HR = 0.62) and composite-beam cemented stems (HR = 0.45) were protective. In this large nationwide registry study, femoral stem design independently influenced PFF risk after primary THA. Cementless anatomic stems increased the risk, whereas composite-beam cemented stems and the presence of a collar conferred a protective effect. These findings support personalized implant selection, particularly for older patients or those with frailty. Prognostic Level III . See Instructions for Authors for a complete description of levels of evidence.
中文摘要:假体周围股骨骨折(PFF)是翻修全髋关节置换术(THA)日益常见的指征。患者相关危险因素已有较多记录,股骨柄设计对PFF风险的影响仍不明确。本研究利用全国数据评估股骨柄设计与PFF风险的关联。分析瑞士国家关节登记系统(SIRIS)2015至2023年施行的182,118例初次THA。非骨水泥柄按Kheir分型分类,骨水泥柄分为双锥度抛光柄、三锥度抛光柄、复合梁型和定制柄。采用多变量Cox回归模型,纳入年龄、性别、美国麻醉医师学会(ASA)分级、体重指数(BMI)、手术指征、同侧髋部手术史、股骨柄设计、领托、双动髋臼杯、摩擦界面和球头尺寸等变量。报告风险比(HR)及95%置信区间(CI)。182,118例THA(患者平均年龄68.9±11.5岁;女性53.1%)中,1,226例(0.7%)发生PFF。PFF累积发生率5年为0.7%,10年为1.3%。PFF风险较高与年龄75至84岁(HR=1.68[95%CI=1.44至1.96])和≥85岁(HR=1.86[95%CI=1.47至2.35])、ASA 3至5级(女性HR=1.70;男性HR=1.73)、BMI<18.5 kg/m2(HR=1.61)或≥40 kg/m2(HR=1.64)、同侧髋部手术史(HR=1.32)及使用双动髋臼杯(HR=1.56)相关。择期手术(HR=0.36)和带领托股骨柄(HR=0.26)与较低风险相关。与非骨水泥3型柄相比,非骨水泥7型(解剖型)柄PFF风险更高(HR=1.88),非骨水泥1B型(HR=0.62)和复合梁型骨水泥柄(HR=0.45)具有保护作用。在这项大型全国登记研究中,股骨柄设计独立影响初次THA后PFF风险。非骨水泥解剖型柄增加风险,复合梁型骨水泥柄和带领托股骨柄具有保护效应。这些发现支持个体化植入物选择,尤其针对老年或衰弱患者。预后证据等级III级。证据等级完整说明见作者须知。
Socioeconomic disadvantage is increasingly recognized as an important factor associated with outcomes after total joint arthroplasty (TJA). The Area Deprivation Index (ADI) has emerged as a validated measure of socioeconomic disadvantage that specifically captures individual neighborhood levels of structural and material deprivation based on income, education, employment, and housing characteristics. Prior research has demonstrated ADI to be associated with surgical outcomes; however, its relationship to postoperative outcomes after THA and TKA, procedures in which outcomes depend highly on institutional and structural support, home environment, and accessible postacute care resources, has not been well synthesized. Prior studies provide a broad overview of heterogeneous measures of socioeconomic disadvantage that are not directly comparable. (1) Is a higher ADI associated with increased postoperative healthcare utilization after primary THA and TKA? (2) Is a higher ADI associated with differences in patient-reported outcome measures (PROMs)? (3) Is a higher ADI associated with increased postoperative complications? (4) Is ADI associated with differences in implant survivorship after TJA? A systematic review of four databases-Ovid Medline, Embase, Cochrane Library, and Web of Science Core Collection-was performed from their inception to March 27, 2025. Each database was last searched on March 27, 2025. In all, 128 records were available. Studies were included if they evaluated patients receiving primary THA or TKA and examined ADI in the Results section of the manuscript in terms of any of the following: 90-day outcomes, healthcare utilization, complications, reoperations, revisions, cost, or PROMs. Studies were excluded if they examined revision hip or knee arthroplasty, hemiarthroplasty, or arthroplasty of any other joint; did not evaluate outcomes in association with ADI; or were case reports, systematic reviews, conference abstracts, editorials, or narrative reviews. Sixteen studies were included for final review. Two reviewers independently screened studies, extracted data, and assessed methodological quality using the Newcastle-Ottawa Scale (NOS), which has a maximum quality score of nine stars. Included studies had a median (range) NOS score of 8 stars (7 to 9), suggesting that most were of good quality with a low risk of bias. Results were synthesized qualitatively; meta-analyses were not performed because of the heterogeneity of included studies. A higher ADI was consistently associated with greater healthcare utilization, including prolonged length of stay, increased likelihood of nonhome discharge, and increased odds of emergency department visits. PROMs demonstrated worse absolute postoperative scores and lower likelihood of achieving patient acceptable symptom states among patients who live in high ADI neighborhoods despite comparable levels of improvement across all groups. Overall, ADI was not associated with reaching the standard minimum clinically important difference (MCID). All groups achieved the MCID on all domains of the Hip Disability and Osteoarthritis Outcome Score, Knee Injury and Osteoarthritis Outcome Score, and Patient-Reported Outcomes Measurement Information System short forms regardless of ADI. A higher ADI was associated with increased odds of medical complications such as infection, venous thromboembolism, cardiopulmonary events, and acute kidney injury. Evidence on implant survivorship was limited but suggested increased odds of reoperation and periprosthetic joint infection within 90 days and increased odds of aseptic revision beyond 90 days in populations with more severe levels of deprivation as measured by the ADI. Higher neighborhood socioeconomic deprivation was independently associated with worse postoperative outcomes, greater resource utilization, and signals of inferior early implant survivorship after THA and TKA. The ADI provides meaningful insight into neighborhood-level social risk beyond traditional clinical factors and individual patient demographics and may help identify patients who may benefit from interventions such as more intensive preoperative medical management of comorbidities, tailored perioperative support, easily accessible rehabilitation, or closer postoperative follow-up. Incorporating the ADI into risk-adjustment models and care pathways may help clinicians better anticipate possible barriers to recovery and may help ensure that patients from less affluent communities achieve the results they seek after lower extremity arthroplasty. Level III, therapeutic study.
中文摘要:社会经济劣势日益被视为与全关节置换(TJA)术后结局相关的重要因素。区域剥夺指数(ADI)是一种经验证的社会经济劣势测量工具,基于收入、教育、就业和住房特征,具体反映个体所在社区的结构性和物质性剥夺水平。既有研究显示ADI与手术结局相关,但其与THA和TKA术后结局的关系尚未得到充分整合;这两类手术的结局高度依赖机构与结构性支持、家庭环境以及可获得的急性期后护理资源。既往研究提供的是异质性社会经济劣势测量的概览,彼此不直接可比。研究问题包括:(1)较高的ADI是否与初次THA和TKA术后医疗资源利用增加相关?(2)较高的ADI是否与患者报告结局测量(PROMs)差异相关?(3)较高的ADI是否与术后并发症增加相关?(4)ADI是否与TJA后植入物生存率差异相关?系统检索Ovid Medline、Embase、Cochrane Library和Web of Science Core Collection四个数据库,检索时间自建库至2025年3月27日,各数据库最后检索日期均为2025年3月27日。共获得128条记录。纳入标准为研究初次THA或TKA患者,并在结果部分分析ADI与以下任一结局的关系:90天结局、医疗资源利用、并发症、再手术、翻修、费用或PROMs。排除标准为研究髋或膝翻修置换、半髋置换或其他关节置换;未评估ADI与结局关系;或为病例报告、系统综述、会议摘要、社论或叙述性综述。最终纳入16项研究。两名评审者独立筛选研究、提取数据,并使用Newcastle-Ottawa量表(NOS,最高9星)评估方法学质量。纳入研究中位(范围)NOS评分为8星(7至9星),提示多数研究质量良好、偏倚风险低。因纳入研究异质性,结果采用定性整合,未进行meta分析。较高的ADI一致与医疗资源利用增加相关,包括住院时间延长、非家庭出院可能性增加和急诊就诊 odds 增加。PROMs显示,居住在高ADI社区的患者术后绝对评分更差,达到患者可接受症状状态的可能性更低,但各组改善程度相当。总体而言,ADI与达到标准最小临床重要差异(MCID)无关;无论ADI如何,所有组在髋关节功能障碍与骨关节炎结局评分、膝关节损伤与骨关节炎结局评分以及患者报告结局测量信息系统简表的各领域均达到MCID。较高的ADI与感染、静脉血栓栓塞、心肺事件和急性肾损伤等内科并发症 odds 增加相关。植入物生存率证据有限,但提示在ADI所测剥夺程度更严重的人群中,90天内再手术和假体周围关节感染 odds 增加,90天后无菌性翻修 odds 增加。较高的社区社会经济剥夺独立与THA和TKA术后更差结局、更高资源利用以及早期植入物生存率较差的信号相关。ADI可提供超越传统临床因素和个体人口学特征的社区层面社会风险信息,有助于识别可能从更密集的术前合并症内科管理、个体化围手术期支持、易获得的康复或更密切术后随访等干预中获益的患者。将ADI纳入风险校正模型和照护路径,可能帮助临床医生更好地预判康复障碍,并帮助确保来自较不富裕社区的患者在下肢关节置换后获得其所期望的结果。证据等级为III级,治疗性研究。
Robot-assisted THA is becoming more common, and evidence suggests that robot assistance improves the accuracy of acetabular cup positioning. By means of reducing implant malpositioning, robot-assisted THA has been proposed as a method to reduce the risk of revision surgery and particularly revision due to dislocation. However, this has not yet been explored using an arthroplasty registry. (1) In a dataset drawn from the American Joint Replacement Registry (AJRR) and its Medicare claims data linkage, after controlling for confounding variables, is robot-assisted THA associated with a decreased risk of all-cause revision at minimum 2-year follow-up? (2) After controlling for confounding variables, is robot-assisted THA associated with a decreased risk of revision for dislocation at minimum 2-year follow-up? The AJRR and its Medicare claims data linkage were used to create a retrospective comparative study of patients aged 65 years or older who underwent primary elective robot-assisted THA (n = 10,988) or conventional THA (n = 113,477) between 2017 and 2021. All patients within the AJRR who had undergone primary THA and had complete records with respect to robot data were included. The AJRR was selected for this study because of its Medicare linkage, and therefore follow-up data are considered near complete. Both cohorts had the same mean age (74 ± 6 years; p = 0.15) and the same proportion of females (60% [67,903 of 113,447] for conventional THA versus 60% [6540 of 10,988] for robot-assisted THA; p = 0.51). Mixed-effect Cox regression models were used to determine the hazard of all-cause revision and revision for dislocation at 2 years. Variables included within these models were age, Charlson comorbidity index (CCI), length of stay (LOS), sex, anesthesia type, and race. Surgeon and institution were controlled as the random effect within these models. After controlling for confounding variables, the risk of all-cause revision at 2 years did not differ between robot-assisted THA and conventional THA (1.9% [208 of 10,988] versus 2.1% [2357 of 113,477], HR 0.9 [95% confidence interval (CI) 0.7 to 1.1]; p = 0.42). Revision for dislocation was lower in robot-assisted THA (0.3% [35 of 10,988]) compared to conventional THA (0.6% (689 of 113,477), HR 0.5 [95% CI 0.3 to 0.9]; p = 0.03). Robot-assisted THA did not demonstrate a difference in all-cause revision at 2 years, but robot-assisted THA was associated with a reduced risk of revision for dislocation compared to conventional THA. This study demonstrates that robotic assistance is a potentially useful adjunct during THA to decrease the risk of early revision for dislocation. In clinical scenarios where early dislocation might be a concern, robot-assisted THA might be considered a means to mitigate this risk. However, until or unless robot assistance demonstrates clear improvement regarding revision-free implant survival, surgeons should remain cautious of widespread adoption of this technology. Level III, therapeutic study.
中文摘要:机器人辅助全髋关节置换术(THA)日益常见,有证据提示机器人辅助可提高髋臼杯放置的准确性。通过减少假体位置不良,机器人辅助THA被视为降低翻修手术风险、尤其是脱位所致翻修风险的方法。但此前尚未利用关节置换登记数据对此进行探讨。(1)在美国关节置换登记系统(AJRR)及其Medicare理赔数据链接所形成的数据集中,控制混杂变量后,机器人辅助THA是否与至少2年随访时全因翻修风险降低相关?(2)控制混杂变量后,机器人辅助THA是否与至少2年随访时脱位翻修风险降低相关?研究使用AJRR及其Medicare理赔数据链接,构建回顾性比较研究,纳入2017年至2021年接受初次择期机器人辅助THA(n=10,988)或传统THA(n=113,477)的65岁及以上患者。AJRR中接受初次THA且机器人相关数据记录完整的患者均被纳入。选择AJRR是因为其与Medicare链接,随访数据被认为接近完整。两队列平均年龄相同(74±6岁;p=0.15),女性比例相同(传统THA为60%[67,903/113,447],机器人辅助THA为60%[6,540/10,988];p=0.51)。采用混合效应Cox回归模型评估2年时全因翻修与脱位翻修的风险。模型变量包括年龄、Charlson合并症指数(CCI)、住院时间(LOS)、性别、麻醉类型和种族。外科医生与机构作为随机效应纳入模型控制。控制混杂变量后,机器人辅助THA与传统THA在2年全因翻修风险上无差异(1.9%[208/10,988] vs 2.1%[2,357/113,477],HR 0.9[95% CI 0.7-1.1];p=0.42)。机器人辅助THA的脱位翻修低于传统THA(0.3%[35/10,988] vs 0.6%[689/113,477],HR 0.5[95% CI 0.3-0.9];p=0.03)。机器人辅助THA在2年全因翻修上未显示差异,但与传统THA相比,机器人辅助THA与脱位翻修风险降低相关。该研究表明,机器人辅助是THA中可能有用的辅助手段,可降低早期脱位翻修风险。在早期脱位可能成为顾虑的临床情形中,可考虑将机器人辅助THA作为减轻该风险的方式。但在机器人辅助明确显示无翻修假体生存改善之前,外科医生应对该技术的广泛采用保持谨慎。III级,治疗性研究。
基础研究 (1篇)
An important and often overlooked legacy and orthopaedic innovation of Dr. David G. Murray is the Variable Axis knee prosthesis. Conceptualized by Dr. Murray in 1972 and engineered over the ensuing 2 years, the unique "ball-in-socket" design of the prosthesis represented the first unconstrained cruciate-substituting knee prosthesis. Its metal-backed tibial component with modular polyethylene inserts of varying thicknesses and angular designs was also an innovative first and is a design feature that was incorporated into virtually all subsequent prosthetic knees. Released for clinical application in 1974, the Variable Axis knee prosthesis enjoyed over a decade of successful clinical use but was ultimately supplanted by the more anatomically configured Total Condylar-type designs.
中文摘要:David G. Murray 博士一项重要却常被忽视的学术遗产与骨科创新是可变轴膝关节假体。Murray 博士于1972年提出构想,随后两年完成工程设计,该假体独特的「球窝式」设计是首个非限制性交叉韧带替代型膝关节假体。其金属背衬胫骨部件搭配不同厚度与角度设计的模块化聚乙烯衬垫,同样是创新性的首创,这一设计特征几乎被其后所有膝关节假体采纳。可变轴膝关节假体于1974年投入临床应用,成功应用十余年,最终被解剖形态更接近的全髁型设计取代。
6脊柱外科 (5篇)
临床研究 (4篇)
The purpose of this study was to determine whether placement of triangular titanium implants (TTI) suprajacent to S2-alar-iliac (S2AI) pelvic fixation screws during multilevel spinal fusion surgery for adult spine deformity reduces pelvic fixation failures. This prospective, multicenter, international, partially blinded randomized clinical trial included 222 patients scheduled for multilevel spinal fusion surgery with S2AI-based pelvic fixation. In the S2AI+TTI group, the mean age was 64.9 years, 54.1% were female, 3.7% were Hispanic, 5.5% were African American, and 1.8% were Asian. In the S2AI-alone group, the mean age was 64.8 years, 58.4% were female, 3.5% were Hispanic, 7.1% were African American, and 0.9% were Asian. Subjects were randomized to pelvic fixation using S2AI screws alone versus S2AI+TTI. Scheduled follow-up included a 24-month full-spine radiograph and a high-resolution computed tomography (CT) scan, which was independently interpreted. The primary composite radiographic end point (S2AI screw breakage, lucency, or pullout, or posterior spinal rod breakage distal to S1) occurred less frequently in the S2AI+TTI group than in the S2AI-alone group (11.0% versus 20.4%, p = 0.0415). Except for rod-screw dissociation and rod fracture distal to S1, all components of the primary composite end point occurred less frequently in the S2AI+TTI group. TTI placement did not affect sagittal or coronal spinal alignment parameters. The rate of rod fracture throughout the spinal construct was slightly higher in the S2AI+TTI group (9.2% versus 5.3%) but the difference was not significant (p = 0.197). Placement of TTI suprajacent to S2AI screws reduced the rate of pelvic fixation failure in patients undergoing multilevel spinal fusion with pelvic fixation. Therapeutic Level I . See Instructions for Authors for a complete description of levels of evidence.
中文摘要:本研究旨在确定在多节段脊柱融合手术治疗成人脊柱畸形时,于S2-髂骨(S2AI)骨盆固定螺钉上方放置三角形钛植入物(TTI)是否降低骨盆固定失败。这项前瞻性、多中心、国际、部分盲法随机临床试验纳入222例计划接受以S2AI为基础的骨盆固定的多节段脊柱融合手术患者。S2AI+TTI组平均年龄64.9岁,女性54.1%,西班牙裔3.7%,非裔美国人5.5%,亚裔1.8%。S2AI单独组平均年龄64.8岁,女性58.4%,西班牙裔3.5%,非裔美国人7.1%,亚裔0.9%。受试者随机分配至单独S2AI螺钉骨盆固定或S2AI+TTI。计划随访包括24个月全脊柱X线片和高分辨率计算机断层扫描(CT),由独立判读。主要复合影像学终点(S2AI螺钉断裂、透亮或拔出,或S1以远后路脊柱棒断裂)在S2AI+TTI组发生率低于S2AI单独组(11.0%对比20.4%,p=0.0415)。除棒-螺钉分离和S1以远棒断裂外,主要复合终点的各组成部分在S2AI+TTI组均较低。TTI放置未影响矢状面或冠状面脊柱序列参数。整个脊柱构造内棒断裂率在S2AI+TTI组略高(9.2%对比5.3%),差异无统计学意义(p=0.197)。在行骨盆固定的多节段脊柱融合患者中,于S2AI螺钉上方放置TTI降低了骨盆固定失败率。治疗证据等级I。有关证据等级的完整说明见作者须知。
Randomized trials have shown limited benefits and increased risks of adding spinal fusion surgery to decompression for degenerative spondylolisthesis. Decompression with fusion has increasingly been used in the United States. To examine the comparative effectiveness of decompression with fusion versus decompression alone for patient subgroups. Cohort study using the target trial framework. Norwegian Registry for Spine Surgery and nested NORDSTEN-DS (Norwegian degenerative spondylolisthesis and spinal stenosis) randomized trial. Adults aged 18 to 80 years with lumbar degenerative spondylolisthesis and symptomatic back or leg pain lasting at least 3 months. Lumbar spinal decompression surgery with fusion versus lumbar spinal decompression surgery alone. The primary outcomes were Oswestry Disability Index (ODI) score and reoperation at 12 months. Linear regression models with inverse probability weighting to control for baseline confounding were used to obtain effect estimates with 95% CIs for decompression with fusion versus decompression alone for prespecified subgroups, including sex, age, smoking, body mass index (BMI), back pain intensity, and American Society of Anesthesiologists (ASA) grade. Of 2252 patients, 236 were in the NORDSTEN-DS randomized trial. The mean age was 66 years, and 1576 (70%) women were included. A total of 1446 patients had decompression alone, and 806 had decompression with fusion; respective unadjusted baseline ODI scores were 38.9 (SD, 14.9) and 41.4 (SD, 14.7). At 12 months, the ODI score was 22.3 (95% CI, 15.5 to 29.1) for decompression alone and 20.0 (CI, 13.9 to 26.2) for decompression with fusion; the mean difference was 2.2 (CI, -1.6 to 6.1). In exploratory analyses, the ODI score was worse for decompression with fusion for men with BMI of 30 kg/m2 or higher. Reoperation risk at 12 months did not differ. Possible residual confounding. Patient subgroups did not have differential effects from the addition of fusion to decompression at 12 months. Research Council of Norway.
中文摘要:随机试验显示,在退化性腰椎滑脱的减压手术中加入脊柱融合获益有限且风险增加。减压融合术在美国的使用逐渐增多。研究比较减压融合术与单纯减压术在患者亚组中的效果。采用目标试验框架的队列研究,数据来自挪威脊柱外科登记处及嵌套的NORDSTEN-DS随机试验。研究对象为18至80岁、患腰椎退化性滑脱并伴有症状性背痛或腿痛至少3个月的成人。干预为腰椎减压融合术对比单纯腰椎减压术。主要结局为12个月时Oswestry功能障碍指数(ODI)评分和再手术。使用线性回归模型并结合逆概率加权控制基线混杂,获得预设亚组中减压融合术对比单纯减压术的效应估计及95%CI,亚组包括性别、年龄、吸烟、体重指数(BMI)、背痛强度和美国麻醉医师学会(ASA)分级。2252例患者中236例来自NORDSTEN-DS随机试验。平均年龄66岁,女性1576例(70%)。1446例接受单纯减压,806例接受减压融合;未调整基线ODI分别为38.9(SD 14.9)和41.4(SD 14.7)。12个月时,单纯减压组ODI为22.3(95%CI 15.5至29.1),减压融合组为20.0(95%CI 13.9至26.2);平均差异为2.2(95%CI -1.6至6.1)。探索性分析中,BMI≥30 kg/m2的男性接受减压融合术时ODI更差。12个月再手术风险无差异。可能存在残余混杂。患者亚组在12个月时未显示加用融合术存在差异效应。挪威研究理事会资助。
Postoperative pain after lumbar spine surgery often requires substantial opioid use. Perineural adjuvants such as dexamethasone and dexmedetomidine are increasingly used to prolong the duration of regional blocks and improve analgesic quality; however, their comparative effects remain uncertain. Ultrasound-guided erector spinae plane block (ESPB) is widely used as part of multimodal analgesia, but the selection of perineural adjuvants remains uncertain. (1) Does adding adjuvants (dexamethasone or dexmedetomidine) to the ESPB result in longer time to first rescue opioid? (2) Do patients who received adjuvants have lower total opioid consumption in the first 48 hours after surgery, and do they have lower pain scores? (3) Does dexamethasone or dexmedetomidine result in lower postoperative systemic inflammatory indices? This study was conducted at a tertiary academic referral center specializing in spine surgery. In this prospective, randomized, triple-blinded controlled trial, between March 2024 and December 2025, a total of 103 patients were assessed for eligibility. Of these, 94 were randomized. Four patients were excluded after randomization because of intraoperative changes in surgical plan or hemodynamic instability, leaving 96% (90) of adult patients undergoing posterior lumbar decompression with instrumented fusion. These patients were randomly assigned to receive ESPB in three groups: the ropivacaine alone (control), the ropivacaine plus dexamethasone, and the ropivacaine plus dexmedetomidine groups. The primary outcome was time to first rescue opioid administration. Secondary outcomes included cumulative opioid consumption within 48 hours, postoperative pain scores, and systemic inflammatory markers (neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and systemic immune-inflammation index). Patients were followed for 48 hours postoperatively. Patients receiving dexamethasone or dexmedetomidine required rescue opioids later than those receiving ropivacaine alone. The mean ± SD time to first opioid administration was 6.2 ± 0.8 hours with ropivacaine alone versus 12.7 ± 2.7 hours with dexamethasone (mean difference 6.6 hours [95% confidence interval (CI) 5.6 to 7.7]; p < 0.001) and 15.5 ± 2.0 hours with dexmedetomidine (mean difference 9.6 hours [95% CI 8.5 to 10.5]; p < 0.001). Postoperative pain scores were reduced in both adjuvant groups at all assessed time points. Compared with dexmedetomidine and ropivacaine alone, dexamethasone was associated with lower postoperative systemic inflammatory indices, indicating greater attenuation of the inflammatory response. Dexamethasone and dexmedetomidine demonstrate distinct and complementary effects when used as adjuvants to ESPB in lumbar spine surgery. Dexmedetomidine primarily enhances early postoperative analgesia, whereas dexamethasone more effectively reduces cumulative opioid consumption and systemic inflammation. These findings support a clinically actionable, mechanism-informed approach to selecting ESPB adjuvants according to the desired temporal analgesic profile and risk of prolonged postoperative opioid requirement. Level I, therapeutic study.
中文摘要:腰椎手术后疼痛常需要大量阿片类药物。神经周围辅助药如地塞米松和右美托咪定越来越多用于延长区域阻滞持续时间并改善镇痛质量,但两者的比较效果仍不确定。超声引导下竖脊肌平面阻滞(ESPB)广泛用于多模式镇痛,但神经周围辅助药的选择仍不明确。(1)在ESPB中加入辅助药(地塞米松或右美托咪定)是否延长首次补救阿片类用药时间?(2)接受辅助药的患者术后48小时内阿片类药物总用量是否更低,疼痛评分是否更低?(3)地塞米松或右美托咪定是否降低术后全身炎症指标?本研究在一家以脊柱手术为特色的三级学术转诊中心开展。在这项前瞻性、随机、三盲对照试验中,2024年3月至2025年12月共评估103例患者是否符合条件,其中94例被随机分组。随机分组后4例因术中手术方案改变或血流动力学不稳定被排除,最终纳入90例(96%)接受后路腰椎减压联合器械融合的成年患者。患者被随机分配接受三组ESPB:单用罗哌卡因(对照)、罗哌卡因加地塞米松、罗哌卡因加右美托咪定。主要结局为首次补救阿片类药物给药时间。次要结局包括48小时内累积阿片类药物用量、术后疼痛评分和全身炎症标志物(中性粒细胞与淋巴细胞比值、血小板与淋巴细胞比值和全身免疫炎症指数)。术后随访48小时。接受地塞米松或右美托咪定的患者需要补救阿片类药物的时间晚于单用罗哌卡因者。首次阿片类药物给药时间(均值±标准差)为单用罗哌卡因6.2±0.8小时,地塞米松12.7±2.7小时(平均差6.6小时,95%置信区间5.6至7.7;p<0.001),右美托咪定15.5±2.0小时(平均差9.6小时,95%置信区间8.5至10.5;p<0.001)。两个辅助药组在所有评估时间点的术后疼痛评分均降低。与右美托咪定和单用罗哌卡因相比,地塞米松与更低的术后全身炎症指标相关,提示对炎症反应的抑制作用更强。地塞米松和右美托咪定作为腰椎手术ESPB辅助药时表现出不同且互补的作用。右美托咪定主要增强术后早期镇痛,而地塞米松更有效降低累积阿片类药物用量和全身炎症。这些发现支持根据所需的时间性镇痛特征和术后长期阿片类药物需求风险来选择ESPB辅助药的临床可操作、机制导向方法。证据等级I,治疗性研究。
Mechanical complications remain a major concern after adult spinal deformity surgery. Diabetes has been associated with impaired bone quality and delayed healing in orthopaedic surgery, but its relationship with mechanical complications and patient-reported outcomes after adult spinal deformity surgery remains incompletely understood. (1) Is diabetes associated with a higher odds of mechanical complications after adult spinal deformity surgery? (2) Is revision-free survivorship for proximal junctional failure lower in patients with diabetes than in those without diabetes? (3) Do radiographic alignment parameters differ between groups after surgery? (4) Are patient-reported outcomes lower in patients with diabetes at 2 years? Between January 2010 and December 2023, a total of 585 patients underwent corrective fusion for adult spinal deformity at our institution. Of these, 11% (65) had diabetes and 89% (520) did not. Among patients with diabetes, none died before 2 years, but 3% (2 of 65) were lost to follow-up for reasons other than death. Among patients without diabetes, 0.6% (3 of 520) died, and 4% (23) were lost to follow-up before 2 years. This analysis therefore consisted of 557 patients, of whom 11% (63) had diabetes and 89% (494) did not; their data were analyzed at least 2 years after the index fusion. Diabetes was defined as a documented diagnosis being treated with medical therapy or hemoglobin A1c of at least 6.5%. Patients with diabetes were propensity score matched 1:2 with patients without diabetes based on age, gender, BMI, bone mineral density, deformity characteristics, osteotomy, pelvic fixation, and number of fused levels. The purpose of propensity matching was to improve comparability between groups by adjusting for measured baseline covariates rather than to establish causal inference. Proximal junctional failure was defined as structural failure at the upper instrumented vertebra or adjacent segment, accompanied by concordant symptoms and subsequent revision surgery. We compared the matched groups of patients with and without diabetes in terms of mechanical complications, revision-free survivorship using Kaplan-Meier analysis, postoperative alignment parameters on standing full-length AP and lateral radiographs, and patient-reported outcome scores (Oswestry Disability Index [ODI] and Scoliosis Research Society-22 [SRS-22] scores). For patient-reported outcomes, we focused on whether between-group differences exceeded prespecified minimum clinically important differences (MCIDs). Patients with diabetes had a higher odds of proximal junctional failure compared with patients without diabetes (19% [12 of 63] versus 9% [11 of 126], OR 2.5 [95% confidence interval (CI) 1.02 to 5.9]; p = 0.04). Revision-free survivorship for proximal junctional failure at 2 years was lower in patients with diabetes than in those without it (85% [95% CI 83% to 97%] versus 93% [95% CI 93% to 99%]; p = 0.02). We found no difference between groups in most radiographic alignment parameters at 1 and 2 years after surgery. Sagittal vertical axis was greater at the first standing radiograph in patients with diabetes than in those without it (mean ± SD 71 ± 53 mm versus 54 ± 49 mm, mean difference 17 [95% CI 1 to 33]; p = 0.04). Although patient-reported outcomes improved in both groups, none of the between-group differences exceeded reasonable MCID thresholds for the ODI or SRS-22 domains. Patients with diabetes undergoing corrective fusion for adult spinal deformity had a higher odds of proximal junctional failure and lower revision-free survivorship. Surgeons may consider discussing the possibility of junctional complications when counseling patients with diabetes and may consider closer postoperative surveillance and improvement of metabolic control in this population. Future studies should examine how glycemic control and bone quality influence junctional complications after deformity correction. Level Ⅲ, therapeutic study.
中文摘要:机械并发症仍是成人脊柱畸形术后主要问题。糖尿病与骨科手术中骨质量受损和愈合延迟相关,但其与成人脊柱畸形术后机械并发症及患者报告结局的关系仍未完全明确。(1)糖尿病是否与成人脊柱畸形术后机械并发症更高几率相关?(2)糖尿病患者近端交界性失败的无翻修生存率是否低于非糖尿病患者?(3)术后两组影像学对线参数是否不同?(4)糖尿病患者2年时患者报告结局是否更低?2010年1月至2023年12月,本院共585例成人脊柱畸形患者接受矫形融合术。其中11%(65例)有糖尿病,89%(520例)无糖尿病。糖尿病患者中2年内无死亡,但3%(65例中2例)因非死亡原因失访。非糖尿病患者中0.6%(520例中3例)死亡,4%(23例)在2年内失访。因此本分析纳入557例,其中11%(63例)有糖尿病,89%(494例)无糖尿病;其数据在指数融合术后至少2年进行分析。糖尿病定义为有记录诊断并接受药物治疗或血红蛋白A1c至少6.5%。糖尿病患者按年龄、性别、BMI、骨密度、畸形特征、截骨、骨盆固定和融合节段数与无糖尿病患者1:2倾向评分匹配。倾向匹配旨在通过调整已测量的基线协变量提高组间可比性,而非建立因果推断。近端交界性失败定义为上端固定椎或邻近节段的结构性失败,伴一致症状并随后接受翻修手术。比较匹配后糖尿病与非糖尿病患者的机械并发症、Kaplan-Meier分析的无翻修生存率、站立位全长正侧位X线片术后对线参数以及患者报告结局评分(Oswestry功能障碍指数[ODI]和脊柱侧凸研究学会-22[SRS-22]评分)。对于患者报告结局,关注组间差异是否超过预设最小临床重要差异(MCID)。糖尿病患者近端交界性失败的几率高于非糖尿病患者(19%[63例中12例]对9%[126例中11例],OR 2.5[95%置信区间(CI) 1.02至5.9];p=0.04)。糖尿病患者2年时近端交界性失败的无翻修生存率低于非糖尿病患者(85%[95% CI 83%至97%]对93%[95% CI 93%至99%];p=0.02)。术后1年和2年时,两组大多数影像学对线参数无差异。糖尿病患者首次站立位X线片矢状面垂直轴大于非糖尿病患者(均值±标准差71±53 mm对54±49 mm,平均差17[95% CI 1至33];p=0.04)。尽管两组患者报告结局均改善,但ODI或SRS-22各域的组间差异均未超过合理MCID阈值。接受成人脊柱畸形矫形融合术的糖尿病患者近端交界性失败几率更高,无翻修生存率更低。外科医生在与糖尿病患者沟通时可讨论交界性并发症的可能性,并可考虑更密切的术后监测和改善代谢控制。未来研究应探讨血糖控制和骨质量如何影响畸形矫正术后交界性并发症。Ⅲ级,治疗性研究。
基础研究 (1篇)
Low back pain (LBP) affects approximately 619 million people globally and is the leading cause of years lived with disability, yet the pathogenesis of chronic LBP remains incompletely understood despite extensive research into structural and biomechanical factors. Emerging evidence suggests that the gut microbiota, through its influence on systemic inflammation, immune regulation, metabolic homeostasis, and neuromodulation, plays a previously unrecognized role in lumbar spine pathology. While prior frameworks such as the "gut-disc axis" and "gut-spine axis" have addressed intervertebral disc degeneration or vertebral bone metabolism in relative isolation, we propose the "gut-lumbar axis" as an integrative framework that systematically unifies the intervertebral discs, vertebrae, paraspinal musculature, and neural structures of the lumbar spine within a single physiological and pathological continuum. This review synthesizes current evidence on the bidirectional communication between intestinal microbiota and lumbar spine health, covering intervertebral disc degeneration, chronic LBP, lumbar spinal stenosis, and vertebral osteoporosis. Multiple pathways linking gut dysbiosis to lumbar pathology are identified, supporting the gut-lumbar axis as a paradigm-shifting framework. However, large-scale longitudinal cohorts and well-designed randomized controlled trials are urgently needed to translate these findings into clinical practice. Microbiome-targeted therapies, including probiotics, dietary interventions, and fecal microbiota transplantation, hold promise as novel adjunctive strategies for managing chronic lumbar spine disorders, and key knowledge gaps for future investigation are highlighted.
中文摘要:下背痛影响全球约6.19亿人,是伤残所致生存年数损失的首位原因,尽管对结构性与生物力学因素已有大量研究,慢性下背痛的发病机制仍未完全阐明。新出现的证据提示,肠道菌群通过影响全身炎症、免疫调节、代谢稳态与神经调控,在腰椎病理中扮演此前未被认识的角色。既有框架如「肠-椎间盘轴」与「肠-脊柱轴」分别相对孤立地讨论椎间盘退变或椎体骨代谢,我们提出「肠-腰椎轴」这一整合框架,把腰椎的椎间盘、椎体、椎旁肌肉与神经结构纳入同一生理与病理连续体。本综述整合了肠道菌群与腰椎健康双向交流的现有证据,涵盖椎间盘退变、慢性下背痛、腰椎管狭窄与椎体骨质疏松。多条将肠道菌群失调与腰椎病理联系起来的通路得到识别,支持肠-腰椎轴作为范式转变性框架。大规模纵向队列与设计良好的随机对照试验仍亟待开展,以把这些发现转化为临床实践。以微生物组为靶点的治疗,包括益生菌、饮食干预与粪菌移植,有望成为处理慢性腰椎疾患的新型辅助策略,文中并指出未来研究的关键知识空白。
7运动医学/关节镜 (5篇)
临床研究 (4篇)
While many metrics are used to subjectively assess a patient's knee function with patellofemoral instability (PFI), psychological readiness to return to sport (RTS) after patellar stabilization surgery is not well established in this population. The Anterior Cruciate Ligament Return to Sport After Injury (ACL-RSI) scale assesses psychological readiness to RTS after anterior cruciate ligament reconstruction and may be similarly beneficial in understanding this domain in those with PFI. Higher ACL-RSI scores in patients with PFI are associated with an increased likelihood of RTS after patellar stabilization surgery. Cohort study; Level of evidence, 3. A retrospective review was conducted of adolescent patients (10-19 years old) treated surgically for PFI (medial patellofemoral ligament reconstruction [MPFLR] with or without tibial tubercle osteotomy) at a single institution from January 2020 to October 2024. Patients actively participating in sports at their first orthopaedic visit who completed the ACL-RSI during postoperative rehabilitation were included. Patient demographics, injury characteristics, surgical procedure, ACL-RSI scores, and RTS status were recorded. Descriptive statistics and bivariate analysis were performed. Based on the euclidean distance, the optimal ACL-RSI cutoff score for predicting successful RTS was determined, and diagnostic accuracy was evaluated with a receiver operating curve. A multivariate logistic regression, adjusted for sex, was used to identify predictors of RTS. Study criteria identified 97 patients with a median (IQR) age of 15.6 years (14.2-16.4). Seventy underwent isolated MPFLR and 27 underwent MPFLR with tibial tubercle osteotomy. Successful RTS was achieved in 78.3% (n = 76). RTS was associated with higher ACL-RSI scores (P = .012), isolated MPFLR (P = .011), and male sex (P = .03). An ACL-RSI score ≥59.2 was identified as being indicative of successful RTS (area under the curve, 0.70; 95% CI, 0.56-0.83). While procedure type and ACL-RSI scores were both associated with RTS in univariate analysis, the multivariable analysis adjusting for sex revealed that the ACL-RSI cutoff remained the only significant predictor of RTS (odds ratio, 3.56; 95% CI, 1.10-11.51; P = .033). ACL-RSI scores ≥59.2 are associated with an increased likelihood of successful RTS after surgical treatment for PFI in adolescents. Patient demographics and the studied injury characteristics do not appear to influence the likelihood of successful RTS.
中文摘要:尽管许多指标用于主观评估髌股不稳(PFI)患者的膝关节功能,但髌骨稳定手术后重返运动(RTS)的心理准备在该人群中尚未明确。前交叉韧带重返运动后损伤(ACL-RSI)量表用于评估前交叉韧带重建后RTS心理准备,也可能有助于理解PFI患者的这一领域。PFI患者ACL-RSI评分较高与髌骨稳定手术后RTS可能性增加相关。队列研究;证据等级3。回顾性分析2020年1月至2024年10月单中心接受手术治疗的青少年PFI患者(10-19岁),术式为内侧髌股韧带重建(MPFLR)伴或不伴胫骨结节截骨。纳入首次骨科就诊时积极参加运动并在术后康复期间完成ACL-RSI的患者。记录患者人口学资料、损伤特征、手术方式、ACL-RSI评分和RTS状态。进行描述性统计和双变量分析。基于欧氏距离确定预测成功RTS的最佳ACL-RSI截断值,并用受试者工作特征曲线评估诊断准确性。采用校正性别的多因素logistic回归识别RTS预测因素。研究标准确定97例患者,年龄中位数(IQR)15.6岁(14.2-16.4)。70例接受单纯MPFLR,27例接受MPFLR联合胫骨结节截骨。78.3%(n=76)实现成功RTS。RTS与较高ACL-RSI评分(P=.012)、单纯MPFLR(P=.011)和男性(P=.03)相关。ACL-RSI评分≥59.2被认为提示成功RTS(曲线下面积0.70;95%CI 0.56-0.83)。单变量分析中手术方式和ACL-RSI评分均与RTS相关,校正性别后的多变量分析显示ACL-RSI截断值仍是唯一显著预测因素(比值比3.56;95%CI 1.10-11.51;P=.033)。ACL-RSI评分≥59.2与青少年PFI手术治疗后成功RTS可能性增加相关。患者人口学资料和所研究的损伤特征似乎不影响成功RTS的可能性。
Synovial fluid biomarkers reflect the intra-articular response to an anterior cruciate ligament (ACL) rupture and may provide insight into biological processes associated with posttraumatic joint degeneration. While increasing age has been associated with inferior clinical outcomes after ACL reconstruction, age-dependent differences in biomarker expression and their relationship to longer term outcomes remain unclear. The purpose of this study was to evaluate the association between patient age and preoperative synovial biomarker concentrations after an ACL injury to determine whether age modifies biomarker-outcome relationships at longer term follow-up. The authors hypothesized that increasing age would be associated with an elevated inflammatory response and modify biomarker-outcome associations. Cohort study; Level of evidence, 3. Patients undergoing ACL reconstruction between July 2011 and December 2020 were prospectively enrolled. Synovial fluid was aspirated before incision, and concentrations of proinflammatory and anti-inflammatory biomarkers were quantified. Patients completed patient-reported outcome (PRO) measures, including the visual analog scale for pain, Lysholm scale, Tegner Activity Scale, and Knee injury and Osteoarthritis Outcome Score-Physical Function Short Form, at a minimum of 5 years postoperatively. Multivariable regression assessed associations between age and biomarker concentrations. Conditional process analysis evaluated moderation by symptom duration and mediation by cartilage injury severity. Associations between age and long-term PROs were assessed using multivariable regression and minimal clinically important difference analyses. A total of 100 patients were included (mean age, 30.8 ± 9.5 years). Increasing age was independently associated with lower preoperative synovial TIMP-1 concentrations (β = -0.0775; P = .014). This association was moderated by symptom duration, with significant effects at <3.0 and >8.5 months. Cartilage injury severity did not mediate age-biomarker associations. Increasing age was associated with worse long-term PROs and the decreased likelihood of achieving the minimal clinically important difference for pain, function, and activity. After adjusting for age, higher MIP-1β concentrations were associated with worse functional outcomes, higher MMP-3 concentrations were associated with greater pain, higher TIMP-2 concentrations were associated with lower activity levels, and higher bFGF concentrations were associated with improved physical function. Significant age-dependent interactions were observed for TIMP-1, TIMP-2, and MIP-1β with selected PROs. Age-stratified analysis demonstrated heterogeneous biomarker-outcome associations. Patient age at the time of ACL reconstruction was associated with selective alterations in synovial biomarker expression and long-term clinical outcomes. Age modified the prognostic significance of key biomarkers, highlighting the importance of incorporating age into biomarker interpretation and risk stratification after an ACL injury.
中文摘要:滑液生物标志物反映前交叉韧带(ACL)断裂后的关节内反应,可能揭示与创伤后关节退变相关的生物学过程。年龄增长与ACL重建后临床结局较差相关,但生物标志物表达的年龄差异及其与远期结局的关系仍不清楚。本研究旨在评估ACL损伤后患者年龄与术前滑液生物标志物浓度之间的关联,以判断年龄是否会在较长期随访中改变生物标志物与结局的关系。作者假设年龄增长与炎症反应升高相关,并会改变生物标志物与结局的关联。队列研究;证据等级3。2011年7月至2020年12月接受ACL重建的患者被前瞻性纳入。切皮前抽取滑液,定量促炎和抗炎生物标志物浓度。患者在术后至少5年完成患者报告结局(PRO)测量,包括疼痛视觉模拟量表、Lysholm量表、Tegner活动量表和膝关节损伤与骨关节炎结局评分-躯体功能简表。多变量回归评估年龄与生物标志物浓度的关联。条件过程分析评估症状持续时间的调节作用和软骨损伤严重程度的中介作用。采用多变量回归和最小临床重要差异分析评估年龄与长期PRO的关联。共纳入100例患者(平均年龄30.8±9.5岁)。年龄增长独立关联于较低的术前滑液TIMP-1浓度(β=-0.0775;P=.014)。该关联受症状持续时间调节,在<3.0个月和>8.5个月时效应显著。软骨损伤严重程度未中介年龄-生物标志物关联。年龄增长与较差的长期PRO及达到疼痛、功能和活动最小临床重要差异的可能性降低相关。校正年龄后,较高的MIP-1β浓度与较差的功能结局相关,较高的MMP-3浓度与更重疼痛相关,较高的TIMP-2浓度与较低活动水平相关,较高的bFGF浓度与更好的躯体功能相关。TIMP-1、TIMP-2和MIP-1β与部分PRO之间存在显著的年龄依赖交互作用。按年龄分层分析显示生物标志物-结局关联具有异质性。ACL重建时的患者年龄与滑液生物标志物表达的选择性改变及长期临床结局相关。年龄改变了关键生物标志物的预后意义,提示在ACL损伤后将年龄纳入生物标志物解释和风险分层的重要性。
Labral reconstruction has become an essential technique for treating irreparable acetabular labral pathology. While both segmental and circumferential reconstruction techniques are utilized, it remains unclear whether one provides superior clinical outcomes. To compare patient-reported outcomes, complications, and reoperation rates between segmental and circumferential labral reconstruction. Meta-analysis. A systematic review of the PubMed, Embase, and Scopus databases was performed in accordance with PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines on February 2, 2025. Studies were included if they reported clinical outcomes after arthroscopic hip labral reconstruction using either segmental or circumferential techniques. Data were extracted on patient characteristics, surgical details, patient-reported outcome measures, complications, revision arthroscopy, and conversion to total hip arthroplasty (THA). Meta-analyses were performed using random-effects models, and heterogeneity was assessed using the I2 statistic. A total of 28 studies consisting of 1817 hips were included, with 1086 undergoing segmental and 731 undergoing circumferential reconstruction. Patient characteristics were similar between groups, except for a lower proportion of women in the segmental cohort than circumferential cohort (44.6% vs 73.2%; P < .001). Both techniques resulted in significant improvements in all patient-reported outcomes, including the Harris Hip Score, Hip Outcome Score-Activities of Daily Living, Hip Outcome Score-Sports, International Hip Outcome Tool-12 score, Short Form-12 score, and visual analog scale pain score, with no significant differences between groups (all P > .05). Complication rates and revision rates were comparable (P = .05 and P = .06, respectively). However, circumferential reconstruction was associated with a significantly lower conversion to THA compared with segmental reconstruction (P = .01). Both segmental and circumferential labral reconstruction techniques provide significant and comparable improvements in functional outcomes and pain. Circumferential reconstruction was associated with a lower pooled rate of conversion to THA; however, causality cannot be inferred given the heterogeneity, nonrandomized design, and differences in follow-up duration between studies.
中文摘要:唇重建已成为治疗不可修复髋臼唇病变的重要技术。节段性与环周重建均在应用,但哪种技术能提供更优临床结局仍不清楚。比较节段性与环周唇重建的患者报告结局、并发症和再手术率。按照PRISMA指南于2025年2月2日系统检索PubMed、Embase和Scopus数据库。纳入报告关节镜下髋唇重建采用节段性或环周技术后临床结局的研究。提取患者特征、手术细节、患者报告结局指标、并发症、翻修关节镜和转为全髋关节置换术(THA)的数据。采用随机效应模型进行Meta分析,用I2统计量评估异质性。共纳入28项研究、1817髋,其中1086髋行节段性重建,731髋行环周重建。除节段性队列女性比例低于环周队列(44.6% vs 73.2%;P < .001)外,两组患者特征相似。两种技术均使所有患者报告结局显著改善,包括Harris髋关节评分、髋关节结局评分-日常生活活动、髋关节结局评分-运动、国际髋关节结局工具-12评分、Short Form-12评分和视觉模拟疼痛评分,组间无显著差异(均P > .05)。并发症率和翻修率相当(分别为P = .05和P = .06)。环周重建与节段性重建相比,转为THA的比例显著更低(P = .01)。节段性和环周唇重建技术均能显著且相当地改善功能结局和疼痛。环周重建与较低的合并转为THA率相关;但鉴于异质性、非随机设计和研究间随访时间差异,不能推断因果关系。
Return to work (RTW), particularly return to full-duty occupational function, is a clinically meaningful outcome after sports-related orthopaedic surgery. However, reporting across procedures is heterogeneous and often lacks occupational context. To synthesize full-duty RTW outcomes after common sports-related orthopaedic procedures in civilian populations. Secondary objectives were to describe the time to RTW and to evaluate outcomes stratified by occupational intensity and workers' compensation (WC) status. Systematic review; Level of evidence, 4. A systematic review was conducted in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Civilian studies reporting RTW outcomes after meniscectomy, meniscal repair, anterior cruciate ligament (ACL) reconstruction (ACLR), rotator cuff repair (RCR), distal biceps repair, biceps tenodesis, or hip arthroscopy were included. Data were extracted at the cohort level. Full-duty RTW rates were calculated using sample-size weighted pooled estimates. Time to RTW was summarized using the median of reported cohort-level mean RTW times. Occupational intensity-specific and WC-specific outcomes were analyzed descriptively when reported separately at the cohort level. A total of 87 unique studies met the inclusion criteria. Pooled full-duty RTW rates exceeded 90% after meniscectomy, meniscal repair, ACLR, and distal biceps repair. In contrast, pooled full-duty RTW rates after biceps tenodesis, RCR, and hip arthroscopy ranged from 74.2% to 76.7%. The median time to RTW ranged from 33 days after meniscectomy to 185 days after RCR. Across procedures with available data, WC cohorts and higher occupational intensity were associated with prolonged RTW timelines. Full-duty RTW outcomes vary by procedure type, with longer rehabilitation procedures demonstrating lower pooled RTW rates and longer median RTW timelines. WC status and higher occupational intensity were consistently associated with delayed RTW. Standardized reporting of occupational intensity, RTW definitions, and WC status is needed to improve clinical counseling and enhance comparability in future orthopaedic outcomes research.
中文摘要:重返工作,尤其是重返全职职业功能,是运动相关骨科手术后具有临床意义的结局。但不同术式的报告异质性较大,且常缺乏职业背景信息。旨在汇总平民人群中常见运动相关骨科手术后全职重返工作结局。次要目标为描述重返工作时间,并按职业强度和工伤保险状态分层评估结局。系统综述;证据等级4级。按照PRISMA指南开展系统综述。纳入报告半月板切除术、半月板修复、前交叉韧带重建、肩袖修复、远端肱二头肌修复、肱二头肌腱固定术或髋关节镜术后重返工作结局的平民研究。在队列层面提取数据。全职重返工作率采用样本量加权合并估计计算。重返工作时间以报告队列层面平均重返工作时间的中位数汇总。职业强度特异性和工伤保险特异性结局在队列层面单独报告时进行描述性分析。共87项独立研究符合纳入标准。半月板切除术、半月板修复、前交叉韧带重建和远端肱二头肌修复后的合并全职重返工作率超过90%。相较之下,肱二头肌腱固定术、肩袖修复和髋关节镜术后的合并全职重返工作率为74.2%至76.7%。重返工作时间中位数从半月板切除术后的33天到肩袖修复后的185天。在有可用数据的手术中,工伤保险队列和更高职业强度与重返工作时间延长相关。全职重返工作结局随术式类型变化,康复时间较长的手术显示较低的合并重返工作率和较长的重返工作时间中位数。工伤保险状态和更高职业强度始终与重返工作延迟相关。需要标准化报告职业强度、重返工作定义和工伤保险状态,以改善临床咨询并提高未来骨科结局研究的可比性。
基础研究 (1篇)
Short-term clinical outcomes of meniscal centralization are promising, but questions remain whether it can protect articular cartilage and delay osteoarthritis progression. To assess cartilage status and healing potential after isolated medial meniscus posterior root (MMPR) repair (RR) versus MMPR repair augmented with a centralization procedure (RR-CP) in a rabbit stifle model. Controlled laboratory study. MMPR tears were surgically induced in 16 New Zealand White rabbits. Eight underwent RR and 8 underwent RR-CP using interlocking knotless anchors; contralateral limbs served as controls. After 4 months, animals were euthanized and articular cartilage was harvested for macro- and microscopic evaluation, including repair tissue assessment for healing potential. Microscopic assessment was performed using the Osteoarthritis Research Society International (OARSI) scoring system. Cartilage thickness and meniscal extrusion (ME) were assessed using high-resolution magnetic resonance imaging (MRI) at 9.4 T. The medial femoral condyle was divided into 3 regions of interest (anterior, central, and posterior), and zone-specific changes were evaluated. The mean ± standard deviation gross pathology joint degeneration score was significantly higher in the RR group compared with the RR-CP group (12.3 ± 2.2 vs 9.1 ± 2.0; P = .01). The mean OARSI score was significantly lower in the RR-CP group compared with the RR group (3.1 ± 1.6 vs 4.2 ± 1.5; P = .04). Nonhealed root repairs were more frequent in the RR group, and repair healing scores favored the RR-CP group (1.75 ± 0.5 vs 2.5 ± 0.7; P = .041). MRI demonstrated significantly reduced central and posterior cartilage thickness in the RR group compared with the RR-CP and control knees (P ≤ .02), with no difference anteriorly (P = .23). ME did not differ between the RR and RR-CP goups (P = .12). Both experimental groups showed greater chondral damage compared with contralateral controls (P < .001). RR-CP was associated with reduced total joint cartilage damage and improved repair healing compared with isolated RR. MRI showed greater loss of central and posterior cartilage thickness after RR, while no difference in postoperative ME was detected. Both treatment groups demonstrated increased chondral damage compared with control knees. This study provides important biological insights into a clinically relevant question and establishes a foundation for future clinical investigations aimed at defining patient selection criteria and surgical indications for a concomitant meniscal centralization procedure.
中文摘要:半月板中央化术的短期临床结局令人鼓舞,但其能否保护关节软骨并延缓骨关节炎进展仍存疑问。为评估单纯内侧半月板后根部(MMPR)修复(RR)与MMPR修复联合中央化术(RR-CP)后兔膝关节软骨状态及愈合潜能。采用对照实验室研究。在16只新西兰白兔中手术诱导MMPR撕裂。8只行RR,8只使用交锁无结锚钉行RR-CP;对侧肢体作为对照。4个月后处死动物,取关节软骨进行宏观和微观评价,包括修复组织愈合潜能评估。微观评估采用国际骨关节炎研究学会(OARSI)评分系统。采用9.4 T高分辨率磁共振成像(MRI)评估软骨厚度和半月板外突(ME)。将内侧股骨髁分为3个感兴趣区(前部、中部和后部),评估区域特异性变化。RR组大体病理关节退变评分均值±标准差显著高于RR-CP组(12.3±2.2 vs 9.1±2.0;P=.01)。RR-CP组OARSI评分均值显著低于RR组(3.1±1.6 vs 4.2±1.5;P=.04)。RR组未愈合的根部修复更常见,修复愈合评分倾向RR-CP组(1.75±0.5 vs 2.5±0.7;P=.041)。MRI显示RR组中部和后部软骨厚度较RR-CP组和对照膝显著减少(P≤.02),前部无差异(P=.23)。RR组与RR-CP组ME无差异(P=.12)。两个实验组软骨损伤均大于对侧对照(P<.001)。与单纯RR相比,RR-CP与总体关节软骨损伤减少和修复愈合改善相关。MRI显示RR后中部和后部软骨厚度丢失更多,术后ME未检测到差异。两种治疗组软骨损伤均较对照膝增加。该研究为临床相关问题提供重要生物学见解,并为未来临床研究奠定基础,以确定合并半月板中央化术的患者选择标准和手术指征。
8肩肘外科 (4篇)
临床研究 (2篇)
Combined radial head and coronoid fractures, including terrible triad injuries, are challenging patterns associated with elbow instability, poor clinical outcomes, and other complications. While both radial head and coronoid fractures contribute to joint stability, the relationship between their fracture morphologies remains poorly understood. Clarifying these associations may aid in preoperative planning and guide surgical decision-making for restoring elbow stability. (1) In patients with combined coronoid and radial head fractures, what radial head fracture patterns are most common? (2) Are radial head fracture patterns associated with coronoid fracture types? This study was a secondary data analysis of a retrospective, multicenter descriptive study of patients with combined coronoid and radial head fractures identified on elbow CT scans. The cohort was derived from two urban tertiary level 1 trauma centers with specialized upper extremity and orthopaedic trauma services. Of 10,016 patients with elbow or forearm injuries who underwent CT imaging, 2% (175) met eligibility criteria for combined coronoid and radial head fractures; eight patients were excluded because of prior pathophysiologic conditions of the elbow, previous surgery, or inadequate imaging quality, leaving 167 patients for analysis, 54% (90) of whom were female, with a mean ± SD age of 50 ± 15 years. The radial head was divided into four quadrants (anterolateral, anteromedial, posterolateral, and posteromedial) using the radial tuberosity as a reference landmark on axial CT images. The anterolateral quadrant corresponds approximately to the surgical "safe zone," the region opposite the radial tuberosity and in line with the radial styloid. Coronoid fractures were classified according to the O'Driscoll classification, which categorizes fractures into Type 1 (tip fractures involving the coronoid apex), Type 2 (anteromedial facet), and Type 3 (basal fractures involving the coronoid base) patterns. Interrater reliability was determined using the Cohen kappa, yielding substantial agreement for the radial head quadrant involvement (κ = 0.715) and O'Driscoll classification (κ = 0.658) and reflecting typical reliability for CT-based fracture classification, with disagreements resolved through consensus. The most common radial head fracture pattern was a single fragment involving both the anterolateral and anteromedial quadrants (31% [51 of 167]), followed by two separate fragments involving the anterolateral and anteromedial quadrants (15% [25 of 167]). Most fractures consisted of one fragment (49% [82 of 167]). Radial head fracture patterns were not associated with coronoid fracture type. Radial head fractures in combined coronoid and radial head fractures most commonly involved the anterolateral and anteromedial quadrants, often as a single fragment. We found no association between coronoid fracture types and radial head fracture patterns, suggesting that these injury components occur independently. These findings may help surgeons anticipate fragment location in relation to surgical exposure, while emphasizing the importance of evaluating the radial head and coronoid as separate elements during preoperative planning and intraoperative assessment. Level IV, prognostic study.
中文摘要:合并桡骨头与冠突骨折,包括恐怖三联征损伤,是与肘关节不稳、临床结局不佳及其他并发症相关的棘手损伤模式。桡骨头骨折与冠突骨折均影响关节稳定性,但二者骨折形态之间的关系仍知之甚少。明确这些关联可能有助于术前规划,并为恢复肘关节稳定的手术决策提供指导。(1)在合并冠突与桡骨头骨折的患者中,何种桡骨头骨折形态最常见?(2)桡骨头骨折形态是否与冠突骨折类型相关?本研究为一项回顾性、多中心描述性研究的二次数据分析,对象为经肘关节CT扫描发现的合并冠突与桡骨头骨折患者。队列来自两家城市三级一级创伤中心,均设有专门的上肢与骨科创伤服务。在10 016例因肘部或前臂损伤接受CT成像的患者中,2%(175例)符合合并冠突与桡骨头骨折的入选标准;8例因既往肘关节病理生理状况、既往手术或影像质量不足被排除,最终167例纳入分析,其中54%(90例)为女性,平均±标准差年龄为50±15岁。以轴位CT图像上的桡骨结节为参考标志,将桡骨头分为四个象限(前外侧、前内侧、后外侧、后内侧)。前外侧象限大致对应手术安全区,即与桡骨结节相对、并与桡骨茎突对齐的区域。冠突骨折按O'Driscoll分类,分为1型(累及冠突尖端的尖端骨折)、2型(前内侧缘)和3型(累及冠突基底的基底骨折)。采用Cohen kappa确定评分者间信度,桡骨头象限受累(κ=0.715)与O'Driscoll分类(κ=0.658)达到较高一致性,反映基于CT的骨折分类的典型信度,分歧通过共识解决。最常见的桡骨头骨折形态为单一骨折块同时累及前外侧与前内侧象限(31%[51/167]),其次为两个独立骨折块分别累及前外侧与前内侧象限(15%[25/167])。多数骨折由单一骨折块构成(49%[82/167])。桡骨头骨折形态与冠突骨折类型无关联。在合并冠突与桡骨头骨折中,桡骨头骨折最常累及前外侧与前内侧象限,且常为单一骨折块。未发现冠突骨折类型与桡骨头骨折形态之间存在关联,提示这些损伤组成部分独立发生。这些发现可能帮助外科医生预判骨折块位置与手术显露的关系,同时强调在术前规划和术中评估中将桡骨头与冠突作为独立要素进行评估的重要性。证据等级IV,预后研究。
Rotator cuff tears with concomitant preoperative shoulder stiffness present a clinical challenge because the rehabilitation needed to restore motion may conflict with the protection typically used to support tendon healing after rotator cuff repair. Although recent studies suggest that preoperative stiffness may not be associated with inferior long-term outcomes, whether it is associated with a different pattern of postoperative improvement and distinct inflammatory features in the torn tendon remains unclear. (1) Do a greater proportion of patients with preoperative shoulder stiffness achieve improvements in functional outcomes that exceed the minimum clinically important difference (MCID) at 3, 6, 12, and 24 months? (2) Do supraspinatus tendons from patients with shoulder stiffness show molecular and histologic features consistent with greater inflammation than tendons from patients without stiffness? This prospective, observational cohort study included patients scheduled to undergo arthroscopic rotator cuff repair for unilateral rotator cuff tears with medium-sized, full-thickness supraspinatus tears, with or without concomitant preoperative shoulder stiffness. A medium-sized tear was defined as a supraspinatus tendon tear measuring 3 cm or less on preoperative coronal MRI. Preoperative shoulder stiffness was defined as passive shoulder ROM of less than 120° in forward flexion, less than 30° in external rotation at the side, or internal rotation lower than the L3 spinal level. Patients who met any one of these three criteria were assigned to the stiffness group. Between March 2020 and December 2023, 474 patients from both urban and rural areas who were scheduled to undergo repair for rotator cuff tears were evaluated at our shoulder pain specialty clinic. The inclusion criteria were: (1) full-thickness unilateral supraspinatus tendon tears measuring 3 cm or less in the AP dimension, confirmed on T2-weighted MRI, and (2) radiographs and MRI demonstrating no other shoulder pathology, including fracture, arthritis, dislocation, or glenoid labral tear. After strict eligibility assessment, 39% (186 of 474) of patients met all inclusion criteria and were enrolled into either the stiffness group (92 patients) or the without stiffness group (94 patients) based on predefined criteria. Specifically, 28% (135 of 474) of patients were excluded because symptom duration exceeded 12 months, 1% (2 of 474) were excluded because of missing MRI data, and 4% (20 of 474) were excluded because they had received more than three glucocorticoid injections. In addition, 18% (84 of 474) of patients were excluded because of systemic comorbidities or a history of surgery on the affected shoulder: rheumatoid arthritis in 1% (2 of 474), thyroid disorders in 3% (12 of 474), diabetes in 9% (43 of 474), gout in 1% (1 of 474), osteoporosis in 1% (5 of 474), hyperlipidemia in 4% (17 of 474), previous shoulder surgery in 1% (3 of 474), and concomitant upper limb fracture in 1% (1 of 474). A preoperative MRI evaluation resulted in the exclusion of patients with labral lesions (1% [5 of 474]), calcific tendinitis (1% [3 of 474]), massive tears (4% [21 of 474]), and partial-thickness tears (4% [18 of 474]). The enrolled cohort comprised 186 patients, with a mean age of 62 ± 7 years and a mean BMI of 24.1 ± 2.8 kg/m 2 . Women accounted for 68% (127 of 186) of the cohort. Of the 186 enrolled patients, 4% (8 of 186) were lost to follow-up by 12 months and an additional 15% (27 of 186) by 24 months, leaving 81% (151 of 186) for the final analysis; there were 75 patients with stiffness and 76 without stiffness. Clinical outcomes, including ROM, the VAS, Oxford shoulder score (OSS), and Constant-Murley Score (CMS), were assessed preoperatively and at 3, 6, 12, and 24 months postoperatively. MRI was performed preoperatively and at 24 months. Retears were assessed using the Sugaya classification at 24-month follow-up, with Types IV and V defined as postoperative retears. Intraoperative supraspinatus tendon samples were collected and analyzed using histology and bulk RNA sequencing. To address our first study question, we evaluated postoperative recovery at two levels. First, we applied anchor-based MCID thresholds reported in previous studies: 10 points for the CMS, 6 points for the OSS, and 1.4 points for the VAS. We then compared the proportions of patients in the two groups who achieved clinically meaningful improvement at each postoperative follow-up time point (3, 6, 12, and 24 months) to determine whether patients with preoperative stiffness were more likely to achieve meaningful improvement at scheduled follow-up visits. Second, we used repeated-measures ANOVA and mixed-effects models to analyze the longitudinal trajectories of the CMS and OSS across follow-up and to evaluate whether the postoperative pattern of improvement differed between groups. To address our second study question, supraspinatus tendon tissue was collected intraoperatively for histologic and bulk RNA sequencing. Histologic differences were assessed using the revised Bonar scoring system, and transcriptomic differences were evaluated using differential gene expression and functional enrichment analyses. At 3 months, a greater proportion of patients in the stiffness group achieved the MCID in the CMS (43% [32 of 75] versus 13% [10 of 76], OR 4.9 [95% CI 2.2 to 11.0]; p < 0.001), OSS (59% [44 of 75] versus 21% [16 of 76], OR 5.3 [95% CI 2.6 to 10.9]; p < 0.001), and VAS-movement (33% [25 of 75] versus 17% [13 of 76], OR 2.4 [95% CI 1.1 to 5.2]; p = 0.02). Similar patterns were observed at 6 and 12 months, with higher proportions of patients in the stiffness group achieving clinically meaningful improvement across the CMS, OSS, and VAS-movement. By 24 months, the patients with stiffness still had higher MCID achievement proportions for the CMS (100% [75 of 75] versus 83% [63 of 76], OR 32.1 [95% CI 1.9 to 550.8]; p < 0.001), OSS (99% [74 of 75] versus 88% [67 of 76], OR 9.9 [95% CI 1.2 to 80.6]; p = 0.02), and VAS-movement (83% [62 of 75] versus 68% [52 of 76], OR 2.2 [95% CI 1.0 to 4.7]; p = 0.04), whereas we found no differences between groups for VAS-rest or VAS-sleep at any follow-up timepoint. Longitudinal analyses showed different postoperative improvement patterns for the CMS and OSS between groups (group-by-time interaction: CMS, ges = 0.121; p < 0.001; OSS, ges = 0.075; p < 0.001), although these differences were no longer observed after adjustment for baseline score (CMS: β 0.1 [95% CI -0.1 to 0.2]; p = 0.63). With respect to tendon biology, patients with and without preoperative stiffness showed different molecular and histologic features. The patients with stiffness had 254 upregulated genes and 554 downregulated genes, were enriched in the inflammatory tendinopathy subtype (NES 2.6; adjusted p < 0.01), and showed more inflammatory cell infiltration and higher revised Bonar inflammation scores. By contrast, the patients without stiffness were enriched in the hypoxia-white subtype (NES -2.8; adjusted p < 0.01) and in metabolic, muscle-development, and neurodevelopment pathways. Immune deconvolution also supported a more immune-activated tendon microenvironment in the patients with stiffness. In patients with medium-sized rotator cuff tears, preoperative shoulder stiffness was not associated with worse long-term outcomes after arthroscopic rotator cuff repair. Although patients with stiffness started with worse shoulder function, they were more likely to achieve clinically meaningful improvement during the early postoperative period, a pattern that likely reflects lower baseline function and greater room for improvement rather than superior final recovery. In addition, inflammatory tendon features from patients with shoulder stiffness reflected a distinct biologic context. For surgeons, these findings may help when counseling patients with rotator cuff tears that satisfactory recovery is achievable even with concomitant preoperative shoulder stiffness. Future work should focus on whether this inflammatory tendon feature can be validated in broader patient populations and can be used to refine biologic classification and postoperative management. Level II, therapeutic study.
中文摘要:合并术前肩关节僵硬的肩袖撕裂在临床处理上存在矛盾,恢复活动度所需的康复可能与肩袖修复后支持肌腱愈合通常采用的保护措施相冲突。近期研究提示术前僵硬可能不与较差的长期结局相关,但其是否与不同的术后改善模式以及撕裂肌腱中独特的炎症特征相关仍不清楚。(1)术前肩关节僵硬患者中,在3、6、12和24个月时达到超过最小临床重要差异(MCID)的功能结局改善的比例是否更高?(2)肩关节僵硬患者的冈上肌腱是否显示出比无僵硬患者肌腱更明显炎症的分子和组织学特征?这项前瞻性观察性队列研究纳入计划接受关节镜肩袖修复的单侧肩袖撕裂患者,撕裂为中等大小全层冈上肌腱撕裂,伴或不伴术前肩关节僵硬。中等大小撕裂定义为术前冠状位MRI上冈上肌腱撕裂长度不超过3 cm。术前肩关节僵硬定义为被动肩关节活动度满足以下任一条件:前屈小于120°,体侧外旋小于30°,或内旋低于L3棘突水平。符合三项标准中任一项的患者归入僵硬组。2020年3月至2023年12月,在我们肩痛专病门诊评估了474例计划接受肩袖撕裂修复的患者,患者来自城市和农村地区。纳入标准为:(1)T2加权MRI证实单侧全层冈上肌腱撕裂,前后径不超过3 cm;(2)X线片和MRI显示无其他肩部病变,包括骨折、关节炎、脱位或盂唇撕裂。经过严格资格评估,39%(474例中186例)的患者符合全部纳入标准并入选,依据预设标准分为僵硬组(92例)和无僵硬组(94例)。具体而言,28%(474例中135例)因症状持续时间超过12个月被排除,1%(474例中2例)因MRI数据缺失被排除,4%(474例中20例)因接受过超过3次糖皮质激素注射被排除。同时,18%(474例中84例)因全身合并症或患肩手术史被排除:类风湿关节炎1%(474例中2例)、甲状腺疾病3%(474例中12例)、糖尿病9%(474例中43例)、痛风1%(474例中1例)、骨质疏松1%(474例中5例)、高脂血症4%(474例中17例)、既往肩部手术1%(474例中3例)、合并上肢骨折1%(474例中1例)。术前MRI评估还排除了盂唇病变(1%[474例中5例])、钙化性肌腱炎(1%[474例中3例])、巨大撕裂(4%[474例中21例])和部分厚度撕裂(4%[474例中18例])。入选队列共186例,平均年龄62±7岁,平均BMI 24.1±2.8 kg/m2。女性占68%(186例中127例)。186例入选患者中,4%(186例中8例)在12个月时失访,另有15%(186例中27例)在24个月时失访,最终81%(186例中151例)进入最终分析;其中僵硬组75例,无僵硬组76例。临床结局包括活动度、VAS、牛津肩关节评分(OSS)和Constant-Murley评分(CMS),在术前及术后3、6、12和24个月评估。术前和术后24个月进行MRI。术后24个月随访时采用Sugaya分型评估再撕裂,IV型和V型定义为术后再撕裂。术中采集冈上肌腱样本,进行组织学和bulk RNA测序分析。针对第一个研究问题,我们在两个层面评估术后恢复。在第一个层面,采用既往研究报告的锚定法MCID阈值:CMS 10分,OSS 6分,VAS 1.4分。然后比较两组在各术后随访时间点(3、6、12和24个月)达到临床有意义改善的患者比例,以判断术前僵硬患者是否更可能在预定随访时达到有意义改善。在第二个层面,采用重复测量方差分析和混合效应模型分析CMS和OSS随随访的纵向轨迹,并评估两组的术后改善模式是否不同。针对第二个研究问题,术中采集冈上肌腱组织进行组织学和bulk RNA测序。组织学差异采用修订Bonar评分系统评估,转录组差异采用差异基因表达和功能富集分析评估。术后3个月,僵硬组达到CMS的MCID比例更高(43%[75例中32例]比13%[76例中10例],OR 4.9[95% CI 2.2至11.0];p < 0.001)、OSS(59%[75例中44例]比21%[76例中16例],OR 5.3[95% CI 2.6至10.9];p < 0.001)和VAS-活动(33%[75例中25例]比17%[76例中13例],OR 2.4[95% CI 1.1至5.2];p = 0.02)。6个月和12个月观察到相似模式,僵硬组在CMS、OSS和VAS-活动中达到临床有意义改善的比例更高。到24个月,僵硬组在CMS(100%[75例中75例]比83%[76例中63例],OR 32.1[95% CI 1.9至550.8];p < 0.001)、OSS(99%[75例中74例]比88%[76例中67例],OR 9.9[95% CI 1.2至80.6];p = 0.02)和VAS-活动(83%[75例中62例]比68%[76例中52例],OR 2.2[95% CI 1.0至4.7];p = 0.04)的MCID达标比例仍更高,而VAS-静息或VAS-睡眠在任何随访时间点两组均无差异。纵向分析显示两组CMS和OSS的术后改善模式不同(组别×时间交互:CMS,ges = 0.121;p < 0.001;OSS,ges = 0.075;p < 0.001),但在校正基线评分后这些差异不再存在(CMS:β 0.1[95% CI -0.1至0.2];p = 0.63)。在肌腱生物学方面,伴和不伴术前僵硬的患者显示出不同的分子和组织学特征。僵硬组有254个上调基因和554个下调基因,富集于炎症性肌腱病亚型(NES 2.6;校正p < 0.01),并显示更多炎性细胞浸润和更高的修订Bonar炎症评分。相反,无僵硬组富集于缺氧-白色亚型(NES -2.8;校正p < 0.01)以及代谢、肌肉发育和神经发育通路。免疫去卷积也支持僵硬组肌腱微环境更呈免疫激活状态。在中等大小肩袖撕裂患者中,术前肩关节僵硬与关节镜肩袖修复后较差的长期结局无关。尽管僵硬患者起始肩关节功能更差,但他们在术后早期更可能达到临床有意义改善,这一模式可能反映基线功能较低和改善空间更大,而非最终恢复更优。肩关节僵硬患者的炎症性肌腱特征反映了不同的生物学背景。对术者而言,这些发现可能有助于向肩袖撕裂患者说明,即使合并术前肩关节僵硬,仍可获得满意恢复。未来工作应关注这种炎症性肌腱特征能否在更广泛患者人群中得到验证,并用于细化生物学分类和术后管理。Level II,治疗性研究。
基础研究 (2篇)
Although the cGAS-STING (cyclic GMP-AMP synthase-stimulator of interferon genes) pathway is a key driver of inflammaging in age-related musculoskeletal disorders, its role in age-related rotator cuff tears (RCTs) remains unknown. This study investigated whether inhibition of the cGAS-STING pathway with H-151 could improve tendon-to-bone healing in aged rats after rotator cuff repair (RCR). Forty-eight Sprague-Dawley rats were assigned to 4 groups: young control (sham surgery), aged control (sham surgery), aged RCT (RCR with fibrin), and aged RCT+H-151 (RCR with H-151-loaded fibrin). Rats in the RCT groups underwent bilateral RCR, after which the tendon-bone enthesis was treated with the respective fibrin gel. The status of the cGAS-STING pathway, expression of inflammaging and differentiation markers, and histological and biomechanical properties of the supraspinatus-humerus complex were evaluated. The cGAS-STING pathway was markedly activated at the tendon-bone enthesis in the aged rats. Treatment with H-151 effectively suppressed its downstream effectors (Ifnb and Cxcl10), reduced inflammaging markers (Cdkn2a, Cdkn1a, Il1b, and Il6), and enhanced the expression of chondrogenic (Acan and Col2a1) and tenogenic (Tnmd and Scx) differentiation markers. Histological assessment revealed improved collagen organization and enhanced cartilage regeneration at the enthesis in the aged RCT+H-151 group, which also achieved a higher histological score. Biomechanically, the aged RCT+H-151 group exhibited significantly increased failure load, stiffness, and tensile stress compared with the aged RCT group. The cGAS-STING pathway was activated at the tendon-bone enthesis in aged rats. The inhibition of STING with H-151 in similar rats attenuated inflammaging, promoted collagen maturation and fibrocartilage regeneration, and substantially improved the biomechanical properties of the repaired enthesis. Inhibition of the cGAS-STING pathway using STING antagonists may be a promising therapeutic strategy for enhancing rotator cuff healing in older patients.
中文摘要:cGAS-STING(环鸟苷酸-腺苷酸合成酶-干扰素基因刺激因子)通路是年龄相关肌肉骨骼疾病中炎性衰老的关键驱动因素,但其在年龄相关肩袖撕裂(RCTs)中的作用仍不清楚。本研究探讨用H-151抑制cGAS-STING通路能否改善老龄大鼠肩袖修复(RCR)后的腱骨愈合。48只Sprague-Dawley大鼠分为4组:年轻对照(假手术)、老龄对照(假手术)、老龄RCT(纤维蛋白修复RCR)和老龄RCT+H-151(H-151负载纤维蛋白修复RCR)。RCT组大鼠接受双侧RCR,随后用相应纤维蛋白凝胶处理腱骨止点。评估cGAS-STING通路状态、炎性衰老与分化标志物表达,以及冈上肌腱-肱骨复合体的组织学和生物力学特性。老龄大鼠腱骨止点处cGAS-STING通路明显激活。H-151治疗有效抑制其下游效应因子(Ifnb和Cxcl10),降低炎性衰老标志物(Cdkn2a、Cdkn1a、Il1b和Il6),并增强软骨分化(Acan和Col2a1)与腱分化(Tnmd和Scx)标志物表达。组织学评估显示,老龄RCT+H-151组止点处胶原排列改善、软骨再生增强,组织学评分更高。生物力学方面,与老龄RCT组相比,老龄RCT+H-151组的失败载荷、刚度和拉伸应力显著增加。老龄大鼠腱骨止点处cGAS-STING通路被激活。在同类大鼠中抑制STING可减轻炎性衰老,促进胶原成熟和纤维软骨再生,并明显改善修复止点的生物力学特性。使用STING拮抗剂抑制cGAS-STING通路可能成为促进老年患者肩袖愈合的有前景治疗策略。
Rotator cuff repair failures are primarily driven by intrinsic tissue degeneration. While mitochondrial dysfunction is implicated in this cascade, the specific metabolic signals driving structural tendon failure remain poorly defined. The succinate-SUCNR1 axis may function as a critical metabolic checkpoint in this process. The authors hypothesized that the succinate-SUCNR1 axis is clinically hyperactivated in rotator cuff tears (RCTs), and that targeted blockade of this axis would mitigate overuse-induced tissue degeneration and preserve ultimate biomechanical integrity. Controlled laboratory study. Human supraspinatus specimens (10 RCTs, 10 controls) were analyzed for succinate levels, SUCNR1 expression, and histological severity. A murine treadmill overuse model was established in wild-type (WT) and Sucnr1-deficient (Sucnr1-/-) mice (21 per group) to evaluate histological degeneration, pathological neovascularization, and biomechanical properties (ultimate failure load and stiffness). Mechanistically, senescent human tendon stem cells (hTSCs) (n = 6) were treated with a selective SUCNR1 antagonist (Compound 20) to evaluate mitochondrial bioenergetic rescue via seahorse analysis. In RCT specimens, tissue degeneration strongly correlated with succinate accumulation and SUCNR1 upregulation (Pearson r = 0.81; P < .001). In vivo, Sucnr1 deficiency protected mice from overuse-induced tendinopathy, significantly suppressing inflammatory infiltration and aberrant neovascularization while maintaining collagen architecture. Sucnr1 ablation prevented the significant loss of tendon stiffness and ultimate failure load observed in the WT overuse group (P < .01). In vitro, SUCNR1 antagonism restored mitochondrial respiration, preserved cristae ultrastructure, and attenuated the stress-induced senescent phenotype in hTSCs. The succinate-SUCNR1 axis is a potent driver of structural failure. Targeting this axis may help restore mitochondrial homeostasis and break the "inflamm-aging" cycle, potentially reducing retear rates after rotator cuff repair. Pharmacological blockade of SUCNR1 represents a promising, biology-preserving strategy to improve intrinsic tendon quality. By helping restore mitochondrial homeostasis and halting the degenerative cascade, targeting this axis may reduce structural failure rates after rotator cuff repair.
中文摘要:肩袖修复失败主要由组织本身退变驱动。线粒体功能障碍被认为参与这一级联过程,但驱动肌腱结构性失败的具体代谢信号仍不明确。琥珀酸-SUCNR1轴可能在该过程中充当关键代谢检查点。作者假设琥珀酸-SUCNR1轴在肩袖撕裂(RCTs)中临床过度激活,靶向阻断该轴可减轻过度使用诱导的组织退变并保留最终生物力学完整性。受控实验室研究。分析人冈上肌腱标本(10例RCT,10例对照)的琥珀酸水平、SUCNR1表达和组织学严重程度。建立野生型(WT)和Sucnr1缺陷(Sucnr1-/-)小鼠跑步机过度使用模型(每组21只),评估组织学退变、病理性新生血管化和生物力学特性(极限失败载荷和刚度)。机制上,用选择性SUCNR1拮抗剂(Compound 20)处理衰老的人肌腱干细胞(hTSCs)(n=6),通过Seahorse分析评估线粒体生物能量学挽救。在RCT标本中,组织退变与琥珀酸蓄积和SUCNR1上调强相关(Pearson r=0.81;P<.001)。体内,Sucnr1缺陷保护小鼠免受过度使用诱导的肌腱病,显著抑制炎症浸润和异常新生血管化,同时维持胶原结构。Sucnr1敲除阻止了WT过度使用组观察到的肌腱刚度和极限失败载荷显著下降(P<.01)。体外,SUCNR1拮抗恢复线粒体呼吸,保留嵴超微结构,并减轻hTSCs中应激诱导的衰老表型。琥珀酸-SUCNR1轴是结构性失败的有力驱动因素。靶向该轴可能有助于恢复线粒体稳态并打破「炎症-衰老」循环,可能降低肩袖修复后再撕裂率。SUCNR1的药理学阻断代表一种有前景的、保留生物学的策略,可改善肌腱内在质量。通过帮助恢复线粒体稳态并阻止退变级联,靶向该轴可能降低肩袖修复后的结构性失败率。
9创伤骨科 (2篇)
临床研究 (2篇)
➢ Brazil has one of the world's largest universal public health systems, the Unified Health System (Sistema Único de Saúde, or SUS), serving a population of more than 200 million people.➢ Brazil has strong orthopaedic training, an active national society, and a growing research culture.➢ Orthopaedic and trauma care in Brazil is delivered through a mixed public-private model that includes high-volume public hospitals, university centers, private hospitals, and regional referral centers.➢ The major national challenge is not only the availability of orthopaedic expertise but inequality of access, particularly between major urban centers and underserved North, Northeast, and interior regions.➢ Managing a high-volume of trauma cases is a hallmark of Brazilian orthopaedics, with major public trauma centers handling complex injuries, late-presenting cases, and cases of infection or nonunion, while facing barriers to rehabilitation.➢ The reality of orthopaedics in Brazil demonstrates the need for more robust registries and multicenter collaborations, and better integration of outcome data.
中文摘要:巴西拥有全球规模最大的全民公共医疗系统之一,即统一医疗系统(Sistema Único de Saúde,SUS),服务人口超过2亿。巴西骨科培训体系较强,拥有活跃的全国性学会和不断成长的研究文化。巴西的骨科与创伤救治由公私混合模式提供,包括服务量大的公立医院、大学中心、私立医院和区域转诊中心。国家面临的主要挑战不只是骨科专业力量的可用性,还包括获取医疗服务的不平等,尤其是大城市中心与欠发达的北部、东北部和内陆地区之间的差距。处理大量创伤病例是巴西骨科的显著特征,大型公立创伤中心收治复杂损伤、就诊较晚的病例以及感染或不愈合病例,同时在康复方面面临障碍。巴西骨科的现实表明,需要更完善的登记系统、多中心协作,以及更好的结局数据整合。
One in four surgical patients carries a drug allergy label, of which an estimated 90% are incorrect. Avoidance of first-choice drug therapies can lead to worse postoperative outcomes. We sought to determine the nature and extent of any association between drug allergy labels and postoperative complications. A multicentre observational study was performed in 21 UK National Health Service hospitals. Eligible patients were ≥18 yr of age and undergoing common surgical procedures: primary hip or knee replacement, internal fixation of closed long bone fracture, colorectal resection, transurethral resection of prostate or bladder tumour, Caesarean delivery, or hysterectomy. Exclusion criteria were the use of antibiotics in the two weeks before surgery or previous participation in the study. The primary outcome was postoperative complications within 30 days after surgery, a composite outcome comprising all postoperative infections, anastomotic leak, acute respiratory distress syndrome, myocardial infarction, postoperative bleeding, pulmonary embolism, stroke, antimicrobial side-effects, and death. Among 13 646 patients, 3924 (29%) carried ≥1 drug allergy label. Labelled patients were more likely to develop postoperative complications (989/3924 [25%] vs 1926/9722 [20%]; odds ratio [OR] 1.21 [1.10-1.34]; P<0.001). They were more likely to develop surgical site infections (337/3924 [9%] vs 760/9722 [8%]; OR 1.19 [1.03-1.38]; P<0.018), and any postoperative infection (750/3924 [19%] vs 1472/9722 [15%]; OR 1.24 [1.11-1.38]; P<0.001). Labelled patients experienced an increased risk of allergic drug reactions (31/3924 [0.01%] vs 29/9722 [<0.01%]; OR 3.00 [1.77-5.09]; P<0.001), but no increase in mortality. Drug allergy labels are common, but often incorrect. Patients with drug allergy labels experience worse postoperative outcomes, including infective and noninfective complications and an increased risk of allergic drug reactions. ISRCTN Registry (ISRCTN15775657).
中文摘要:每四名手术患者中约有一人带有药物过敏标签,其中估计90%并不正确。回避首选药物治疗可能导致术后结局变差。研究旨在明确药物过敏标签与术后并发症之间关联的性质和程度。研究在21家英国国家医疗服务体系医院开展多中心观察性研究。纳入患者年龄≥18岁,接受常见手术:初次髋或膝关节置换、闭合性长骨骨折内固定、结直肠切除、经尿道前列腺或膀胱肿瘤切除、剖宫产或子宫切除。排除标准为术前两周内使用抗生素或既往参加过本研究。主要结局为术后30天内并发症,采用复合结局,包括所有术后感染、吻合口漏、急性呼吸窘迫综合征、心肌梗死、术后出血、肺栓塞、卒中、抗菌药物副作用和死亡。13646例患者中,3924例(29%)带有至少1个药物过敏标签。带标签患者更易发生术后并发症(989/3924[25%]比1926/9722[20%];比值比[OR]1.21[1.10-1.34];P<0.001)。他们更易发生手术部位感染(337/3924[9%]比760/9722[8%];OR 1.19[1.03-1.38];P<0.018)和任何术后感染(750/3924[19%]比1472/9722[15%];OR 1.24[1.11-1.38];P<0.001)。带标签患者发生过敏性药物反应的风险升高(31/3924[0.01%]比29/9722[<0.01%];OR 3.00[1.77-5.09];P<0.001),但死亡率未升高。药物过敏标签常见,但常不正确。带有药物过敏标签的患者术后结局更差,包括感染性和非感染性并发症,且过敏性药物反应风险增加。ISRCTN注册号(ISRCTN15775657)。
10感染/假体周围感染 (2篇)
基础研究 (2篇)
The rise of antibiotic resistance, particularly among pathogens such as methicillin-resistant Staphylococcus aureus, necessitates innovative antibacterial strategies. Here we introduce FibriLysins, a class of engineered enzymes combining staphylokinase and endolysin, which dismantle fibrin-encapsulated multicellular staphylococcal communities, including biofilms and staphylococcal abscess communities (SACs). We characterized diverse staphylokinases, developing a library of 27 FibriLysins, with a 78% positive hit rate. The lead variant, FL-028, has significant antibacterial activity against prevalent clinical S. aureus isolates. In vitro, FL-028 reduced bacterial counts in SACs by 3.4 log and in biofilms by 2.3 log. In vivo, FL-028 exhibits superior efficacy in a mouse model of bone fracture-related infection, outperforming vancomycin by 1 log and eliminating SAC presence in tissues. FL-028 shows no adverse effects on bone healing, as confirmed by histological examination, mechanical testing and micro-computed tomography analyses. These preclinical findings highlight the potential of FibriLysins as a robust and safe therapeutic approach against difficult-to-treat staphylococcal infections.
中文摘要:抗生素耐药性上升,尤其是耐甲氧西林金黄色葡萄球菌等病原体,需要创新抗菌策略。这里介绍 FibriLysins,一类工程酶,结合葡萄球菌激酶和内溶素,可拆解纤维蛋白包裹的多细胞葡萄球菌群落,包括生物膜和葡萄球菌脓肿群落(SACs)。我们表征了多种葡萄球菌激酶,构建了含27种FibriLysins的库,阳性命中率78%。先导变体FL-028对常见临床金黄色葡萄球菌分离株具有显著抗菌活性。体外,FL-028使SACs中细菌数降低3.4 log,使生物膜中降低2.3 log。体内,FL-028在小鼠骨折相关感染模型中疗效优于万古霉素1 log,并清除组织中的SAC。组织学检查、力学测试和微计算机断层扫描分析证实FL-028对骨愈合无不良影响。这些临床前发现提示FibriLysins可作为应对难治性葡萄球菌感染的强效且安全的治疗途径。
Orthopedic device-related infection (ODRI) is a devastating complication, often requiring repeated revision surgeries and prolonged antibiotic treatment. Injectable biodegradable biomaterials that deliver and maintain high local concentrations of antibiotics to the surgical field may eliminate the need for additional surgeries while improving treatment outcomes. In this study, we introduce a Gel for Delivery of Antibiotics (GEDAI) for local administration of tobramycin (T), gentamicin (G) or gentamicin-vancomycin (GV). GEDAI was developed with translatability and ease of intraoperative handling as design goals. GEDAI displayed storage and loss moduli, shear thinning, and elastic recovery properties appropriate for intraoperative applications, with good adhesion to stainless steel and tissues but reduced adhesion to surgical gloves. In vitro assays showed no adverse effects of the GEDAI on viability of fibroblasts, macrophages and endothelial cells, or osteogenic differentiation of human bone marrow stromal cells (hBMSCs). Methicillin susceptible and resistant Staphylococcus aureus (MSSA and MRSA), growing in planktonic culture or biofilm, were significantly reduced after exposure to the antibiotic loaded-GEDAI compared to GEDAI without antibiotics (p < 0.05). In three distinct in vivo studies in sheep, GEDAI-T reached a peak local concentration above 2000 μg/mL within 2 h and substantially reduced bacterial counts in two models with implant retention (GEDAI-T or GEDAI-G), and completely eradicated infection in an implant exchange model (GEDA-GV). GEDAI directly targets two unmet needs in ODRI: achieving bactericidal local concentrations without systemic toxicity and providing a ready-to-use formulation. The antibiotic-loaded GEDAI formulations promise to improve treatment outcomes in challenging infection cases, potentially reducing healthcare costs and patient burden in postoperative infection management.
中文摘要:骨科器械相关感染(ODRI)是严重并发症,常需反复翻修手术和长期抗生素治疗。可注射、可降解的生物材料若能在手术部位释放并维持高局部抗生素浓度,可能免除额外手术并改善治疗结局。本研究介绍一种用于局部递送妥布霉素(T)、庆大霉素(G)或庆大霉素-万古霉素(GV)的抗生素递送凝胶(GEDAI)。GEDAI以可转化性和术中易操作性为设计目标,其储能模量、损耗模量、剪切变稀和弹性回复性能适合术中应用,对不锈钢和组织黏附良好,对手术手套黏附较低。体外实验显示GEDAI不影响成纤维细胞、巨噬细胞和内皮细胞活力,也不影响人骨髓基质细胞(hBMSCs)成骨分化。浮游培养或生物膜状态生长的甲氧西林敏感和耐药金黄色葡萄球菌(MSSA和MRSA)暴露于载抗生素GEDAI后,较无抗生素GEDAI显著减少(p < 0.05)。在羊的三项体内研究中,GEDAI-T在2 h内局部浓度峰值超过2000 μg/mL,并在两个保留植入物的模型中显著降低细菌计数(GEDAI-T或GEDAI-G),在植入物更换模型中完全清除感染(GEDA-GV)。GEDAI直接针对ODRI的两个未满足需求:在不产生全身毒性的情况下达到杀菌性局部浓度,并提供即用型制剂。载抗生素GEDAI制剂有望改善困难感染病例的治疗结局,并可能降低术后感染管理中的医疗成本和患者负担。
11小儿骨科 (1篇)
临床研究 (1篇)
Mucopolysaccharidosis type I (MPS IH), or Hurler syndrome, is a lysosomal disorder caused by glycosaminoglycan accumulation due to an α-L-iduronidase deficiency. It is characterized by progressive skeletal impairment and impaired cognitive development. Hip dysplasia is a major skeletal manifestation for which conventional treatments (allogeneic hematopoietic stem cell transplantation with or without enzyme replacement therapy) does not prevent progression. Among patients with MPS IH, does hematopoietic stem cell gene therapy (HSC-GT) result in (1) longitudinal improvement in bony measurements of hip dysplasia, specifically the acetabular index (the angle between the Hilgenreiner line and the line drawn from the Y-cartilage to the lateral edge of the acetabular roof) and migration percentage (the proportion of the femoral head lateral to a Perkins line drawn from the lateral edge of the acetabular roof); (2) improvement in the cartilaginous acetabular index and migration percentage, accounting for the cartilaginous components of the acetabular roof and femoral head; and (3) an increase in the proportion of patients with an acetabular index and cartilaginous acetabular index within published norms? Between 2018 and 2019, 8 patients (6 males, 2 females) with MPS IH received OTL-203, an HSC-GT, in a Phase I/II clinical trial. All patients met the trial eligibility criteria, including absence of a suitable allogeneic donor and a Developmental Quotient or Intelligence Quotient score ≥ 70. Median (range) age at treatment was 23.5 months (14 to 34). All patients had dysplastic hip morphology at baseline, with abnormal acetabular index values and reduced femoral head coverage. This secondary analysis used prospectively collected orthopaedic and skeletal data from the same trial cohort, including hip radiographs and MRIs obtained during multidisciplinary follow-up. All patients completed the 5-year follow-up and entered the approved long-term follow-up program (up to 15 years after HSC-GT); no patients were lost to follow-up. One patient with pretreatment bilateral hip dislocation underwent hip surgery and was excluded from the subsequent longitudinal analysis, with radiological data retained up to surgery. One additional patient had missing radiographic assessments because behavioral difficulties precluded imaging; all other patients had 4-year assessments available. Hip dysplasia was assessed at baseline and 1, 2, 3, and 4 years after HSC-GT using acetabular index and migration percentage on radiographs and MRIs, as well as cartilaginous acetabular index and cartilaginous migration percentage on MRI. Radiological measurements were compared with published age- and sex-specific normative values. Mean ± SD age at last follow-up was 5.8 ± 0.5 years. Radiographic acetabular index and migration percentage decreased longitudinally (acetabular index: fixed effect estimate = -2.7° per year [95% CI -3.5° to -1.9°]; p < 0.001; migration percentage: fixed effect estimate = -8.1% per year [95% CI -9.8% to -6.3%]; p < 0.001). MRI acetabular index, migration percentage, and cartilaginous acetabular index decreased longitudinally (acetabular index: fixed effect estimate = -2.2° per year [95% CI -3.1° to -1.2°]; p < 0.001; migration percentage: fixed effect estimate = -2.6% per year [95% CI -4.4% to -0.9%]; p = 0.003; cartilaginous acetabular index: fixed effect estimate = -0.8° per year [95% CI -1.6° to -0.1°]; p = 0.02). However, there was no overall longitudinal change in cartilaginous migration percentage when all timepoints were considered (fixed effect estimate = -0.8% per year [95% CI -1.8% to 0.3%]; p = 0.15). The proportion of hips with acetabular measurements within published normative ranges increased during follow-up: acetabular index consistent with hip dysplasia decreased from 12 of 14 hips at baseline to 6 of 12 hips at 4 years, and severe hip dysplasia decreased from 11 of 14 hips to 1 of 12 hips within the same time frame. MRI measurements showed a similar shift toward published normative values from individuals without MPS IH. Radiographic and MRI measurements were positively correlated across examinations obtained at the same timepoints (acetabular index: r = 0.61 [95% CI 0.42 to 0.75]; p < 0.001; migration percentage: r = 0.54 [95% CI 0.32 to 0.70]; p < 0.001). Variations between baseline and 4-year follow-up in bony and cartilaginous measurements were also positively correlated (acetabular index and cartilaginous acetabular index: r = 0.53 [95% CI 0.001 to 0.83]; p = 0.05; migration percentage and cartilaginous femoral head coverage: r = 0.61 [95% CI 0.06 to 0.88]; p = 0.03). These findings suggest that hip dysplasia may stabilize or improve after OTL-203 treatment, supporting continued radiological surveillance in young children after HSC-GT. Longer-term prospective multicenter studies are needed to assess durability and clinical relevance and to compare outcomes with bone marrow transplantation. Level IV, therapeutic study.
中文摘要:黏多糖贮积症I型(MPS IH),即Hurler综合征,是由α-L-艾杜糖醛酸酶缺乏导致糖胺聚糖蓄积的溶酶体病。其特征为进行性骨骼损害和认知发育受损。髋关节发育不良是主要骨骼表现,常规治疗(异基因造血干细胞移植,联合或不联合酶替代治疗)不能阻止其进展。在MPS IH患者中,造血干细胞基因治疗(HSC-GT)是否能带来以下结果:(1)髋关节发育不良骨性测量指标的纵向改善,具体为髋臼指数(Hilgenreiner线与从Y软骨至髋臼顶外缘连线之间的夹角)和迁移百分比(股骨头位于从髋臼顶外缘所作Perkins线外侧的比例);(2)考虑髋臼顶和股骨头软骨成分后,软骨性髋臼指数和迁移百分比的改善;(3)髋臼指数和软骨性髋臼指数处于已发表正常范围内的患者比例增加?2018年至2019年间,8例MPS IH患者(6例男性,2例女性)在I/II期临床试验中接受HSC-GT OTL-203。所有患者均符合试验入组标准,包括无合适异基因供者以及发育商或智商评分≥70。治疗时年龄中位数(范围)为23.5个月(14至34)。所有患者基线时均有髋关节发育不良形态,表现为髋臼指数异常和股骨头覆盖减少。本二次分析使用同一试验队列前瞻性收集的骨科和骨骼数据,包括多学科随访期间获得的髋关节X线片和MRI。所有患者完成5年随访并进入批准的长期随访计划(HSC-GT后最长15年);无患者失访。1例治疗前双侧髋关节脱位患者接受髋关节手术,被排除在后续纵向分析之外,影像学数据保留至手术时。另1例患者因行为困难无法成像而缺失影像学评估;其他所有患者均有4年评估资料。HSC-GT前及治疗后1、2、3、4年,通过X线片和MRI上的髋臼指数和迁移百分比,以及MRI上的软骨性髋臼指数和软骨性迁移百分比评估髋关节发育不良。影像学测量与已发表的年龄和性别特异性正常值进行比较。末次随访时平均±SD年龄为5.8±0.5岁。X线片髋臼指数和迁移百分比呈纵向下降(髋臼指数:固定效应估计值为每年-2.7°[95% CI -3.5°至-1.9°];p < 0.001;迁移百分比:固定效应估计值为每年-8.1%[95% CI -9.8%至-6.3%];p < 0.001)。MRI髋臼指数、迁移百分比和软骨性髋臼指数呈纵向下降(髋臼指数:固定效应估计值为每年-2.2°[95% CI -3.1°至-1.2°];p < 0.001;迁移百分比:固定效应估计值为每年-2.6%[95% CI -4.4%至-0.9%];p = 0.003;软骨性髋臼指数:固定效应估计值为每年-0.8°[95% CI -1.6°至-0.1°];p = 0.02)。但考虑所有时间点时,软骨性迁移百分比无总体纵向变化(固定效应估计值为每年-0.8%[95% CI -1.8%至0.3%];p = 0.15)。随访期间髋臼测量值处于已发表正常范围内的髋关节比例增加:符合髋关节发育不良的髋臼指数从基线的14个髋关节中的12个降至4年时的12个髋关节中的6个,重度髋关节发育不良在同一时间段内从14个髋关节中的11个降至12个髋关节中的1个。MRI测量也显示向无MPS IH个体的已发表正常值相似偏移。同一时间点获得的X线片和MRI测量呈正相关(髋臼指数:r = 0.61 [95% CI 0.42至0.75];p < 0.001;迁移百分比:r = 0.54 [95% CI 0.32至0.70];p < 0.001)。基线与4年随访之间骨性和软骨性测量值的变化也呈正相关(髋臼指数与软骨性髋臼指数:r = 0.53 [95% CI 0.001至0.83];p = 0.05;迁移百分比与软骨性股骨头覆盖:r = 0.61 [95% CI 0.06至0.88];p = 0.03)。这些发现提示OTL-203治疗后髋关节发育不良可能稳定或改善,支持HSC-GT后幼儿继续接受影像学监测。需要更长期的前瞻性多中心研究评估耐久性和临床意义,并与骨髓移植结局比较。IV级,治疗性研究。
12假体周围感染 (1篇)
临床研究 (1篇)
SUMMARYPeriprosthetic joint infections (PJIs) have become a costly complication of total joint arthroplasty, and the incidence continues to rise, given an increasing elderly population requiring total knee and total hip replacements. Traditionally, two-stage exchange (TSE) is the standard of care to combat chronic PJIs. The first stage of a TSE is defined by the removal of the prosthesis with implantation of an antibiotic-loaded cement spacer. There is a lack of guidance regarding the dosing of antimicrobials in cement spacers and a lack of safety data available in the infectious diseases literature. This paper aims to provide a comprehensive review of antibiotic-loaded cement spacers (ALCS) by reviewing published literature from peer-reviewed journals dating from 1988 to 2024 and discussing the authors' clinical experience. It was noted that with improvements to ALCS over the years, associated complications also evolved. Not only do mechanical challenges such as increased joint subluxation persist, but also complications of nephrotoxicity and allergic reactions occur due to unknown levels of systemic absorption of antibiotics. A multidisciplinary approach involving orthopedic surgeons, infectious diseases specialists, and pharmacists, in conjunction with patient-specific anti-microbial spacer dosing, would likely lead to improved outcomes in patients with chronic PJIs.
中文摘要:假体周围关节感染已成为全关节置换术的一种高成本并发症,随着需要全膝和全髋置换的老年人口增加,其发生率持续上升。传统上,两阶段置换是治疗慢性假体周围关节感染的标准方案。两阶段置换的第一阶段包括取出假体并植入载抗生素骨水泥间隔物。骨水泥间隔物中抗菌药物的剂量缺乏指导,感染病学文献中也缺乏安全性数据。本文通过回顾1988年至2024年同行评议期刊已发表文献并结合作者临床经验,对载抗生素骨水泥间隔物作全面综述。多年来载抗生素骨水泥间隔物不断改进,相关并发症也随之演变。不仅关节半脱位增加等机械性问题持续存在,还因抗生素全身吸收水平不明而出现肾毒性和过敏反应。由骨科外科医生、感染病专家和药师参与的多学科协作,结合患者个体化的抗菌药物间隔物剂量,可能改善慢性假体周围关节感染患者的结局。
13运动医学 (1篇)
基础研究 (1篇)
Tendinopathy represents a heterogeneous spectrum of tendon disorders characterized by persistent pain, impaired function, and progressive disruption of tissue homeostasis. Rather than a single degenerative entity, tendinopathy reflects the interaction between mechanical adaptation failure, immune dysregulation, extracellular matrix remodeling, and systemic metabolic influences. However, its pathophysiological mechanisms remain incompletely understood. Tendinopathy can affect multiple anatomical sites, such as the rotator cuff, Achilles tendon, and patellar tendon, and has a high prevalence in both the general population and athletes. Despite decades of research, there is currently a lack of targeted therapies capable of effectively reversing the pathological process, and clinical management is primarily limited to empirical symptomatic treatment. This review systematically synthesizes the epidemiology and risk factors of tendinopathy and proposes a "multidimensional tendinopathy remodeling network" model encompassing mechanotransduction, inflammatory cascades, pathological angiogenesis, and matrix turnover. Furthermore, we discuss emerging approaches for molecular stratification through multimodal imaging and biomarkers, and evaluate precision-oriented therapeutic strategies, including mechanomodulation, immunomodulation, regenerative medicine, and nano delivery systems. This framework provides a conceptual foundation for understanding the heterogeneity of tendinopathies and facilitates a shift from symptom-oriented treatment to mechanism-oriented approaches, potentially leading to precision treatment strategies. At the same time, it highlights the challenges in current translational research and points to future research directions for personalized tendon repair strategies.
中文摘要:肌腱病代表一组异质性肌腱疾病,特征为持续疼痛、功能受损以及组织稳态的进行性破坏。肌腱病并非单一退变性实体,而是机械适应失败、免疫失调、细胞外基质重塑与系统性代谢影响之间相互作用的结果。其病理生理机制仍未完全阐明。肌腱病可累及多个解剖部位,如肩袖、跟腱和髌腱,在普通人群和运动员中患病率均较高。尽管经过数十年研究,目前仍缺乏能够有效逆转病理过程的靶向治疗,临床处理主要限于经验性对症治疗。该综述系统整合肌腱病的流行病学与危险因素,提出涵盖机械转导、炎症级联、病理性血管生成和基质周转的「多维肌腱病重塑网络」模型。文章还讨论通过多模态影像和生物标志物进行分子分层的新兴方法,并评估精准导向治疗策略,包括机械调节、免疫调节、再生医学和纳米递送系统。该框架为理解肌腱病的异质性提供概念基础,推动从症状导向治疗转向机制导向方法,可能形成精准治疗策略。文章同时强调当前转化研究中的挑战,并指出个性化肌腱修复策略的未来研究方向。
14炎性关节病 (1篇)
临床研究 (1篇)
Rheumatoid arthritis (RA) exhibits clinical and biological heterogeneity, with synovial tissue stratified into histological pathotypes: lympho-myeloid, diffuse-myeloid, and pauci-immune fibroid. Although genome-wide association studies (GWAS) have uncovered RA risk loci, how genetic risk relates to synovial immunopathology remains unclear. To better understand how genetic predisposition may shape divergent early disease mechanisms, we characterised the expression patterns of GWAS-identified RA susceptibility genes and related rheumatic diseases across the synovial pathotypes. Synovial RNA sequencing of patients with early RA (Pathobiology of Early Arthritis Cohort [PEAC] [N = 87] and Flinders [N = 18]) was used for differential gene expression between pathotypes, and pathway enrichment analyses were performed using GWAS-identified susceptibility genes for RA, osteoarthritis (OA), ankylosing spondylitis, psoriatic arthritis, and systemic lupus erythematosus. RA susceptibility gene expression in synovial tissue separated patients by pathotype and correlated with markers of disease activity. RA susceptibility genes were significantly enriched among genes upregulated in lympho-myeloid synovium and linked to lymphocyte activation and differentiation pathways. In contrast, OA susceptibility genes were upregulated in diffuse-myeloid and fibroid synovium. Both patterns were most pronounced in anticitrullinated protein antibody (ACPA)-positive and directionally consistent in ACPA-negative patients. Expression of RA susceptibility genes is not evenly distributed across synovial pathotypes but is strongly biased towards the lympho-myeloid pathotype, indicating that current GWAS signals preferentially capture immune-driven disease mechanisms. Enrichment of OA susceptibility genes in diffuse-myeloid and fibroid pathotypes, even among ACPA-positive patients, suggests shared biological features between autoimmune and noninflammatory degenerative joint diseases in certain RA subtypes. Synovial pathotype stratification is therefore essential for interpreting genetic risk and understanding disease heterogeneity.
中文摘要:类风湿关节炎(RA)在临床和生物学上存在异质性,滑膜组织可分为组织学病理类型:淋巴髓系型、弥漫髓系型和少免疫纤维型。全基因组关联研究(GWAS)已发现RA风险位点,但遗传风险与滑膜免疫病理的关系仍不清楚。为理解遗传易感性如何塑造不同的早期疾病机制,我们分析了GWAS识别的RA易感基因及相关风湿病易感基因在各滑膜病理类型中的表达模式。利用早期RA患者滑膜RNA测序(Pathobiology of Early Arthritis Cohort [PEAC],N=87;Flinders,N=18)比较病理类型间差异基因表达,并对RA、骨关节炎(OA)、强直性脊柱炎、银屑病关节炎和系统性红斑狼疮的GWAS易感基因进行通路富集分析。RA易感基因在滑膜组织中的表达可将患者按病理类型区分,并与疾病活动度标志物相关。RA易感基因在淋巴髓系型滑膜上调基因中显著富集,并与淋巴细胞活化和分化通路相关。相反,OA易感基因在弥漫髓系型和纤维型滑膜中上调。上述模式在抗瓜氨酸化蛋白抗体(ACPA)阳性患者中最明显,在ACPA阴性患者中方向一致。RA易感基因表达在滑膜病理类型间分布不均,明显偏向淋巴髓系型,提示现有GWAS信号主要捕捉免疫驱动的疾病机制。OA易感基因在弥漫髓系型和纤维型中的富集,即使在ACPA阳性患者中也存在,提示某些RA亚型中自身免疫性疾病与非炎症性退行性关节病具有共享生物学特征。因此,滑膜病理类型分层对于解释遗传风险和理解疾病异质性至关重要。
15骨质疏松 (1篇)
基础研究 (1篇)
Impact microindentation (IMI) is a minimally invasive technique for assessing bone material properties that can be performed clinically. In this study, we aimed to determine how measurements obtained by IMI (bone material strength index [BMSi]) relate to bone strength, fracture resistance, and susceptibility to fracture. (1) Is BMSi associated with bone strength of the femur, radius, and vertebrae, and does incorporating BMSi alongside bone mineral density (BMD) improve the estimation of strength? (2) Does BMSi evaluate fracture toughness and mechanical properties of the bone tissue? (3) Can BMSi discriminate fracture susceptibility of the hip and wrist? This single-site laboratory study included the tibiae, femurs, radii, and L4 vertebrae from fresh-frozen cadavers (n = 67; mean ± SD age 71 ± 13 years). To answer the first question, IMI was performed on the tibia midshaft, dual-energy x-ray absorptiometry (DXA) was used to assess hip and spine BMD, and bone strength (ultimate fracture force) was mechanically determined for each site. To address the second question, stress intensity factor (K C ) was quantified from notched cortical bone beam specimens from tibiae using the fracture toughness test. Bone mechanical behavior (ultimate stress, elastic modulus, work-to-fracture), microstructure (cortical porosity, tissue mineral density), and organic matrix quality (percentage of collagen denaturation, concentration of advanced glycation end products) were quantified from beam specimens from the femoral midshaft. To address the last question, hip and wrist fracture susceptibility was defined using the fall-load to fracture-load ratio, where values ≥ 1 indicate susceptibility. Receiver operating characteristic (ROC) curve analyses evaluated the ability of IMI and DXA to discriminate fracture susceptibility. Primary outcomes included evaluating the association between BMSi and BMD with bone strength and ROC analysis for discriminating fracture susceptibility. Higher BMSi values were positively associated with higher bone strength, showing moderate association at the femur (r = 0.62 [95% confidence interval (CI) 0.49 to 0.72]; p < 0.001) and radius (r = 0.52 [95% CI 0.34 to 0.72]; p < 0.001) and weaker association at the L4 vertebrae (r = 0.31 [95% CI 0.03 to 0.53]; p = 0.02). At the femur, BMSi was more strongly associated with strength than total hip BMD (TH-BMD) (r = 0.45 [95% CI 0.3 to 0.62]; p < 0.001), and the inclusion of BMSi in multivariate analyses improved the explained variance in femur strength from 28% to 52% (ΔR 2 = 0.24; p < 0.001). At the radius, both BMSi and TH-BMD (r = 0.50 [95% CI 0.31 to 0.71]; p < 0.01) showed moderate association with radius strength, with the combined model improving the explained variance in radius strength from 28% to 39% (ΔR 2 = 0.11; p < 0.001). At the vertebrae, strength was weakly associated with BMSi (r = 0.31 [95% CI 0.03 to 0.53]; p = 0.02) but not with BMD. For the hip and wrist of each donor, BMSi discriminated hip fracture susceptibility with moderate accuracy (area under the curve [AUC] 0.75 [95% CI 0.63 to 0.88]; p < 0.001), whereas TH-BMD could not discriminate hip fracture susceptibility. Both BMSi (AUC 0.77 [95% CI 0.63 to 0.90]; p = 0.003) and TH-BMD (AUC 0.78 [95% CI 0.64 to 0.90]; p = 0.002) classified wrist fracture susceptibility with modest discriminatory performance. Our study demonstrates that BMSi provides information related to bone strength and discriminates fracture susceptibility of the hip and wrist. IMI can be performed at the point of care using an FDA-cleared device and used to evaluate fragility in patients in whom fracture risk or bone strength is uncertain based on BMD alone. Prospective clinical studies are needed to determine whether IMI improves fracture risk prediction and informs patient treatment.
中文摘要:冲击微压痕(IMI)是一种可在临床实施的微创骨材料属性评估技术。本研究旨在确定IMI测得的骨材料强度指数(BMSi)与骨强度、抗骨折能力及骨折易感性之间的关系。(1)BMSi是否与股骨、桡骨和椎体的骨强度相关,将BMSi与骨密度(BMD)联合是否改善强度估计?(2)BMSi是否评估骨组织的断裂韧性和力学性质?(3)BMSi能否区分髋部和腕部骨折易感性?这项单站点实验室研究纳入新鲜冷冻尸体的胫骨、股骨、桡骨和L4椎体(n=67;年龄均值±标准差71±13岁)。为回答第一个问题,在胫骨中段实施IMI,用双能X线吸收法(DXA)评估髋部和脊柱BMD,并对每个部位机械测定骨强度(极限断裂力)。为回答第二个问题,用断裂韧性试验从胫骨带缺口皮质骨梁试样量化应力强度因子(K_C)。从股骨中段梁试样量化骨力学行为(极限应力、弹性模量、断裂功)、微结构(皮质孔隙率、组织矿物质密度)和有机基质质量(胶原变性百分比、晚期糖基化终产物浓度)。为回答最后一个问题,髋部和腕部骨折易感性用跌倒载荷与骨折载荷比值定义,比值≥1表示易感。受试者工作特征(ROC)曲线分析评估IMI和DXA区分骨折易感性的能力。主要结局包括评估BMSi与BMD和骨强度的关联,以及区分骨折易感性的ROC分析。较高的BMSi值与较高的骨强度正相关,股骨处呈中等相关(r=0.62[95%置信区间(CI)0.49至0.72];p<0.001),桡骨处呈中等相关(r=0.52[95%CI 0.34至0.72];p<0.001),L4椎体处关联较弱(r=0.31[95%CI 0.03至0.53];p=0.02)。股骨处BMSi与强度的关联强于全髋BMD(TH-BMD)(r=0.45[95%CI 0.3至0.62];p<0.001),多变量分析纳入BMSi后,股骨强度的解释方差从28%提高到52%(ΔR2=0.24;p<0.001)。桡骨处BMSi和TH-BMD均与桡骨强度呈中等关联(r=0.50[95%CI 0.31至0.71];p<0.01),联合模型将桡骨强度的解释方差从28%提高到39%(ΔR2=0.11;p<0.001)。椎体处强度与BMSi弱相关(r=0.31[95%CI 0.03至0.53];p=0.02),与BMD无关联。对每具供体的髋部和腕部,BMSi以中等准确度区分髋部骨折易感性(曲线下面积(AUC)0.75[95%CI 0.63至0.88];p<0.001),TH-BMD不能区分髋部骨折易感性。BMSi(AUC 0.77[95%CI 0.63至0.90];p=0.003)和TH-BMD(AUC 0.78[95%CI 0.64至0.90];p=0.002)对腕部骨折易感性均具有有限的判别效能。本研究表明,BMSi提供与骨强度相关的信息,并能区分髋部和腕部骨折易感性。IMI可在照护现场使用FDA许可设备实施,用于评估仅凭BMD难以判断骨折风险或骨强度的患者的脆性。仍需前瞻性临床研究确定IMI是否改善骨折风险预测并指导患者治疗。
16足踝外科 (1篇)
临床研究 (1篇)
Bioresorbable fixation devices may be advantageous because they eliminate the question of whether they ought to be removed, have biomimetic qualities, and minimize artifacts seen on MRI. Most bioresorbable devices utilized during orthopaedic surgery consist of thermoplastic polymers derived from lactic and glycolic acids. These devices are linked to implant-related osteolysis, inflammation, and bone tunnel enlargement, and their integration with surrounding bone is inconsistent. Citregen®, a resorbable composite of a citrate-based thermoset polymer and hydroxyapatite, recently has been approved for use in the United States; yet to date, there are no published studies documenting device-related MRI findings. (1) Was there observable bone tunnel enlargement on MRI at a minimum of 2 years after implantation of a resorbable citrate-based bioceramic device? (2) Were there other observable adverse findings (such as bone marrow edema or device breakage) on MRI at a minimum of 2 years after implantation of a resorbable citrate-based bioceramic device? (3) Did citrate-based bioceramic devices demonstrate integration with surrounding bone on MRI at a minimum of 2 years after implantation? (4) What was the frequency of early clinical complications after soft tissue fixation with citrate-based bioceramic interference devices? All 15 patients who underwent tendon transfer or ligament reconstruction in the foot and ankle during a 21-month time period were treated with citrate-based bioceramic interference devices. This group of patients had a median (range) age of 55 years (21 to 75), and 10 were male. Most presented with degenerative or work-related conditions; two had athletic injuries. Two patients were lost to follow-up, and MRI scans performed on 13 patients (25 devices) more than 2 years after surgery were reviewed separately in retrospective, blinded fashion by two investigators. For each device, surrounding bone was assessed for bone tunnel enlargement, which was quantified in millimeters by measuring the width of any gap between the inner surface of the bone tunnel and the outer diameter of the device threads. An intraclass correlation coefficient of 1.0 was achieved, indicating absolute agreement between raters with regard to width of gap measured to the nearest millimeter. The proportion of bone marrow edema abutting the total cross-sectional circumference of each device was quantified using a five-point interval scale (0%, 0% to 25%, 26% to 50%, 51% to 75%, and 76% to 100%). Percentage intervals assessed on the five-point scale demonstrated high interrater reliability (prevalence-adjusted, bias-adjusted kappa [PABAK] = 0.92). Qualitative assessment for other adverse findings, such as cysts, sinus tracts, peridevice fluid, and device breakage, was also performed. The proportion of osseous integration along the long axis of each device was also quantified using a five-point interval scale (0%, 0% to 25%, 26% to 50%, 51% to 75%, and 76% to 100%). Percentage intervals assessed on the five-point scale demonstrated high interrater reliability (PABAK = 0.92). Retrospective chart analysis was used to document the number of complications at the most recent follow-up. There was no measurable bone tunnel enlargement around any of the devices. Two devices showed bone marrow edema limited to 25% or less of device circumference. Osseous integration occurred around all devices, with 21 of 25 implants showing near-complete (76% to 100%) integration along their long axes. Clinically, there were no device-related complications at median follow-up of 36 months in the 13 patients who were accounted for at a minimum of 2 years (range 2 to 4 years). In our study of a citrate-based thermoset polymer with hydroxyapatite, common problems associated with other resorbable devices were not seen. Although these findings are promising, our series was very small and had multiple limitations. Therefore, this study should not serve as a basis to recommend widespread use of this material without publication of larger and more rigorous studies that independently replicate our findings. Level IV, therapeutic study.
中文摘要:生物可吸收固定装置可能具有优势,因为无需再考虑是否应取出,具有仿生特性,并可减少MRI伪影。骨科手术中使用的大多数生物可吸收装置由乳酸和乙醇酸衍生的热塑性聚合物构成。这些装置与植入物相关骨溶解、炎症和骨隧道扩大有关,且与周围骨的整合并不稳定。Citregen®是一种由柠檬酸基热固性聚合物与羟基磷灰石组成的可吸收复合材料,近期在美国获批使用;但迄今尚无已发表研究记录装置相关MRI表现。(1)植入可吸收柠檬酸基生物陶瓷装置至少2年后,MRI上是否可见骨隧道扩大?(2)植入至少2年后,MRI上是否存在其他可见不良表现(如骨髓水肿或装置断裂)?(3)植入至少2年后,柠檬酸基生物陶瓷装置是否在MRI上显示与周围骨整合?(4)使用柠檬酸基生物陶瓷挤压螺钉进行软组织固定后,早期临床并发症的发生频率如何?在21个月期间接受足踝部肌腱转位或韧带重建的全部15例患者均使用柠檬酸基生物陶瓷挤压螺钉。该组患者中位年龄55岁(范围21至75岁),10例为男性。多数表现为退变性或工作相关疾病;2例为运动损伤。2例失访;13例患者(25枚装置)在术后2年以上接受MRI扫描,由两名研究者以回顾性、盲法方式分别审阅。对每枚装置,评估周围骨是否存在骨隧道扩大,并通过测量骨隧道内表面与装置螺纹外径之间任何间隙的宽度以毫米量化。组内相关系数达1.0,表明评分者对所测间隙宽度(精确至毫米)完全一致。紧邻每枚装置全周径的骨髓水肿比例采用五点区间量表量化(0%、0%至25%、26%至50%、51%至75%、76%至100%)。五点量表评估的百分比区间显示高评分者间信度(患病率校正、偏倚校正kappa[PABAK]=0.92)。还对囊肿、窦道、装置周围积液和装置断裂等其他不良表现进行定性评估。沿每枚装置长轴的骨整合比例也采用五点区间量表量化(0%、0%至25%、26%至50%、51%至75%、76%至100%)。五点量表评估的百分比区间显示高评分者间信度(PABAK=0.92)。通过回顾性病历分析记录最近一次随访时的并发症数量。任何装置周围均无可测量的骨隧道扩大。2枚装置显示骨髓水肿局限于装置周径25%或以下。所有装置周围均发生骨整合,25枚植入物中21枚沿长轴显示近完全(76%至100%)整合。临床方面,在至少2年(范围2至4年)可评估的13例患者中,中位随访36个月时无装置相关并发症。在这项柠檬酸基热固性聚合物与羟基磷灰石的研究中,未见其他可吸收装置常见的问题。这些发现虽有希望,但本系列样本很小且存在多项局限。因此,在更大、更严谨且独立重复这些发现的研究发表之前,本研究不应作为推荐广泛使用该材料的依据。IV级,治疗性研究。
17骨代谢/骨病 (1篇)
基础研究 (1篇)
Bone development, homeostasis, and regeneration are governed by complex, dynamic gene regulatory programs, and these processes are disrupted in numerous skeletal diseases. The epigenetic landscape-particularly chromatin accessibility-dictates transcription factor binding and gene expression, which fundamentally shape bone cell fate and function. In recent years, single-cell chromatin accessibility technologies, most notably single-cell assay for transposase-accessible chromatin using sequencing (scATAC-seq), have revolutionized bone epigenome research and enabled single-cell resolution dissection of the skeletal system. This review summarizes recent progress in single-cell chromatin accessibility studies in bone biology, and systematically outlines chromatin-accessibility changes in skeletal development, diseases, and regeneration. We introduce cutting-edge single-cell epigenomic mapping technologies, their bone tissue-specific adaptations, and analytical frameworks for multi-omics data integration. These approaches reveal key biological findings: the identification of bone-resident subpopulations and lineage hierarchies, dynamic enhancer landscapes during osteoblast/chondrocyte differentiation, cellular bases of diseases such as osteoporosis and osteoarthritis, and novel mechanisms of bone tumorigenesis. Moreover, we discuss cross-applications of genomics and functional research, including mapping of disease-associated regulatory elements and emerging epigenome-editing strategies. Finally, we address current challenges, outline future directions, and envision the integration of single-cell epigenomics in precision orthopedics and regenerative medicine.
中文摘要:骨骼发育、稳态维持与再生受复杂且动态的基因调控程序支配,这些过程在多种骨骼疾病中发生紊乱。表观遗传景观尤其是染色质可及性决定转录因子结合与基因表达,从根本上塑造骨细胞命运和功能。近年来,单细胞染色质可及性技术,尤其是基于测序的转座酶可及染色质单细胞检测(scATAC-seq),推动了骨表观基因组研究,使在单细胞分辨率上解析骨骼系统成为可能。本综述总结单细胞染色质可及性研究在骨生物学中的近期进展,系统梳理骨骼发育、疾病与再生中的染色质可及性变化。我们介绍前沿单细胞表观基因组图谱技术、其在骨组织中的适应性调整以及多组学数据整合的分析框架。这些方法揭示关键生物学发现:骨内驻留亚群与谱系层级的鉴定,成骨细胞/软骨细胞分化过程中的动态增强子景观,骨质疏松和骨关节炎等疾病的细胞基础,以及骨肿瘤发生的新机制。我们还讨论基因组学与功能研究的交叉应用,包括疾病相关调控元件的图谱绘制和新兴表观基因组编辑策略。文章还讨论当前挑战,概述未来方向,并展望单细胞表观基因组学在精准骨科和再生医学中的整合应用。
18其他 (3篇)
临床研究 (1篇)
Musculoskeletal disorders are common and can profoundly affect the survival, mobility, and independence of patients. The overall objective of the Musculoskeletal Adaptive Platform Trial (MAPT) is to incrementally compare the effectiveness of available interventions to improve outcomes for adult patients with health conditions affecting physical mobility. The MAPT framework is flexible, allowing the detection of varying levels of meaningful benefit or harm (or equivalence) on the basis of the burden of disease and the available treatments. Treatment comparisons will be evaluated as intervention domains on the platform in order to achieve the overarching objective. Specific objectives for each intervention domain will be included in intervention domain-specific protocol appendices. The primary outcome is a hierarchically assessed composite of death within 120 days, ambulation status at 120 days, and days alive and out of the hospital within 120 days of randomization. Secondary outcomes will include the components of the composite outcome and patient-reported outcomes. Participants will be contacted at 6 weeks, 4 months, 8 months, and 12 months after randomization to ascertain trial outcomes. The MAPT will enable researchers to efficiently evaluate multiple treatment options for patients with musculoskeletal impairments, which may improve patient care and outcomes globally. The MAPT is clinically relevant because it provides a practical framework for rapidly identifying which treatments improve survival, mobility, and recovery in patients with musculoskeletal conditions. It can directly guide better treatment decisions regarding a leading cause of disability.
中文摘要:肌肉骨骼疾病常见,且可深刻影响患者的生存、活动能力和独立性。肌肉骨骼自适应平台试验(MAPT)的总体目标是在影响身体活动能力的成人患者中,逐步比较现有干预措施改善结局的有效性。MAPT框架具有灵活性,可依据疾病负担和可用治疗,检测不同水平的有意义获益或危害(或等效性)。治疗比较将作为平台上的干预领域进行评估,以实现总体目标。各干预领域的具体目标将纳入相应干预领域的方案附录。主要结局为分层评估的复合终点,包括随机化后120天内死亡、120天时行走状态以及120天内存活且不在医院的天数。次要结局将包括复合终点的各组成部分和患者报告结局。参与者将在随机化后6周、4个月、8个月和12个月接受联系,以确定试验结局。MAPT将使研究人员能够高效评估肌肉骨骼损伤患者的多种治疗选择,这可能改善全球患者照护和结局。MAPT具有临床相关性,因为它提供了一个实用框架,可快速识别哪些治疗能改善肌肉骨骼疾病患者的生存、活动能力和康复。它可以直接指导针对主要致残原因的更优治疗决策。
基础研究 (2篇)
The use of large language models (LLMs) is increasingly common. However, LLMs may exhibit sycophancy, echoing users' beliefs while avoiding contradiction. In the present study, we describe sycophancy in general-purpose LLMs when applied to orthopaedic contexts. We investigated sycophancy in 2 general-purpose LLMs. We evaluated performance on 3 tasks: (1) accuracy on benchmark answering: LLMs were tested on validated benchmark orthopaedic questions, with correct and incorrect cues, and the change in accuracy and sycophancy error rate were determined; (2) user belief agreement: LLMs were provided with ambiguous statements and a user belief, and LLM agreement, contradiction, and uncertainty were described; and (3) false information detection: false information was placed within a task prompt to measure noncontradiction and propagation rates. Baseline factual accuracy on benchmark questioning was 78%, decreasing with correct hints (71%) (p = 0.49). With incorrect hints, LLM accuracy declined significantly (48%) (p < 0.001), with a sycophancy error rate of 52%. Presented with user beliefs about an indefinite, controversial statement, models echoed user beliefs in 56%, expressed uncertainty in 12%, and contradicted users in 32% of statements. In noncontradiction tasks, models perpetuated incorrect attributions 99% of the time yet reliably corrected statistical distortions 97% of the time. Although popular general-purpose LLMs have useful orthopaedic applications, they exhibit sycophancy, with a tendency toward agreement and without recognition of ambiguity. This is a key weakness to be addressed. Findings should be interpreted cautiously given the variability in model design, prompting, and models evaluated. The tendency of general-purpose LLMs to agree without recognizing clinical ambiguity may limit their reliability in orthopaedic applications.
中文摘要:大语言模型(LLM)的使用日益普遍,但LLM可能表现出迎合性,即附和用户信念而回避矛盾。本研究描述通用LLM在骨科情境中的迎合性。我们评估了2个通用LLM在3项任务中的表现:(1)基准答题准确性:用经过验证的骨科基准问题测试LLM,并给出正确或错误提示,测定准确性变化和迎合性错误率;(2)用户信念一致性:向LLM提供含义不明确且有争议的陈述及用户信念,描述LLM的同意、反驳和不确定表现;(3)虚假信息检测:在任务提示中加入虚假信息,测量不反驳率和传播率。基准提问的基线事实准确性为78%,给予正确提示后降至71%(p=0.49)。给予错误提示后,LLM准确性显著下降至48%(p<0.001),迎合性错误率为52%。面对含义不明确且有争议的陈述所对应的用户信念,模型在56%的陈述中附和用户信念,在12%中表达不确定,在32%中反驳用户。在不反驳任务中,模型在99%的情况下延续错误归因,但在97%的情况下能可靠纠正统计失真。尽管常用通用LLM在骨科中有实用价值,它们仍表现出迎合性,倾向于同意且不能识别模糊性。这是需要解决的关键弱点。鉴于模型设计、提示方式和所评估模型的差异,应谨慎解读这些发现。通用LLM在不识别临床模糊性的情况下倾向同意,可能限制其在骨科应用中的可靠性。
Extracellular vesicles (EVs) are nanoscale membrane structures secreted by cells and play a key mediating role in intercellular communication. Their biosynthesis and function are profoundly modulated by mechanical signals from the cellular microenvironment. Mechanical forces, including shear stress, tensile strain, and matrix stiffness, exert fundamental effects on cellular behavior and disease progression by regulating the biogenesis, composition, and function of EVs. This review summarizes current knowledge on how biomechanical cues regulate EV-mediated intercellular communication in diseases such as atherosclerosis, osteoarthritis, and cancer. Specifically, we explore the mechanisms by which abnormal mechanical forces alter the cargo of EVs, such as miRNAs, proteins, and lipids, thereby driving disease progression through pathways like plaque instability, metastatic niche formation, and bone metabolism imbalance. Additionally, this review evaluates the therapeutic potential of mechanically regulated EVs, with a focus on their roles as diagnostic biomarkers and targeted drug delivery vehicles. By integrating cutting-edge perspectives from mechanobiology and EV research, this review lays a theoretical foundation for developing novel precision medicine strategies targeting biomechanically driven diseases.
中文摘要:细胞外囊泡(EVs)是细胞分泌的纳米级膜结构,在细胞间通讯中起关键介导作用。细胞微环境中的机械信号深刻调控其生物合成与功能。剪切应力、拉伸应变和基质刚度等机械力通过调节EVs的生成、组成和功能,对细胞行为与疾病进展产生基础性影响。本综述总结生物力学线索如何调控EVs介导的细胞间通讯,涉及动脉粥样硬化、骨关节炎和癌症等疾病。文章具体探讨异常机械力改变EVs货物(如miRNAs、蛋白质和脂质)的机制,并通过斑块不稳定、转移龛形成和骨代谢失衡等途径推动疾病进展。文章还评估机械调控EVs的治疗潜力,重点关注其作为诊断生物标志物和靶向药物递送载体的作用。通过整合机械生物学与EV研究的前沿视角,本综述为开发针对生物力学驱动疾病的精准医学新策略奠定理论基础。